



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## The effectiveness of an anti-inflammatory diet versus low-fat diet for knee osteoarthritis: the FEAST randomised controlled trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-079374
Article Type:	Protocol
Date Submitted by the Author:	30-Aug-2023
Complete List of Authors:	<p>Law, Lynette; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre</p> <p>Heerey, Joshua; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre</p> <p>Devlin, Brooke; University of Queensland, School of Human Movement and Nutrition Sciences</p> <p>Brukner, Peter; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre</p> <p>Kemp, Joanne; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre</p> <p>Attanayake, Amanda; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre</p> <p>Hulett, Mark; La Trobe University, Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science</p> <p>De Livera, Alysha; La Trobe University, Department of Mathematics and Statistics; The University of Melbourne, School of Population and Global Health</p> <p>Mosler, Andrea; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre</p> <p>Morris, Hayden; Melbourne Knee Centre</p> <p>White, Nathan; Melbourne Knee Centre</p> <p>Culvenor, Adam; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre</p>
Keywords:	Knee < ORTHOPAEDIC & TRAUMA SURGERY, Chronic Disease, REHABILITATION MEDICINE, NUTRITION & DIETETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1     **The effectiveness of an anti-inflammatory diet versus low-**  
2     **fat diet for knee osteoarthritis: the FEAST randomised**  
3     **controlled trial protocol**  
4  
5     Lynette Law<sup>1</sup>, Joshua J Heerey<sup>1</sup>, Brooke L Devlin<sup>2</sup>, Peter Brukner<sup>1</sup>, Joanne L Kemp<sup>1</sup>, Amanda  
6     Attanayake<sup>1</sup>, Mark D Hulett<sup>3</sup>, Alysha De Livera<sup>4, 5, 6</sup>, Andrea B Mosler<sup>1</sup>, Hayden G Morris<sup>7</sup>,  
7     Nathan P White<sup>7</sup>, Adam G Culvenor<sup>1</sup>  
8         1. La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health,  
9             Human Services and Sport, La Trobe University, Bundoora, Victoria, Australia  
10        2. School of Human Movement and Nutrition Sciences, University of Queensland,  
11             Brisbane, Australia  
12        3. Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science,  
13             La Trobe University, Bundoora, Victoria, Australia  
14        4. Department of Mathematics and Statistics, La Trobe University, Bundoora, Victoria,  
15             Australia  
16        5. School of Population and Global Health, The University of Melbourne, Victoria,  
17             Australia  
18        6. Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia  
19        7. Melbourne Knee Centre, Melbourne, Victoria, Australia.  
20  
21     **Corresponding Author:**  
22     Dr Adam Culvenor  
23     La Trobe Sport and Exercise Medicine Research Centre,  
24     La Trobe University,  
25     Kingsbury Drive, Bundoora, 3086  
26     Victoria, Australia  
27     Phone: +61 9479 5116  
28     Email: a.culvenor@latrobe.edu.au  
29     **Word count:** 3,998

## ABSTRACT

**Introduction:** Chronic inflammation plays a key role in knee osteoarthritis pathophysiology and increases risk of comorbidities, yet most interventions do not typically target inflammation. Our study will investigate if an anti-inflammatory dietary program is superior to a standard care low-fat dietary program for improving knee pain, function and quality-of-life in people with knee osteoarthritis.

**Methods and analysis:** The FEAST (eFECT of an Anti-inflammatory diet for knee oSTeoarthritis) Study is a parallel-group, assessor-blinded, superiority randomised controlled trial. Following baseline assessment, 140 participants aged 45-85 years with symptomatic knee osteoarthritis will be randomly allocated to one of two treatment groups (1:1 ratio). Participants randomised to the anti-inflammatory dietary program will receive six dietary consultations over 12 weeks (2 in-person, 4 phone/videoconference) and additional educational and behaviour change resources. The consultations and resources emphasise nutrient-dense minimally processed anti-inflammatory foods and discourage pro-inflammatory processed foods. Participants randomised to the standard care low-fat dietary program will receive three dietary consultations over 12 weeks (2 in-person, 1 phone/videoconference) consisting of healthy eating advice and education based on the Australian Dietary Guidelines, reflecting usual care in Australia. Adherence will be assessed with 3-day food diaries. Outcomes are assessed at 12 weeks and 6 months. The primary outcome will be change from baseline to 12 weeks in the mean score on four Knee injury and Osteoarthritis Outcome Score (KOOS<sub>4</sub>) subscales: knee pain, symptoms, function in daily activities and knee-related quality-of-life. Secondary outcomes include change in individual KOOS subscale scores, patient-perceived improvement, health-related quality-of-life, body mass and composition using dual-energy X-ray absorptiometry, inflammatory (high-sensitivity C-Reactive Protein, Interleukins, Tumour Necrosis Factor- $\alpha$ ) and metabolic blood biomarkers (glucose, HbA1c, insulin, liver function, lipids), lower-limb function and physical activity.

**Ethics and Dissemination:** Approved by La Trobe University Human Ethics Committee. Results will be presented in peer-reviewed journals and at international conferences.

**Trial registration:** ACTRN12622000440729

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Inflammation, Low-carbohydrate, Anti-inflammatory, Pain, Osteoarthritis, Knee, Chronic disease, Rehabilitation, Diet

**STRENGTHS AND LIMITATIONS OF THIS STUDY**

- The anti-inflammatory dietary program was codeveloped and piloted with patients and clinicians, with the comparison low-fat dietary program representing usual care.
- Sufficiently powered trial evaluating change from baseline to 12 weeks (primary endpoint) and 6 months facilitating longer-term effectiveness evaluation of the anti-inflammatory dietary program.
- This trial will evaluate both self-reported and objective outcomes to understand potential mechanisms of symptomatic changes.
- While outcome assessors are blinded to group allocation, the health professionals delivering the interventions and participants are unable to be blinded to group allocation due to the type of interventions.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

## INTRODUCTION

Osteoarthritis (OA) is the most common rheumatic disease affecting approximately 15% of the population, with OA of the knee being most prevalent<sup>1</sup>. Knee OA and its associated symptoms can be disabling and lead to substantial societal and healthcare costs<sup>2</sup>. In Australia alone, annual OA-related healthcare expenditure exceeds \$2.1 billion<sup>3</sup>. Although the main symptom of knee OA is pain, individuals with knee OA have an increased risk of other chronic diseases, including cardiovascular disease and diabetes<sup>4</sup>. As many as two-thirds of older adults with knee OA have more than one comorbidity<sup>5</sup>.

Clinical guidelines for knee OA recommend exercise-therapy and weight-loss as first-line management strategies due to their excellent safety profile and therapeutic effects similar to commonly used analgesics<sup>2 6</sup>. However, the effectiveness of exercise-therapy has recently been questioned due to its lack of benefit over an open-label placebo<sup>7</sup>, and findings that one-third of people completing an exercise program do not achieve a clinically meaningful improvement in pain<sup>8 9</sup>. Weight-loss programs in those who are overweight or obese typically consist of caloric restrictive diets, which are challenging to adhere to and sustain<sup>10</sup>. A meta-analysis highlighted that, within two years of a calorie-restrictive program, over half of initial weight lost was regained, and by 5 years, this figure jumped to >80%<sup>11</sup>.

Anti-inflammatory diets provide an alternative to calorie-restrictive approaches by targeting local and systemic inflammation, both contributors to OA disease onset, progression and symptom burden<sup>12-14</sup>. Anti-inflammatory diets are typically high in minimally processed, nutrient rich foods such as fruit, vegetables, spices and extra virgin olive oil, which are dense in nutrients such as polyphenols, carotenoids, fibre, monounsaturated and polyunsaturated fatty acids<sup>15-18</sup>. These nutrients can significantly reduce inflammation even in the absence of weight loss<sup>19</sup> via antioxidant and anti-inflammatory properties by neutralising free radicals and associated cell damage, as well as improved lipid profiles<sup>15 16 20</sup>. Due to their focus on real foods and consumption to satiety, anti-inflammatory diets are likely more sustainable than traditional calorie-restrictive approaches<sup>16</sup>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

104 Anti-inflammatory diets have garnered much interest in recent years due to their  
105 effectiveness in alleviating symptoms and improving biomarkers for a variety of chronic  
106 diseases, including diabetes<sup>17</sup>, cardiovascular disease<sup>21</sup>, epilepsy<sup>22</sup> and rheumatoid arthritis<sup>23</sup>.  
107 Small studies investigating anti-inflammatory diets for knee OA have demonstrated feasibility  
108 and effectiveness in reducing symptoms and inflammation over 12-16 weeks<sup>14 24 25</sup>. To date,  
109 no fully powered randomised controlled trial (RCT) has evaluated the effectiveness of an anti-  
110 inflammatory diet in knee OA.  
111  
112 The primary aim of this RCT is to estimate the average effect of an anti-inflammatory dietary  
113 program compared to a standard care low-fat dietary program on knee-related pain, function  
114 and quality of life in individuals with knee OA. We hypothesise that the anti-inflammatory  
115 dietary program will result in greater improvements in knee-related pain, function and quality  
116 of life after 12 weeks (primary endpoint) and 6 months (secondary endpoint) compared to  
117 the standard care low-fat dietary program. Secondary aims are to assess 12-week and 6-  
118 month effectiveness of the anti-inflammatory dietary program on: i) self-reported global  
119 rating of change and achievement of acceptable symptoms; ii) health-related quality of life;  
120 iii) body mass and composition using dual-energy X-ray absorptiometry (DXA); iv)  
121 inflammatory and metabolic blood biomarkers, global lower-limb function and physical  
122 activity.  
123  
**METHODS AND ANALYSIS**  
**Study Design**  
This protocol describes a pragmatic, 2-arm, parallel-group assessor-blinded superiority RCT  
conforming to the Standard Protocol Items: Recommendations for Interventional Trials  
(SPIRIT) statement<sup>26</sup>. Reporting of the completed RCT will conform to the Consolidated  
Standards of Reporting Trials (CONSORT) statement<sup>27</sup>. The FEAST trial will be conducted at a  
single site (La Trobe University) in Melbourne, Australia with enrolment anticipated to occur  
over 24 months (2022-2024) and 6-month follow-up completed in 2024. The primary  
endpoint will be at 12 weeks, with additional follow-up at 6 months (further longer-term  
follow-up dependent on funding). The study was prospectively registered on the Australian  
and New Zealand Clinical Trial Registry (ACTRN 12622000440729).

## Participants

One hundred and forty adults 45-85 years old with chronic knee pain consistent with a clinical OA diagnosis using criteria from the National Institute for Health and Care Excellence, which does not require radiographic evidence<sup>28</sup>, will be enrolled (table 1).

**Table 1.** Eligibility criteria

Inclusion criteria	Exclusion criteria
Fulfil National Institute for Health and Care Excellence <sup>28</sup> clinical criteria for osteoarthritis: <ul style="list-style-type: none"> <li>• Activity-related joint pain with average knee pain severity <math>\geq 4</math> on 11-point numeric rating scale (NRS, where 0 = no pain, 10 = worst pain possible) in the past week;</li> <li>• No morning stiffness or morning stiffness <math>\leq 30</math> min; and</li> <li>• Age <math>\geq 45</math> years</li> </ul>	Knee injection, injury or surgery in the past 3 months
Age $\leq 85$ years – due to potential safety reasons and additional co-morbidities	Had all eligible knee joints replaced by arthroplasty
History of knee pain on most days for at least 3 months	Planning to have knee surgery in next six months
Be willing and able to attend 3-4 phone consults and 12-week and 6-month follow-up assessments	Already strictly following an anti-inflammatory diet (e.g., low carbohydrate, high-fat, paleo, Mediterranean) or strict exclusion diet (e.g., vegan)
Able to understand written and spoken English, and to give informed consent	Unable to follow anti-inflammatory diet (e.g., medically contraindicated, history of food allergy/hypersensitivity, family reasons)
	Taking the following medication that affects blood sugar levels: insulin, SGLT 2 inhibitors, sulfonylureas
	Contraindications for DXA scans (e.g., pregnant, breastfeeding, planning pregnancy in next 6 months, $>200$ kg body weight)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	>5kg weight fluctuation in past 3 months (i.e., unstable weight)
	Dietary intervention (by a qualified dietitian) in past 3 months
	A diagnosed psychiatric disorder (excluding anxiety and depression), eating disorder or past bariatric surgery

143 NRS, numeric rating scale; SGLT, sodium glucose co-transporter; DXA, dual-energy X-ray  
144 absorptiometry

145  
146 **Recruitment and screening procedure**

147 Trial flow is outlined in figure 1. Participants will be recruited from our network of  
148 collaborating orthopaedic surgeons in Victoria, Australia. Consistent with our prior work in  
149 other musculoskeletal conditions<sup>29 30</sup>, potentially eligible participants (i.e., individuals aged  
150 45-85 years with a history of knee pain for which medical care was sought) will be sent a study  
151 information letter inviting them to contact the research team. Additional recruitment  
152 strategies will include advertisements in local newspapers, community/university  
153 magazines/posters, community market stalls and social media.

154  
155 **\*\*\*FIGURE ONE HERE\*\*\***  
156

157 Potential participants will be screened for eligibility via telephone. Once eligibility is  
158 confirmed, participants will attend a study orientation session via videoconference to explain  
159 further study details (e.g., fasting requirements) and be orientated to the dietary assessment  
160 tool (3-day food diary). If both knees meet the inclusion criteria, the most symptomatic knee  
161 will be considered as the index knee.

162  
163 *Randomisation procedure, concealment of allocation and blinding*

164 Upon completion of baseline assessment, participants will be randomised to either the anti-  
165 inflammatory dietary program or standard care low-fat dietary program. Study treatments,  
166 but not study hypotheses, will be revealed to participants. A computer-generated  
167 randomisation schedule has been developed *a priori* by an independent statistician in random  
168 permuted blocks of 4-8 and stratified by sex and body mass index ( $\geq 30\text{kg.m}^{-2}$  vs  $<30\text{kg.m}^{-2}$ ).

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

To ensure concealed allocation, the randomisation schedule will be stored electronically in the secure Research Electronic Data Capture (REDCap®) system and only accessible to an unblinded researcher once baseline measures have been obtained, who will communicate treatment allocation to the participant. Investigators conducting the follow-up assessments will be blinded to group allocation. As the primary outcome is self-reported, participants are considered assessors; therefore, participants (and thus assessors) will be blinded to previous scores. Health professionals delivering the interventions and participants cannot be blinded to group allocation owing to the type of interventions. An independent statistician, blinded to group allocation, will perform the primary RCT analysis.

## Interventions

The anti-inflammatory dietary program and standard care low-fat dietary program are summarised aligning to Template for Intervention Description and Replication (TIDieR) guidelines<sup>31</sup> (table 2). The same health professionals will deliver the intervention for both groups.

### *Anti-inflammatory dietary program*

Participants allocated to the anti-inflammatory dietary program will receive specific anti-inflammatory dietary education and an individualised eating plan, as well as a suite of resources to support behaviour change. The anti-inflammatory dietary program will be delivered over 12 weeks by a qualified dietitian or by another health professional specially trained to deliver the intervention (e.g., physiotherapist).

Participants will be encouraged to follow a diet containing minimal processed foods and high amounts of healthy fats and nutrient-dense wholefoods known to fight inflammation (e.g., fresh fruits low in natural sugar such as berries, non-starchy vegetables, nuts and seeds, seafood, poultry, red meat, eggs, full-fat dairy). Healthy fats include monounsaturated and polyunsaturated fats with optimal omega-3: omega-6 ratios as found in seafood, nuts, and extra-virgin olive oil. Participants will be advised to limit processed foods, refined carbohydrates (e.g., pasta, bread, rice), confectionary and foods with added sugar.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

199 Participants will be encouraged to consume a normocaloric diet and to eat to satiety, with no  
200 specific percentage of total energy intake targets for carbohydrate, fat or protein.

201  
202 An initial in-person consultation (~45 minutes) will occur immediately following group  
203 allocation to constructively review participant’s current dietary intake (using baseline 3-day  
204 food diary) and develop an individualised meal plan. Participants will be provided with a  
205 comprehensive explanation of anti-inflammatory dietary principles, its rationale (e.g., the role  
206 of inflammation in OA, link between foods and inflammation) and its potential benefits and  
207 side-effects, and address questions and/or concerns. The following educational and  
208 behaviour change resources will also be provided at the initial consultation to support  
209 adherence: i) bespoke information booklet providing anti-inflammatory eating information,  
210 example meal plans, and foods that are encouraged and foods to avoid; ii) complimentary  
211 subscription to an anti-inflammatory program (Defeat Diabetes phone app/website),  
212 providing anti-inflammatory recipes, masterclasses, meal plans and educational articles; iii)  
213 complimentary links to recommended documentaries exploring the benefits of anti-  
214 inflammatory nutrition (i.e., Fat Fiction, Cereal Killers, That Sugar Film); and iv) complimentary  
215 copy of a book exploring benefits of anti-inflammatory approach (A Fat Lot of Good<sup>32</sup>).

216  
217 Follow-up phone/videoconference consultations (~30 minutes) will be scheduled in weeks 2,  
218 4, 6, and 9, with timing to be negotiated between each participant and the health professional  
219 delivering the intervention. A final in-person consultation will be delivered immediately  
220 following the completion of the 12-week assessment. These follow-up consultations will  
221 provide participants with ongoing support, education and accountability. A 3-day food diary,  
222 completed prior to each consultation (see outcomes/adherence section), will guide  
223 individualised feedback and support to adapt meal plans to optimise adherence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
ErasmusHogeschool

224 **Table 2:** Overview of intervention delivery described according to the TiDieR guidelines

1. BRIEF NAME	Anti-inflammatory dietary program	Standard care low-fat dietary program
2. WHY	Anti-inflammatory diets targeting systemic inflammation assist in the prevention and management of various chronic diseases <sup>15</sup> . Small pilot studies have shown a positive effect of anti-inflammatory diets to improve knee-related symptoms in people with knee osteoarthritis <sup>25</sup> .	Healthy eating guidelines and dietary advice described in the standard care program booklet was based on Australian Dietary Guidelines (ADGs) <sup>33,34</sup> .  Two-to-three dietetic consultations represent usual care for patients referred for dietary management in Australia <sup>18,19</sup> .
3. WHAT (MATERIALS)	Participants receive an intervention handbook containing all study details, key anti-inflammatory eating principles, example meal plans, traffic light system of foods encouraged and discouraged, and education (e.g., common myths, tips for eating out, shopping tips); complimentary access to the Defeat Diabetes program app/website; complimentary links to three movies; and a complimentary copy of the book "A Fat Lot of Good" <sup>32</sup>	Participants receive an educational handbook emphasising ADGs healthy eating principles and are provided links to the online resources from the Eat for Health website ( <a href="https://www.eatforhealth.gov.au/">https://www.eatforhealth.gov.au/</a> ).
4. WHAT (PROCEDURES)	Six consultations providing individualised guidance and support to follow an anti-inflammatory eating pattern, emphasising the consumption of fruits, non-starchy vegetables, fish, poultry, red meat, eggs, full-fat dairy, nuts, seeds, and extra virgin olive oil. Participants will be encouraged to avoid highly processed foods, refined carbohydrates, added sugar, and processed meats.	Three consultations providing general advice and education regarding healthy eating based on the ADGs. The principles focus on consumption of foods from the five food groups, while limiting intake of foods containing saturated fat, added salt, added sugars and alcohol.
5. WHO PROVIDED	A qualified dietitian or health professional specially trained to deliver all components.	A qualified dietitian or health professional specially trained to deliver all components.
6. HOW	Delivered with individual support for 12 weeks, after which, participants will be encouraged to sustain the anti-inflammatory diet unsupported up to 6 months. Consultations are one-to-one.	Delivered with standard healthy eating advice for 12 weeks, after which, participants will be encouraged to sustain the program unsupported up to 6 months. Consultations are one-to-one.
7. WHERE	In-person consultations will occur at La Trobe University Nutrition and Dietetics research laboratory. Additional	In-person consultations will occur at the La Trobe University Nutrition and Dietetics research

	consultations will occur via telephone/videoconference (e.g., Zoom). Participants will integrate the diet principles into their daily consumption of foods and beverages.	laboratory. Additional consultations will occur via telephone/videoconference (e.g., Zoom). Participants will integrate the diet principles into their daily consumption of foods and beverages.
8. WHEN AND HOW MUCH	Two in-person consultations at baseline (~45 mins) and week 12 (~30 mins) Four phone/videoconference follow-up consultations (~30 mins) in week 2, 4, 6, and 9. <b>Total active intervention delivery time:</b> ~3.5 hours  Participants are provided with self-management resources to optimise adherence to the anti-inflammatory diet up to the 6-month follow-up.	Two in-person consultations at baseline (~45 mins) and week 12 (~30 mins) One phone/videoconference follow-up consultation (~30 mins) in week 6. <b>Total active control delivery time:</b> ~1.5 hours  Participants encouraged to sustain their diet up to 6-month follow-up.
9. TAILORING	Individualised anti-inflammatory dietary advice, education, and support aligning with participant preferences and goals.	Advice based on the ADGs.
10. MODIFICATIONS	Any modifications will be reported.	
11. HOW WELL (planned)	Two-three professionals (qualified dietitian and other health professional) receive prior training in how to deliver and supervise the program. Fidelity is assessed through regular auditing. Participant adherence to the anti-inflammatory diet is assessed through consultation attendance, regular 3-day food diaries and self-report.	Two-three professionals (qualified dietitian and health professional) receive prior training in how to deliver and supervise the program. Fidelity assessed through auditing. Participant adherence to the standard care low-fat diet is assessed through consultation attendance, regular 3-day food diaries and self-report.
12. HOW WELL (actual)	This will be reported in the primary paper	

TIDieR, Template for Intervention Description and Replication; ADG, Australian Dietary Guidelines

## 226 *Standard care low-fat dietary program*

227 Participants allocated to the standard care low-fat dietary program will receive advice and  
228 education regarding healthy eating based on the Australian Dietary Guidelines<sup>35</sup>. These  
229 government-endorsed guidelines aim to optimise nutrition intake through adequate  
230 consumption of foods from the five core food groups (grains and cereals; fruit; vegetables and  
231 legumes; lean meats and poultry, fish, eggs, and tofu; reduced fat dairy or alternatives), while  
232 limiting intake of foods containing saturated fat, added salt, added sugars and alcohol. They are  
233 high-carbohydrate and low-fat focused – participants will be encouraged to include at least four  
234 serves of wholegrains daily (e.g., brown rice, pasta, bread, quinoa, oats) and to choose low-fat  
235 protein and dairy foods where possible.

237 The program will be delivered through individual consultations with the treating dietitian or other  
238 specially trained health professional – the first in-person consultation immediately following  
239 baseline assessment (~45 minutes), the second via phone/videoconference at 6 weeks (~30  
240 minutes) and the third in-person at 12-week follow-up with timing individualised as required.  
241 Two to three consultations represents usual care for patients referred for dietary management  
242 in Australia through the current public healthcare (Medicare) rebate system<sup>34 36</sup>. During the initial  
243 in-person consultation, participants will be provided with a bespoke educational booklet and  
244 advice and education emphasising the Australian Dietary Guideline principles  
245 (<https://www.eatforhealth.gov.au/guidelines>) and informed of complementary and publicly  
246 available online resources from the Eat for Health website (<https://www.eatforhealth.gov.au/>).

248 The follow-up phone/videoconference consultation in week-6 and in-person follow-up in week-  
249 12 will provide participants with ongoing support, education and accountability. The 3-day food  
250 diary, completed prior to each consultation (see outcomes/adherence section), will guide  
251 feedback and support to adapt meal plans to optimise adherence. The treating health  
252 professionals delivering the two dietary programs will be based centrally at La Trobe University  
253 and will be trained by the senior study dietitian (BLD) until deemed competent in intervention  
254 delivery.

1  
2 256 Irrespective of group allocation, participants can continue usual medical care and consult with  
3  
4 257 their treating health professionals as necessary (e.g., general practitioner regarding medication  
5  
6 258 changes).

7 259  
8  
9 260 **Data collection procedure**

10  
11 261 Data will be collected at baseline and 6 weeks, 12 weeks and 6 months after randomisation, with  
12  
13 262 12 weeks the *a priori* primary endpoint as this coincides with completion of supported  
14  
15 263 interventions (table 3). Where possible, data will be collected and managed using a secure web-  
16  
17 264 based software platform (REDCap®) hosted at La Trobe University<sup>37</sup>, which has equivalent  
18  
19 265 measurement properties to paper-based completion<sup>38</sup>. This strategy was used in our pilot study<sup>25</sup>  
20  
21 266 and other trials of musculoskeletal conditions<sup>39</sup>. Paper versions will also be available if preferred.  
22 267

23  
24  
25 268 **OUTCOMES**

26  
27 269 **Baseline characteristics**

28  
29 270 Participant characteristics including age, sex, ethnicity, knee pain/surgery details, socioeconomic  
30  
31 271 details (e.g., education level, employment status, living status), medical history and health  
32  
33 272 literacy (assessed with the Rapid Estimate of Adult Literacy in Medicine (REALM)<sup>40</sup>) will be  
34  
35 273 collected (table 3).

36 274  
37  
38 275 **Primary Outcome**

39  
40 276 The primary outcome is the change from baseline to 12 weeks in the mean score on four Knee  
41  
42 277 injury and Osteoarthritis Outcome Score (KOOS<sub>4</sub>) subscales covering knee pain, symptoms,  
43  
44 278 function in daily activities and knee-related quality of life. The KOOS is a 42-item patient-reported  
45  
46 279 outcome measure assessing five separately scored subscales: Pain, Symptoms, Function in Sport  
47  
48 280 and Recreation (Sport/Rec), Activities of Daily Living (ADL), and Quality of Life. The KOOS<sub>4</sub> and all  
49  
50 281 KOOS subscale scores range from 0 (extreme problems) to 100 (no problems). The KOOS is a  
51  
52 282 valid, responsive and reliable questionnaire, with KOOS<sub>4</sub> a primary outcome for other knee OA  
53  
54 283 trials<sup>30 41 42</sup>.

54 284  
55  
56 285  
57  
58 286  
59  
60 287  
288



Table 3. Overview of data collection

Variable	Baseline	6 weeks	12 weeks	6 months
<b>Participant characteristics</b>				
Age	X			
Sex	X			
Ethnicity	X			
Education level	X			
Health literacy (REALM)	X			
Employment status	X			
Smoking status	X			
Civil status, living situation	X			
Medical history, comorbidities	X			
Knee pain/injury/surgery history	X			
<b>Objective Clinical Outcomes</b>				
Height, weight, waist girth	X		X	X
30-second chair stand test	X		X	X
40 metre walk test	X		X	X
Body composition (DXA)	X		X	X
Blood inflammatory and metabolic biomarkers	X		X	X
Blood pressure	X		X	X
<b>Patient-reported Outcomes</b>				
KOOS subscales	X	X	X	X
Global rating of change		X	X	X
Desire for knee surgery	X	X	X	X
Medication use	X	X	X	X
Knee pain (current and worst in past week)	X	X	X	X
EQ-5D-5L	X	X	X	X
Patient acceptable symptom state	X	X	X	X
Brief Pain Inventory	X		X	X
International Physical Activity Questionnaire	X		X	X
Kessler Psychological Distress Scale (K10)	X		X	X
3-day Food Diaries*	X	X	X	X
Adverse events		X	X	X

REALM, Rapid Estimate of Adult Literacy in Medicine; KOOS, Knee injury and Osteoarthritis Outcome Score; DXA, Dual-Energy X-ray absorptiometry

\*3-day food diaries are also assessed prior to anti-inflammatory dietary program consultations at 2, 4 and 9 weeks



1  
2 294  
3  
4 295 **Secondary effectiveness outcomes**  
5  
6 296 *KOOS subscales*  
7  
8 297 To allow for clinical in-depth interpretation, scores for the five KOOS subscales will be reported  
9  
10 298 individually (i.e., pain, symptoms, function in sports and recreational activities, activities of daily  
11  
12 299 living, quality of life)<sup>9 42</sup>.

13 300  
14  
15  
16 301 *Global Rating of Change (GROC) and patient-acceptable state*  
17  
18 302 Self-perceived change in pain and function will be assessed using a 7-point Likert scale ranging  
19  
20 303 from ‘much worse’ to ‘much better’ in response to the questions: “Overall, how has your knee  
21  
22 304 pain changed since the start of the study?” and “Overall, how has your knee function changed  
23  
24 305 since the start of the study?”, respectively. Treatment success will be defined as a response of  
25  
26 306 either ‘better’ or ‘much better’. Satisfaction with current knee function using the self-reported  
27  
28 307 Patient Acceptable Symptom State (PASS) question<sup>43</sup>. Participants not satisfied with current knee  
29  
30 308 function at follow-up assessments will be asked a second question to determine if they  
31  
32 309 considered the treatment to have failed<sup>43</sup>.

33 310  
34  
35 311 *Anthropometrics*  
36  
37 312 Height and weight will be assessed using a seca 217 stadiometer and seca 703 EMR-validated  
38  
39 313 column scale (Hammer Steindamm, Hamburg, Germany), respectively. Waist circumference will  
40  
41 314 be measured using a metal tape measure (Lufkin W606PM ¼ inch x 2m Executive Thinline Pocket  
42  
43 315 Tape).

44 316  
45  
46  
47 317 *Global lower-limb function*  
48  
49 318 Two performance-based tests of lower-limb function recommended by the OA Research Society  
50  
51 319 International (OARSI) will be conducted: the 30-second chair-stand test (number of chair-stands  
52  
53 320 from a standardised height chair in 20 seconds) and 40-metre walk test (time to walk 40 metres  
54  
55 321 safely, using walking aids if required)<sup>44</sup>.

56 322  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

### *Body composition*

A whole-body DXA scan will be acquired using a Hologic Horizon® DXA scanner (Bedford, MA, United States) to assess adiposity (visceral, peripheral) and lean mass<sup>45</sup>.

### *Inflammatory and metabolic biomarkers*

An array of blood inflammatory and metabolic biomarkers will be analysed from samples of blood collected, including high sensitivity C-Reactive Protein (hsCRP), cytokines (IL-1 $\beta$ , IL-6, IL-8, IL-10, TNF- $\alpha$ ), blood glucose, HbA1c, serum insulin, liver function tests (including albumin), and lipids (e.g., high density lipoprotein, triglycerides). Participants will be instructed to fast for at least 10 hours prior to blood collection and a single forearm venepuncture will take place to collect a total of  $\leq 30$  mL blood. All samples will be centrifuged (3000ms, 10 minutes), and plasma and serum frozen (-80°C) for later analysis (Supplementary File 2).

### **Secondary safety outcomes**

#### *Adverse events*

Adverse events and serious adverse events will be recorded at 6-week, 12-week and 6-month follow-up via open probe questioning to optimise collection of sufficient detail. Under the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) harms statement, an adverse event is defined as any undesirable experience causing participants to seek medical treatment (e.g., general practitioner)<sup>46</sup>. A serious adverse event is defined as any undesirable event/illness/injury classified as having the potential to significantly compromise clinical outcome or result in significant disability or incapacity, those requiring inpatient or outpatient hospital care, to be life-threatening or result in death.

### **Exploratory outcomes**

#### *Dietary Analysis*

Participants will record food and beverage intake over three days via the smartphone application *Australia Calorie Counter - Easy Diet Diary* (Xyris Software Pty Ltd) or on paper (personal preference). Easy Diet Diary is a commercial calorie counter and food diary that allows users to email recorded diaries to treating professionals. Once received by the treating health professional, the 3-day food diaries will be imported into, and analysed using, Foodworks®

1  
2 354 Premium Edition nutrient analysis software (Version 10, Brisbane, Australia 2019) and Australian  
3  
4 355 food composition databases. Paper-based 3-day food diaries will be manually entered into  
5  
6 356 FoodWorks®. Total energy intake, macronutrients, micronutrients and core food group analysis  
7  
8 357 will be reported. Dietary analysis data will also be used to calculate the inflammatory potential  
9  
10 358 of participants' diets (e.g., Dietary Inflammatory Index)<sup>47</sup>.

11 359  
12  
13 360 *Quality of life*

15 361 Health-related quality of life will be assessed with the EQ-5D-5L generic health index, which  
16  
17 362 comprises five dimensions of health (mobility, self-care, usual activities, pain or discomfort,  
18  
19 363 anxiety or depression) and a Visual Analogue Scale (VAS) of current overall health status<sup>48</sup>. Both  
20  
21 364 validity and reliability has been demonstrated in arthritic populations<sup>49</sup>.

22 365  
23  
24  
25 366 *Knee pain and interference*

27 367 Self-reported knee pain (current, worst over past week, average over past week) will be assessed  
28  
29 368 using a 100mm VAS (0=no pain, 100=worst pain imaginable). The degree to which knee pain  
30  
31 369 interferes with participant's daily functioning will be assessed using the Brief Pain Inventory<sup>50</sup>, a  
32  
33 370 tool with reliability and validity demonstrated in knee pain populations<sup>51 52</sup>.

34 371  
35  
36  
37 372 *Change in analgesic medication use*

39 373 Change in analgesic medication use from baseline to 12-week and 6-month follow-up will be  
40  
41 374 assessed with a 7-point Likert scale (much less to much more).

42 375  
43  
44  
45 376 *Physical activity*

47 377 Physical activity will be assessed using the International Physical Activity Questionnaire (IPAQ)<sup>53</sup>,  
48  
49 378 a standardised and valid questionnaire providing an estimate of physical activity and sedentary  
50  
51 379 behaviour, which has been widely validated<sup>53 54 55</sup>. Respondents are asked to report time spent  
52  
53 380 in physical activity across three intensities (walking, moderate, vigorous). Using the IPAQ scoring  
54  
55 381 protocol<sup>56</sup>, total weekly physical activity can be estimated by weighting time spent in each activity  
56  
57 382 intensity with its estimated metabolic equivalent (MET) energy expenditure<sup>57</sup>.

58 383  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

### 384 *Blood pressure*

385 A pair of seated blood pressure measurements will be obtained using an automated monitor  
386 (Omron Model HEM-7121). The blood pressure cuff is placed over the mid-upper arm with the  
387 participant seated.

### 389 *Self-perceived wellness*

390 Self-reported sleep quality, hunger, fatigue and energy levels will be assessed using a 100mm  
391 VAS (0=worst outcome, 100=best outcome).

### 393 *Intervention adherence*

394 In both randomised groups, intervention adherence will be collected via: i) secure online app  
395 (e.g., Foodworks® 3-day food diary) and/or self-reported paper logbooks as preferred, completed  
396 in the week prior to each consultation and follow-up assessment; and ii) overall adherence rating  
397 (e.g., 5-point Likert scale) at each follow-up assessment.

## 399 **DATA MANAGEMENT**

400 Most outcome data will be collected and managed electronically via REDCap© web-based  
401 software hosted at La Trobe University. Other data (e.g., DXA reports) will be stored electronically  
402 on the La Trobe University secure research drive. All electronic data will be de-identified  
403 (participant code) and exported for data analysis and saved in a password protected database on  
404 the La Trobe University research drive only accessible to the research team. Paper-based  
405 identifying documents (e.g., consent forms) will be securely stored in a locked filing cabinet  
406 accessible only to members of the research team and separately from re-identifiable (i.e., coded)  
407 data.

409 Due to the minimal known risks associated with the interventions being evaluated, our study will  
410 not have a formal data monitoring committee and does not require an interim analysis. Any  
411 unexpected serious adverse events or outcomes will be discussed by the trial management  
412 committee (authors of this protocol) and reported to the approving human research ethics  
413 committee for monitoring.

414

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
448

**Sample size calculation**

This trial has been powered to detect a clinically significant between-group difference for the primary outcome of KOOS<sub>4</sub>. The estimated effect size for low-inflammatory diets on self-reported pain and function in individuals with arthritis is at least moderate (Cohen’s d 0.62)<sup>58</sup>. Recruiting 112 participants (equally distributed between two arms) would yield 90% power to observe such an effect or larger at a two-tailed Type I error of 0.05. This sample size estimation is conservative since it is based on independent samples t-test. Using an ANCOVA model that includes the baseline value as a covariate and is pre-specified for the analysis should provide higher power for the same sample size. To account for a potential 20% drop-out, we will recruit 140 participants. This sample size will be sufficient to detect a minimal important change (MIC) in KOOS<sub>4</sub> estimated at 10 points in patients with knee OA (with a common between-subject standard deviation of 15). Including 140 participants will also provide ≥90% power to detect a statistically significant between-group difference (two-tailed α=0.05) on the secondary outcome of inflammatory biomarkers (anticipated effect size: Cohen’s d 2.33 for hsCRP/IL-6)<sup>58</sup>.

**Statistical analyses**

Analysis will be performed according to the Estimands Framework<sup>59</sup> with a statistical analyst blinded to group allocation. All outcomes and analyses are prospectively categorised as primary, secondary or exploratory. For the primary hypothesis, a linear model with baseline value, sex and BMI (≥30 vs <30kg.m<sup>-2</sup>) as covariates and treatment condition as a fixed factor will evaluate the treatment effect on KOOS<sub>4</sub> at 12 weeks. A linear mixed model utilising repeated measures at all time-points for secondary hypotheses will allow non-biased estimates of treatment effect in the presence of any potential missing cases, providing data are missing at random. A sensitivity analysis using pattern-mixture model to investigate the deviation from the missingness-at-random assumption will be carried out<sup>60</sup>. For secondary binary outcomes (e.g., treatment success), mixed-effect logistic regression models will be used to assess the effect of treatment. A subsequent analysis of participants classified as adherent to the protocol will be performed.

**Healthcare resource use**

Healthcare resource utilisation (e.g., hospitalisations, medical imaging, healthcare visits, medication use) will be assessed by participant self-report to estimate costs associated with the trial programs (e.g., hospital admissions, medication use, clinician visits, imaging tests, out-of-pocket expenses).

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

## Process Evaluation

Semi-structured interviews will be conducted on a subset of consenting participants (until data saturation reached) at 6 months. Interviews will explore experiences, knowledge and understanding of interventions received including potential benefits; acceptability and perceived effectiveness of the intervention; and reasons for adhering (or not) to the allocated diet. Purposive sampling will be used to recruit interview participants who will then be stratified based upon characteristics and outcomes of the trial (good outcome; poor outcome). Interviews will be audio recorded, transcribed and analysed using Framework Analysis<sup>61</sup>. Data will be coded and an inductive thematic analysis will be applied until no new themes emerge.

## *Patient and public involvement*

Participants and clinicians co-designed the anti-inflammatory intervention, research questions and study methods. This input was gained from: i) qualitative interviews with participants from the pilot study as part of formal process evaluation strategies<sup>25</sup>; ii) participant and clinician focus groups providing feedback on study recruitment material and participant handbooks; and iii) discussion with experienced clinicians managing knee OA and dietary intervention strategies as part of FEAST development. Patients and clinicians will provide input into the dissemination of study results by assisting with the decision on what information to share and in what format.

## ETHICS AND DISSEMINATION

This study complies with the Declaration of Helsinki and has received approval from La Trobe University Human Ethics Committee (HEC-22044). Written informed consent will be obtained from participants prior to enrolment (Supplementary File 1). Anti-inflammatory diets are associated with minimal and transient adverse events, thus there are minimal safety considerations associated with this trial.

Study outcomes will be widely disseminated through a variety of sources. Results will be reported in peer-reviewed publications and presented at key national and international conferences. Only aggregate data will be reported. A lay summary report will be available for study participants. Any important protocol amendments will be reported to the approving ethics committee, registered at ANZCTR and communicated in the primary RCT paper. Any serious adverse events will be recorded and reported to the approving ethics committee.

1  
2 482 **DISCUSSION**

3  
4 483 The current RCT will be the first full-scale trial to evaluate the symptomatic, inflammatory,  
5 484 functional and body composition benefits of an anti-inflammatory dietary program compared to  
6  
7 485 a standard care low-fat dietary program based on Australian Dietary Guidelines. While outcome  
8  
9 486 assessors are blinded to group allocation, owing to the type of interventions (i.e., dietary advice)  
10  
11 487 blinding of participants will not be possible.  
12

13 488  
14  
15 489 The evaluation of a non-pharmacological anti-inflammatory dietary program to improve pain,  
16  
17 490 symptoms, and quality of life for individuals with OA could have important individual and socio-  
18  
19 491 economic benefits – decreased healthcare dollars spent on managing OA and reduced surgery  
20  
21 492 waiting lists. Another benefit is that anti-inflammatory diets are also effective at combating  
22  
23 493 metabolic syndrome, a key risk factor for chronic diseases, and thus the benefits from treating  
24  
25 494 OA could stretch further to improving other medical co-morbidities<sup>62</sup>. This fully-powered RCT  
26  
27 495 represents a crucial step towards the development of a sustainable and cost-effective therapy  
28  
29 496 that can both supplement and complement existing treatment strategies to optimise OA  
30  
31 497 outcomes.  
32

33 498  
34 499  
35 500 **AUTHOR CONTRIBUTIONS**

36 501 AGC, BLD, PB and JLK conceived the study and obtained funding. AGC, BLD, PB, and JLK designed  
37  
38 502 the study protocol with input from LL, JJH and ABM. ADL provided statistical expertise and will  
39  
40 503 conduct primary statistical analysis. MDH provided blood analysis expertise and will lead  
41  
42 504 inflammatory and metabolic marker analyses. HGM and NPW assisted with participant  
43  
44 505 recruitment from their clinical population with knee osteoarthritis. LL drafted the manuscript  
45  
46 506 with input from AGC, JJH, BLD, PB, JLK, AA, MDH, ADL, ABM, HGM and NPW. All authors and read  
47  
48 507 and approved the final manuscript.  
49

50 508  
51 509 **FUNDING**

52 510 This trial is supported by the National Health and Medical Research Council (NHMRC) of Australia  
53  
54 511 through an Investigator Grant held by AGC (GNT2008523), an Investigator Grant held by JLK  
55  
56 512 (APP2017844), and a philanthropic donation from PB.  
57

58 513  
59  
60 514 **COMPETING INTERESTS STATEMENT**

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool



PB is the founder of Defeat Diabetes and author of "A Fat Lot of Good". PB contributed to study design but has no role in study execution, data management, analysis or the decision to publish. The NHMRC has no role in study design and will not have any role in its execution, data management, analysis and interpretation or on the decision to submit the results for publication. JLK is an editor of the British Journal of Sports Medicine (British Medical Journal Group). AGC is an associate editor of British Journal of Sports Medicine (British Medical Journal Group). All other authors have no competing interests.

## ACKNOWLEDGEMENTS

We thank La Trobe University Medical Centre for assistance with blood collection, La Trobe Nutrition and Dietetics department for the use of the nutrition lab and DXA scanner, and Melbourne Pathology for providing pathology collection kits and analysis of biomarkers from blood specimens.

## FIGURE LEGENDS

**Figure 1.** Flow of participants through the trial. DXA, Dual X-ray Absorptiometry; KOOS, Knee injury and Osteoarthritis Outcome Score

\*Optional qualitative interview for process evaluation at 6 months

## SUPPLEMENTARY FILES

**Supplementary File 1.** Patient information and consent form

**Supplementary File 2.** Standard Operating Procedures for blood collection, processing and storage

## REFERENCES

1. Cui A, Li H, Wang D, et al. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. *EClinicalMedicine* 2020;29-30:100587. doi: 10.1016/j.eclinm.2020.100587 [published Online First: 2021/09/11]
2. Weng Q, Goh S-L, Wu J, et al. Comparative efficacy of exercise therapy and oral non-steroidal anti-inflammatory drugs and paracetamol for knee or hip osteoarthritis: a network meta-analysis of randomised controlled trials. *British Journal of Sports Medicine* 2023;bjsports-2022-105898. doi: 10.1136/bjsports-2022-105898
3. Ackerman I, Bohensky M, Pratt C, et al. Counting the Cost: Part 1 Healthcare costs. The current and future burden of arthritis 2016.



1  
2 550 4. Williams A, Kamper SJ, Wiggers JH, et al. Musculoskeletal conditions may increase the risk of chronic  
3 551 disease: a systematic review and meta-analysis of cohort studies. *BMC Med* 2018;16(1):167. doi:  
4 552 10.1186/s12916-018-1151-2 [published Online First: 2018/09/27]  
5 553 5. Pihl K, Roos EM, Taylor RS, et al. Associations between comorbidities and immediate and one-year  
6 554 outcomes following supervised exercise therapy and patient education - A cohort study of  
7 555 24,513 individuals with knee or hip osteoarthritis. *Osteoarthritis Cartilage* 2021;29(1):39-49. doi:  
8 556 10.1016/j.joca.2020.11.001 [published Online First: 2020/11/22]  
9 557 6. Juhl C, Christensen R, Roos EM, et al. Impact of exercise type and dose on pain and disability in knee  
10 558 osteoarthritis: a systematic review and meta-regression analysis of randomized controlled trials.  
11 559 *Arthritis Rheumatol* 2014;66(3):622-36. doi: 10.1002/art.38290 [published Online First:  
12 560 2014/02/28]  
13 561 7. Henriksen M, Hansen JB, Klokke L, et al. Comparable effects of exercise and analgesics for pain  
14 562 secondary to knee osteoarthritis: a meta-analysis of trials included in Cochrane systematic  
15 563 reviews. *J Comp Eff Res* 2016;5(4):417-31. doi: 10.2217/ce-2016-0007 [published Online First:  
16 564 2016/06/28]  
17 565 8. Barton CJ, Kemp JL, Roos EM, et al. Program evaluation of GLA:D® Australia: Physiotherapist training  
18 566 outcomes and effectiveness of implementation for people with knee osteoarthritis.  
19 567 *Osteoarthritis and Cartilage Open* 2021;3(3):100175. doi:  
20 568 <https://doi.org/10.1016/j.ocarto.2021.100175>  
21 569 9. Roos EM, Grønne DT, Skou ST, et al. Immediate outcomes following the GLA:D® program in Denmark,  
22 570 Canada and Australia. A longitudinal analysis including 28,370 patients with symptomatic knee  
23 571 or hip osteoarthritis. *Osteoarthritis Cartilage* 2021;29(4):502-06. doi: 10.1016/j.joca.2020.12.024  
24 572 [published Online First: 2021/02/10]  
25 573 10. Das SK, Gilhooly CH, Golden JK, et al. Long-term effects of 2 energy-restricted diets differing in  
26 574 glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y  
27 575 randomized controlled trial. *Am J Clin Nutr* 2007;85(4):1023-30. doi: 10.1093/ajcn/85.4.1023  
28 576 [published Online First: 2007/04/07]  
29 577 11. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. *Med Clin*  
30 578 *North Am* 2018;102(1):183-97. doi: 10.1016/j.mcna.2017.08.012 [published Online First:  
31 579 2017/11/21]  
32 580 12. Ansari MY, Ahmad N, Haqqi TM. Oxidative stress and inflammation in osteoarthritis pathogenesis:  
33 581 Role of polyphenols. *Biomed Pharmacother* 2020;129:110452. doi:  
34 582 10.1016/j.biopha.2020.110452 [published Online First: 2020/08/10]  
35 583 13. Goldring MB, Otero M. Inflammation in osteoarthritis. *Curr Opin Rheumatol* 2011;23(5):471-8. doi:  
36 584 10.1097/BOR.0b013e328349c2b1 [published Online First: 2011/07/27]  
37 585 14. Strath LJ, Jones CD, Philip George A, et al. The Effect of Low-Carbohydrate and Low-Fat Diets on Pain  
38 586 in Individuals with Knee Osteoarthritis. *Pain Med* 2020;21(1):150-60. doi: 10.1093/pm/pnz022  
39 587 [published Online First: 2019/03/14]  
40 588 15. Galbete C, Kröger J, Jannasch F, et al. Nordic diet, Mediterranean diet, and the risk of chronic  
41 589 diseases: the EPIC-Potsdam study. *BMC Medicine* 2018;16(1):99. doi: 10.1186/s12916-018-1082-  
42 590 y  
43 591 16. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomed*  
44 592 *Pharmacother* 2002;56(8):365-79. doi: 10.1016/s0753-3322(02)00253-6 [published Online First:  
45 593 2002/11/22]  
46 594 17. Esposito K, Maiorino MI, Bellastella G, et al. A journey into a Mediterranean diet and type 2 diabetes:  
47 595 a systematic review with meta-analyses. *BMJ Open* 2015;5(8):e008222. doi: 10.1136/bmjopen-  
48 596 2015-008222  
49 597 18. Hussain T, Tan B, Yin Y, et al. Oxidative Stress and Inflammation: What Polyphenols Can Do for Us?  
50 598 *Oxid Med Cell Longev* 2016;2016:7432797. doi: 10.1155/2016/7432797 [published Online First:  
51 599 2016/10/16]  
52 600 19. Neale EP, Batterham MJ, Tapsell LC. Consumption of a healthy dietary pattern results in significant  
53 601 reductions in C-reactive protein levels in adults: a meta-analysis. *Nutr Res* 2016;36(5):391-401.  
54 602 doi: 10.1016/j.nutres.2016.02.009 [published Online First: 2016/04/23]

20. Ciaffi J, Mitselman D, Mancarella L, et al. The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review. *Frontiers in Medicine* 2021;8 doi: 10.3389/fmed.2021.792846
21. Li J, Lee DH, Hu J, et al. Dietary Inflammatory Potential and Risk of Cardiovascular Disease Among Men and Women in the U.S. *J Am Coll Cardiol* 2020;76(19):2181-93. doi: 10.1016/j.jacc.2020.09.535 [published Online First: 2020/11/07]
22. D'Andrea Meira I, Romão TT, Pires do Prado HJ, et al. Ketogenic Diet and Epilepsy: What We Know So Far. *Front Neurosci* 2019;13:5. doi: 10.3389/fnins.2019.00005 [published Online First: 2019/02/15]
23. Schönenberger KA, Schüpfer AC, Gloy VL, et al. Effect of Anti-Inflammatory Diets on Pain in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Nutrients* 2021;13(12) doi: 10.3390/nu13124221 [published Online First: 2021/12/29]
24. Dyer J, Davison G, Marcora SM, et al. Effect of a Mediterranean Type Diet on Inflammatory and Cartilage Degradation Biomarkers in Patients with Osteoarthritis. *J Nutr Health Aging* 2017;21(5):562-66. doi: 10.1007/s12603-016-0806-y [published Online First: 2017/04/28]
25. Cooper I, Brukner P, Devlin B, et al. An anti-inflammatory diet intervention for knee osteoarthritis: a feasibility study. *BMC Musculoskeletal Disorders* 2022;23 doi: 10.1186/s12891-022-05003-7
26. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ : British Medical Journal* 2013;346:e7586. doi: 10.1136/bmj.e7586
27. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c869. doi: 10.1136/bmj.c869
28. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Osteoarthritis: Care and Management in Adults. London: National Institute for Health and Care Excellence (UK)
- Copyright © National Clinical Guideline Centre, 2014. 2014.
29. Culvenor AG, Collins NJ, Guermazi A, et al. Early knee osteoarthritis is evident one year following anterior cruciate ligament reconstruction: a magnetic resonance imaging evaluation. *Arthritis Rheumatol* 2015;67(4):946-55. doi: 10.1002/art.39005 [published Online First: 2015/02/19]
30. Culvenor AG, Collins NJ, Guermazi A, et al. Early Patellofemoral Osteoarthritis Features One Year After Anterior Cruciate Ligament Reconstruction: Symptoms and Quality of Life at Three Years. *Arthritis Care Res (Hoboken)* 2016;68(6):784-92. doi: 10.1002/acr.22761 [published Online First: 2015/10/17]
31. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ : British Medical Journal* 2014;348:g1687. doi: 10.1136/bmj.g1687
32. Brukner DP. A Fat Lot of Good. 1 ed: Penguin Australia Pty Ltd 2018:368.
33. Wingrove K, Lawrence MA, Russell C, et al. Evidence Use in the Development of the Australian Dietary Guidelines: A Qualitative Study. *Nutrients* 2021;13(11):3748.
34. Cant RP. Patterns of delivery of dietetic care in private practice for patients referred under Medicare Chronic Disease Management: results of a national survey. *Aust Health Rev* 2010;34(2):197-203. doi: 10.1071/ah08724 [published Online First: 2010/05/26]
35. Health N, Council MR. Australian dietary guidelines. Canberra (Australia): National Health and Medical Research Council. 2013
36. Spencer L, O'Shea MC, Ball L, et al. Attendance, weight and waist circumference outcomes of patients with type 2 diabetes receiving Medicare-subsidised dietetic services. *Aust J Prim Health* 2014;20(3):291-7. doi: 10.1071/py13021 [published Online First: 2013/07/05]
37. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019;95:103208. doi: 10.1016/j.jbi.2019.103208 [published Online First: 2019/05/13]
38. Gudbergesen H, Bartels EM, Krusager P, et al. Test-retest of computerized health status questionnaires frequently used in the monitoring of knee osteoarthritis: a randomized crossover trial. *BMC Musculoskeletal Disorders* 2011;12(1):190. doi: 10.1186/1471-2474-12-190

1  
2 657 39. Culvenor AG, West TJ, Bruder AM, et al. SUPervised exercise-therapy and Patient Education  
3 658 Rehabilitation (SUPER) versus minimal intervention for young adults at risk of knee  
4 659 osteoarthritis after ACL reconstruction: SUPER-Knee randomised controlled trial protocol. *BMJ*  
5 660 *Open* 2023;13(1):e068279. doi: 10.1136/bmjopen-2022-068279 [published Online First:  
6 661 2023/01/20]  
7 662 40. Davis TC, Crouch MA, Long SW, et al. Rapid assessment of literacy levels of adult primary care  
8 663 patients. *Fam Med* 1991;23(6):433-5. [published Online First: 1991/08/01]  
9 664 41. Skou ST, Roos EM, Laursen MB, et al. A Randomized, Controlled Trial of Total Knee Replacement. *N*  
10 665 *Engl J Med* 2015;373(17):1597-606. doi: 10.1056/NEJMoa1505467 [published Online First:  
11 666 2015/10/22]  
12 667 42. Collins NJ, Prinsen CA, Christensen R, et al. Knee Injury and Osteoarthritis Outcome Score (KOOS):  
13 668 systematic review and meta-analysis of measurement properties. *Osteoarthritis Cartilage*  
14 669 2016;24(8):1317-29. doi: 10.1016/j.joca.2016.03.010 [published Online First: 2016/03/26]  
15 670 43. Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant states in patient reported  
16 671 outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis*  
17 672 2005;64(1):34-7. doi: 10.1136/ard.2004.023028 [published Online First: 2004/05/08]  
18 673 44. Dobson F, Hinman RS, Roos EM, et al. OARSI recommended performance-based tests to assess  
19 674 physical function in people diagnosed with hip or knee osteoarthritis. *Osteoarthritis and*  
20 675 *Cartilage* 2013;21(8):1042-52. doi: <https://doi.org/10.1016/j.joca.2013.05.002>  
21 676 45. Shepherd JA, Ng BK, Sommer MJ, et al. Body composition by DXA. *Bone* 2017;104:101-05. doi:  
22 677 10.1016/j.bone.2017.06.010 [published Online First: 2017/06/20]  
23 678 46. Zorzela L, Loke YK, Ioannidis JP, et al. PRISMA harms checklist: improving harms reporting in  
24 679 systematic reviews. *Bmj* 2016;352:i157. doi: 10.1136/bmj.i157 [published Online First:  
25 680 2016/02/03]  
26 681 47. Shivappa N, Steck SE, Hurley TG, et al. Designing and developing a literature-derived, population-  
27 682 based dietary inflammatory index. *Public Health Nutr* 2014;17(8):1689-96. doi:  
28 683 10.1017/s1368980013002115 [published Online First: 2013/08/15]  
29 684 48. Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the  
30 685 EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res* 2013;22(7):1717-27.  
31 686 doi: 10.1007/s11136-012-0322-4 [published Online First: 2012/11/28]  
32 687 49. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis:  
33 688 validity, responsiveness and reliability of EuroQol (EQ-5D). *Br J Rheumatol* 1997;36(5):551-9. doi:  
34 689 10.1093/rheumatology/36.5.551 [published Online First: 1997/05/01]  
35 690 50. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singap*  
36 691 1994;23(2):129-38. [published Online First: 1994/03/01]  
37 692 51. Mendoza T, Mayne T, Rublee D, et al. Reliability and validity of a modified Brief Pain Inventory short  
38 693 form in patients with osteoarthritis. *Eur J Pain* 2006;10(4):353-61. doi:  
39 694 10.1016/j.ejpain.2005.06.002 [published Online First: 2005/07/30]  
40 695 52. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-Clock, Controlled-Release Oxycodone Therapy  
41 696 for Osteoarthritis-Related Pain: Placebo-Controlled Trial and Long-term Evaluation. *Archives of*  
42 697 *Internal Medicine* 2000;160(6):853-60. doi: 10.1001/archinte.160.6.853  
43 698 53. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country  
44 699 reliability and validity. *Med Sci Sports Exerc* 2003;35(8):1381-95. doi:  
45 700 10.1249/01.Mss.0000078924.61453.Fb [published Online First: 2003/08/06]  
46 701 54. Maddison R, Ni Mhurchu C, Jiang Y, et al. International Physical Activity Questionnaire (IPAQ) and  
47 702 New Zealand Physical Activity Questionnaire (NZPAQ): a doubly labelled water validation. *Int J*  
48 703 *Behav Nutr Phys Act* 2007;4:62. doi: 10.1186/1479-5868-4-62 [published Online First:  
49 704 2007/12/07]  
50 705 55. Cleland C, Ferguson S, Ellis G, et al. Validity of the International Physical Activity Questionnaire  
51 706 (IPAQ) for assessing moderate-to-vigorous physical activity and sedentary behaviour of older  
52 707 adults in the United Kingdom. *BMC Medical Research Methodology* 2018;18(1):176. doi:  
53 708 10.1186/s12874-018-0642-3  
54 709 56. Guidelines for data processing analysis of the International Physical Activity Questionnaire (IPAQ) -  
55 710 Short and long forms; 2005.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
ErasmusHogeschool

57. AINSWORTH BE, HASKELL WL, WHITT MC, et al. Compendium of Physical Activities: an update of activity codes and MET intensities. *Medicine & Science in Sports & Exercise* 2000;32(9):S498-S516.
58. Genel F, Kale M, Pavlovic N, et al. Health effects of a low-inflammatory diet in adults with arthritis: a systematic review and meta-analysis. *J Nutr Sci* 2020;9:e37. doi: 10.1017/jns.2020.31 [published Online First: 2020/09/29]
59. Lynggaard H, Bell J, Lösch C, et al. Principles and recommendations for incorporating estimands into clinical study protocol templates. *Trials* 2022;23(1):685. doi: 10.1186/s13063-022-06515-2 [published Online First: 2022/08/20]
60. White IR, Kalaitzaki E, Thompson SG. Allowing for missing outcome data and incomplete uptake of randomised interventions, with application to an Internet-based alcohol trial. *Statistics in Medicine* 2011;30:3192-207.
61. Qualitative data analysis for applied policy research; 2002.
62. Peiris CL, Culvenor AG. Metabolic syndrome and osteoarthritis: implications for the management of an increasingly common phenotype. *Osteoarthritis and Cartilage* 2023;Online ahead of print





Participant Information Sheet/Consent Form  
Interventional study - Adult providing own consent

Title	Optimising outcomes for people with knee pain through food: FEAST randomised controlled trial
Short Title	The FEAST trial
Ethics Reference Number	HEC22044
Project Sponsor	La Trobe University
Coordinating Principal Investigator/ Principal Investigator	Dr Adam Culvenor (School of Allied Health, Human Services and Sport (SAHHSS), La Trobe University)
Associate Investigator(s)	Dr Brooke Devlin (School of Human Movement and Nutrition Sciences, University of Queensland) Prof. Peter Brukner (SAHHSS, La Trobe University) Ass. Prof. Joanne Kemp (SAHHSS, La Trobe University) Prof. Kay Crossley (SAHHSS, La Trobe University) Dr Andrea Mosler (SAHHSS, La Trobe University) Dr Josh Heerey (SAHHSS, La Trobe University) Ms Lynette Law (PhD student, SAHHSS, La Trobe University) Ms Amanda Attanayake (SAHHSS, La Trobe University)
Location	La Trobe University

Part 1 What does my participation involve?

1 Introduction

You are invited to take part in this research project because you have knee pain. This research project aims to assess the effectiveness of two different programs provided through advice and education by a qualified dietitian to improve your knee pain, function and quality of life.

This information sheet tells you about the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want to take part in the project. Please read this information carefully. Ask questions about anything that you don't understand or want to know more about. Before deciding whether or not to take part, you might want to talk about it with a relative, friend or your local doctor.

Your participation is voluntary

Participation in this research is completely voluntary and there will be no cost to you. If you don't wish to take part, you don't have to. If you decide you want to take part, you will be given a copy of this Participant Information Sheet and asked to sign the consent section. By signing it you are telling us that you:

- Understand what you have read
- Consent to take part in the research project
- Consent to have the tests and treatments that are described
- Consent to the use of your personal and health information as described.

You will be given a copy of this Participation Information Sheet and Consent Form to keep.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool

## 2 What is the purpose of this research?

As you may be aware, knee pain is very common and is often associated with knee osteoarthritis. Osteoarthritis is the most common form of arthritis and is a leading cause of disability in Australia. Currently, there is no cure for osteoarthritis, therefore it is important to investigate treatments that can improve the main symptoms associated with osteoarthritis: pain, swelling, stiffness and movement difficulties. We will recruit 140 adults who have knee pain.

This study is being conducted by researchers at La Trobe University and is partly funded by the National Health and Medical Research Council (NHMRC) of Australia and Dr Peter Brukner. All assessments and consultations will be at **no cost** to you.

## 3 Who can participate?

You can participate in this study if you meet all the following:

- Between 45-85 years of age and understand written and spoken English
- Activity-related knee pain on most days of the past month
- Knee pain for at least 3 months
- No morning knee stiffness, or morning stiffness that lasts less than 30mins
- Willing to complete the assigned 12-week eating program and attend all appointments (detailed below)

You are not eligible and cannot participate in this study if you meet any of the following:

- Knee pain not primarily due to osteoarthritis (e.g., fibromyalgia, referred pain)
- Bilateral knee replacement
- Already strictly following a specific diet (e.g., low-carb, paleo, Mediterranean, Vegan)
- Received treatment from a dietitian, or knee injection, in the past 3 months
- Experienced  $\geq 5$ kg weight loss in the past 3 months or body weight  $\geq 200$ kg
- Planning to have knee surgery in the next 6 months
- Pregnant or breastfeeding
- History of psychiatric or eating disorder (excluding anxiety/depression) or bariatric surgery

## 4 What does participation in this research involve?

This study will be conducted over 6 months in total (see flowchart on next page).

### ***Pre-baseline (online/phone) appointment***

You will be asked to attend a 30-minute Zoom/telephone appointment prior to your first face-to-face appointment. At this appointment, we will discuss the consent form, outline the fasting process needed to complete your blood test and DEXA scan, and answer any questions you might have. We will also explain how to complete a 3-day food diary, which will be done using a smart phone application or paper-based food diary (personal preference).

### ***Baseline (first) appointment***

This appointment will be arranged at a convenient time for you at La Trobe University, Bundoora and will take approximately 2 hours. You will be asked to not eat/drink anything or conduct any exercise in the morning of your appointment (i.e., fasting for 12-hours) for the purpose of a blood test. At the appointment, we will assess your:

- Height, weight, waist circumference and blood pressure
- Body composition measured via a Dual-energy X-ray Absorptiometry Scan (DEXA).  
This involves laying on the scanner bed for ~7 mins. The machine uses small doses ( $<1\%$  yearly dose) of radiation to assess tissue density (how much muscle and adipose tissue you have). The total effective dose of radiation has been calculated by a Medical Physicist (see risks below). Light clothing with no metal (e.g., zips, clips, underwire) should be worn (gown provided if needed). All measures will be taken by trained

researchers who hold Victorian Government radiation licenses and comply to the Code of Practice set out by the Australian Radiation Protection and Nuclear Safety Agency.

- Blood test: A trained researcher qualified to take blood will collect a small amount of blood (~25 mL, equivalent to ~4 teaspoons) from a forearm vein to assess inflammation levels.
- Questionnaires assessing your pain, activity level and quality of life and food intake
- Functional tests: i) how many times you can stand from a chair in 30 secs; and ii) how fast you can walk 40 metres.

We will provide a snack/drink as soon as you complete the DEXA and blood tests.

**Random assignment to one of two different treatments**

At the end of the first appointment at La Trobe University, you will be randomly assigned (50:50 chance, like a coin toss) to receive a program (from qualified dietitians) to either:


- i) minimise processed foods that are known to promote inflammation and optimise foods shown to reduce inflammation; or
- ii) minimise foods that are known to be high in fat content.

This means neither you nor the researchers will be able to choose which group you are assigned to. We do not know which treatment is best; to find out we need to compare the two programs. Although the two programs involve modifying some types of food that you eat, you can eat as much as you like of these foods. **You do not need to restrict the amount of food that you eat.**

Irrespective of which group you are assigned to, you will receive specific education and advice from an Accredited Practising Dietitian (APD) in a dietary consultation at the start of the study (at the end of your first appointment at La Trobe University). Your dietitian will also work with you to develop a personalised management plan to support you throughout the study. You will be asked to follow the program for 12 weeks (but you can continue for as long as you like). We will ask you to record your food intake for 3 days at up to six different times throughout the study.

### ***Support phone calls***

To support you throughout the study and answer any questions you have, we will arrange up to four follow-up consultations to be conducted over the phone/online during the 12 weeks. This phone call will take approximately 15-20 minutes. At these times, we will also ask you to complete some of the same questionnaires online (via a secure link provided by e-mail).



**Figure 1. Flowchart of study assessments**

### ***Follow-up appointments***

So that we can assess the results of the program you have been assigned, we will ask you to return for face-to-face appointments at La Trobe University at **12 weeks and 6 months after your first appointment**. These follow-up appointments will be like the first appointment where

we will do all the same tests and questionnaires. You will need to fast (not eat/drink anything) the morning of your appointment for the blood test. You will have another dietary consultation with the study dietitian who will provide support for you to continue with the program you have been assigned. You should allow about 2 hours for these appointments. To assess longer-term results, we will ask you to complete the same online questionnaires at 1 and 2 years after your first appointment. The total time commitment for participating will be approximately 6-8 hours.

There are no additional costs associated with participating in this research project. All medical care and tests (i.e., dietitian consultations, DEXA scan, blood tests) required as part of the research project will be provided free of charge. The results of the DEXA scan and blood tests will not be used to diagnose health conditions, but only to evaluate the effects of the intervention. We will provide you with your individual results when the DEXA and blood analyses are completed at the end of the study. Your travel costs to attend the assessments will be reimbursed up to \$100.

At the end of the first 12 weeks, or after 6-12 months, we may also ask if you are willing to have a separate interview with one of the study researchers (this interview is optional and you can take part in the study without needing to complete the interview). The purpose of this interview is to seek feedback on the study treatments, satisfaction with the process received and whether there are any suggestions for improvement. The interview will take approximately 30 minutes, but you can cease the interview at any time. To ensure responses are correctly interpreted, responses to questions will be audio recorded and transcribed. Audio recording transcriptions will be completed by 'Transcription Australia' on their secure, encrypted Australian-based software. Although voice in your audio recording could lead to your identification, this file will not be used during analysis. Instead, a re-identifiable transcription, which you will have the opportunity to check for accuracy, will be used for analysis. Re-identifiable means that we will use a code number and not your name on data collected to ensure your anonymity. Following the completion of analysis of this transcription, the audio file associated with your interview will be deleted. After analysis, overall findings and conclusions from all interviews will also be sent to you, to allow an opportunity to make any further comments. We will seek around 40 participants to be interviewed. It is your decision or not whether you wish to be interviewed.

## 5 What are the alternatives to participation?

You do not have to take part in this research project to receive treatment for your knee. Other options are available; these include seeing a physiotherapist or dietitian (e.g., private or public health centre). The research team will discuss these options with you before you decide to take part in this project. You can also discuss the options with your doctor, dietitian or physiotherapist.

## 6 What are the possible benefits of taking part?

We cannot guarantee or promise that you will receive any benefits from this research. However, possible benefits may include improvement of pain, function, quality of life, physical activity, and confidence in your knee. You may gain valuable insight into how to manage your food intake and specific anti-inflammatory and low-fat foods, nutrients and eating habits. The expected benefit to society is the development of a drug-free and non-invasive treatment option to help manage pain and disability associated with osteoarthritis. This will give doctors and patients alternative ways to manage knee pain, which in turn may lead to improvements in the quality of life for patients.

## 7 What are the possible risks and disadvantages of taking part?

With any medical treatment there are: (i) risks we know about; (ii) risks we don't know about; and (iii) risks we don't expect. We have listed the risks we know about below. You may have none, some or all the effects listed below, and they may be mild, moderate or severe. If you have any of these side effects, or are worried about them, talk with the study coordinator.



Possible Side Effect	How often is it likely to occur?	How severe might it be?	How long might it last?
Emotional distress due to involvement in research and completion of questionnaires	Rarely; although can occur when completing study questionnaires	Minimal	While completing the study questionnaires
Emotional distress due to diet assessment	Rarely; although can occur when assessing food intake prior to, or during, appointments	Minimal	While completing the food diary or assessment
Discomfort due to body measurements	Can occur while measurements are done by your dietitian or researcher	Minimal Mild	During appointment only
Discomfort due to blood test	Rarely; while blood is being collected	Mild	Bruising or swelling may last 1-3 days
Exposure to ionising radiation	1x 7-minute scan at initial, 12-week and 6-month appointment	Minimal	Effect too small to measure
Tiredness/change in bowel patterns with change in diet	Any change in diet can make you feel tired or have different bowel patterns	Minimal	1-2 weeks
Contraction of COVID-19	Can occur during the face-to-face assessments	Minimal Moderate	1-2 weeks

If you become upset or distressed because of your participation in the research, the study coordinator together with the qualified dietitian will assist you with appropriate support. We can also provide you information about services you can access to seek help for emotional distress.

**Risks associated with completing study questionnaires and diet assessment**

Completing questionnaires about your knee pain, function, quality of life and dietary intake may cause emotional distress. If you begin to feel upset or distressed when completing your questionnaires or dietary assessment, please let a member of the research team know. We will provide you with the appropriate support, including a document outlining services you can access to help with your emotional distress.

**Risks associated with blood test**

Having a blood sample taken may cause some discomfort or bruising. On very rare occasions, the blood vessel may swell, or blood may clot in the blood vessel, or the spot from which blood is taken could become inflamed. Some people may feel light-headed when having blood taken and may occasionally faint. Very rarely, there could be a minor infection or bleeding. A qualified person will take a very small amount of your blood (max 30mL each appointment (normal blood donation is 500mL)) using stringent infection control procedures. If you notice increased redness, swelling or other signs of infection in the days following your assessment, tell us immediately.

**Risks associated with eating low-inflammatory foods or low-fat foods**

As you adjust to the eating program you are assigned to, you may experience feelings of tiredness and/or changes in bowel habits and patterns. The researchers will assess your diet and ensure you are meeting your energy and nutrient needs throughout the study intervention. This eating program may be different than your normal diet and therefore influence your usual weekly shopping bill and expenses. As part of the consultations, you will be provided with some advice on how to follow the diet on a budget if required to ensure there is minimal financial burden.

**Exposure to ionising radiation**

If you choose to take part in this research, you will undergo three 7-minute DEXA scans (first, 12-week and 6-month assessments). DEXA scans are a non-invasive, fast and simple procedure. This research study involves exposure to a very small amount of radiation from a DEXA scan that you would not normally receive. As part of everyday living, everyone is exposed to naturally occurring background radiation and receives a dose of about 2 millisieverts (mSv) each year. The effective dose you will receive from all of these DEXA scans is approximately 0.03 mSv. At these

dose levels, no harmful effects of radiation have been demonstrated as any effect is too small to measure. The risk is believed to be minimal.

The scans we are taking are for research purposes and are not intended to be used like scans taken for a full clinical examination or to be used to help diagnose, treat or manage a particular condition. The whole-body DEXA scan may identify participants with a low bone mineral density. However, a whole body DEXA scan is not the established method for detecting low bone mineral density. Therefore, as a precaution if you are identified as having a low bone mineral density you will be encouraged to make an appointment with your General Practitioner to discuss the results.

Have you been involved in any other research studies that involve radiation? If so, please tell us. Please keep information contained within this Patient Information Sheet about your exposure to radiation in this study, including the radiation dose, for at least 5 years. You will be required to provide this dose to researchers of any future research projects involving exposure to radiation.

### **Contraction of COVID-19**

You may be at risk of contracting COVID-19 during one of the face-to-face appointments at La Trobe University. Prior to attending La Trobe University, you will be screened for signs and symptoms of COVID-19 by a member of the research team. You will also need to be fully vaccinated (or hold a valid medical exemption) to be able to attend La Trobe University for your assessments. The research team will put in place the appropriate control measures to reduce the risk of COVID 19 transmission. The risk is believed to be minimal.

## **8 What if I withdraw from this research project?**

You are under no obligation to continue with the research study. You may change your mind at any time about participating in the research. People withdraw from studies for various reasons, and you do not need to provide a reason.

You can withdraw from the study at any time by completing and signing the 'Participant Withdrawal of Consent Form'. This form is provided at the end of this document and is to be completed by you and supplied to the research team if you choose to withdraw at a later date.

If you withdraw from the study, you will be able to choose whether the study will destroy or retain the information it has collected about you. Information about you that has already been analysed (i.e., once you have been allocated to either program), may not be able to be destroyed to ensure accurate and unbiased study reporting. Personal details collected, such as your name and contact details, can be destroyed at any time upon study withdrawal.

## **9 What happens when the research project ends?**

At the completion of the research project, you may continue to use the resources provided and to follow the eating program principles if you choose to. If requested, we will provide you with your individual results including your body composition (DEXA) assessment and whole study results. We, or other researchers, may also use coded information (so that you cannot be identified) collected for this research study in future related studies. If you consent (tick the box on the consent form) to be contacted for future related research, we will store your contact details (name, address, phone number, email) on the secure La Trobe University research drive, only accessible to members of the research team, and may contact you about future related research projects.

## **Part 2 How is the research project being conducted?**

### **10 What will happen to information about me?**

By signing the consent form you agree to the relevant research staff collecting and using personal information about you for the research project. Any information obtained in connection with this research project that can identify you will remain confidential and securely stored. It will be disclosed only with your permission, or in compliance with the law.

### **Storage, retention and destruction**

The anonymity of your participation is assured with our procedure, in which a code number (not your name) will identify you. Data will be kept securely at La Trobe University in a locked filing cabinet and password protected research computer. Identifiable data will be stored for 15 years, then destroyed (electronic records deleted, paper-files shredded). Data will be strictly handled confidentially under guidelines set out by the National Health and Medical Research Council. The principal investigator (Dr Adam Culvenor) is responsible for maintaining this confidentiality.

In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you have the right to request access to your information collected and stored by the research team. You also have the right to request that any information with which you disagree be corrected.

The results of this project may be published and/or presented in a variety of forums and used by research students to obtain a research degree. In any publication, presentation or data files shared with other researchers, information will be provided in such a way that you cannot be identified, except with your permission.

## **11 Who is organising and funding the research?**

This research project is being conducted by Dr Adam Culvenor and a team of researchers. It has been funded by the NHMRC (GNT2008523) and Dr Peter Brukner. Dr Peter Brukner is also an investigator on the project and has written a book and developed an app that will be used as part of the study. He will not be involved in data collection, analysis or the decision to publish results. No member of the research team will receive a personal financial benefit from your involvement in this research project (other than their ordinary wages).

## **12 Who has reviewed the research project?**

All research in Australia involving humans is reviewed by an independent group of people called a Human Research Ethics Committee (HREC). The ethical aspects of this research project have been approved by the HREC of La Trobe University Human Ethics Committee.

This project will be carried out according to the *National Statement on Ethical Conduct in Human Research (2018)*. This statement has been developed to protect the interests of people who agree to participate in human research studies.

## **13 Further information and who to contact**

For all enquiries, you can contact the Clinical Trial Manager, during business hours:  
Dr Adam Culvenor, Senior Research Fellow in Physiotherapy, La Trobe University  
Telephone: 03 9479 5116; E-mail: a.culvenor@latrobe.edu.au

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

Reviewing HREC: La Trobe University Human Research Ethics Committee  
Complaints Contact: Senior Human Ethics Officer, Ethics and Integrity, Research Office  
Telephone: 03 9479 1443 E-mail: humanethics@latrobe.edu.au

\* Please quote the application reference number HEC22044



## Consent Form - Adult providing own consent

**Title** Optimising outcomes for people with knee pain through food: FEAST randomised controlled trial

**Short Title** The FEAST trial

**Ethics Reference Number** HEC22044

**Project Sponsor** La Trobe University

**Coordinating Principal Investigator/  
Principal Investigator** Dr Adam Culvenor (La Trobe University)

**Associate Investigator(s)** Dr Brooke Devlin (University of Queensland)  
Prof. Peter Brukner (La Trobe University)  
Ass. Prof. Joanne Kemp (La Trobe University)  
Prof. Kay Crossley (La Trobe University)  
Dr Andrea Mosler (La Trobe University)  
Dr Josh Heerey (La Trobe University)  
Ms Lynette Law (PhD student, La Trobe University)  
Ms Amanda Attanayake (SAHHSS, La Trobe University)

**Location** La Trobe University

### Consent Agreement

I have read the Participant Information Sheet and I understand the purposes, procedures and risks of the research described in the project.

I understand that data files may be shared with other researchers, and that information will be provided in such a way that I cannot be identified, except with my permission.

I have had an opportunity to ask questions and I am satisfied with the answers I have received. I freely agree to participate in this research project as described and understand that I am free to withdraw at any time during the study without affecting my future health care.

I understand that, if I decide to discontinue the study treatment, I may be asked to attend follow-up visits to allow collection of information regarding my health status. I agree that data gathered for the study may be published provided my name or other identifying information is not used.

- ☐ I wish... / ☐ do not wish... to receive results of the study
- ☐ I consent... / ☐ do not consent... to be contacted for future related research
- ☐ I consent... / ☐ do not consent... to have my interview responses audio-recorded/transcribed.
- ☐ I consent... / ☐ do not consent... to have my samples/data used in future research

I understand that I will be given a signed copy of this document to keep.

Name of Participant (please print) \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

### Declaration by Researcher<sup>†</sup>

I have given a verbal explanation of the research project, its procedures and risks and I believe that the participant has understood that explanation.

Name of Researcher<sup>†</sup> (please print) \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

<sup>†</sup> An appropriately qualified member of the research team must provide the explanation of, and information concerning, the research project.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

FEAST Project

---

Standard Operating Procedure

Blood collection, processing, handling, and storage procedures

---

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

## 1.1 Purpose

The purpose of the current SOP is to provide step-by-step instructions on the exact procedures that the research team needs to follow for conducting venous blood collection for biochemical analysis at baseline and follow-up examination.

## 1.2 General procedures for venous blood collection

Venous blood samples will be obtained from each participant for biochemical analysis following a 12-hour overnight fast, at baseline (T1), 12 weeks (T2) and 6 months (T3) (figure 1)




Figure 1: Study design

The researcher will perform venepuncture to obtain no more than 30mL of blood.

### 1.2.1 Consumables and supplies required for performing venepuncture

The consumables and supplies that will be used for performing the venepuncture in the study are the following:

- Disposable Latex gloves must be worn by the researcher and anyone else assisting with blood collection.
- Alcohol swab will be used to clean the venepuncture site.
- Winged steel needles appropriate for adults with an extension tube (a butterfly) will be used. The butterfly will have either a syringe or an evacuated tube with an adaptor. Sterile gauze pads will be used.
- Adhesive hypo allergic bandages (plasters or Band-Aids) will be applied to the puncture site to minimize the risk of infection.
- Plastic Bag for Waste will be used to dispose all of the biohazardous waste generated as well as a sharps container to dispose of all needles.

### 1.2.2 Steps in obtaining venous blood from the participant

The steps for obtaining venous blood samples from the study participants are provided below:

**Step 1:** Complete general preparation.

- Find an indoor site to encourage privacy during blood collection. The site should have a table or other piece of furniture with a flat surface where you can lay out all consumables/ supplies. An examination bed should be readily available if the respondent feels faint and needs to lie down.
- Ensure that each subject has completed a 10-hour fast.



- Wash and dry hands, put on gloves before initiating blood collection from the participant.
- Take out a clean absorbent paper sheet and spread it over a flat surface to lay out consumable and supplies.

**Step 2:** Prepare the participant for the venepuncture.

- The individual should be seated comfortably in a chair with arm extended on the slanting armrest to form a straight line from the shoulder to the wrist. The arm and elbow should be supported firmly by the armrest and should not be bent at the elbow.
- Ask each volunteer if they have a history of fainting. If so, ensure that the blood sample is only drawn whilst the subject is lying down on a bed.
- Describe to the participant exactly what will be done during the collection of the blood sample.

**Step 3:** Prepare the venepuncture site.

- Apply (tighten) tourniquet.
- Ask the participant to close his/her hand so that the veins will become more prominent and thus easier to enter. Vigorous hand exercise or "pumping" should be avoided.
- Select the vein site. Palpate and trace the path of veins several times with the index finger. If superficial veins are not readily apparent, blood can be forced into the vein by gently massaging the arm from wrist to elbow. Several sharp taps at the vein site with index and second finger will cause the vein to dilate.
- Loosen tourniquet.
- The venepuncture site must be cleansed once with an alcohol swab to prevent any chemical or microbiologic contamination of either the patient or the specimen.
- Check equipment, tube selection and thread needle (or butterfly) securely onto tube holder (barrel).
- Re-apply the tourniquet and relocated vein position and direction. A tourniquet allows the veins to fill with blood, thus making the veins more prominent and easier to enter. Do not leave the tourniquet on for longer than 1 minute otherwise it may result in either hemoconcentration or variation in blood test values.
- Remove needle cover and check bevel is orientated uppermost.

**Step 4:** Blood drawing

- Puncture the skin 3–5 mm away from the vein; this allows good access without pushing the vein away.
- If the needle enters alongside the vein rather than into it, withdraw the needle slightly without removing it completely, and angle it into the vessel.
- Insert the tube into the holder and commence filling the tubes.
- Draw blood slowly and steadily.
- Release the tourniquet as soon as blood flow is established. Tourniquet release allows the blood circulation to return to normal and also reduces bleeding at the venipuncture site.
- Remove the tube from the holder and invert (8-10 times) to mix the blood with tube additives. Place blood samples on ice if required..
- Place a cotton wool above the venepuncture site, withdraw the needle and apply pressure.
- Dispose of needle in a sharps container.
- Check site and apply an adhesive bandage.
- Label all tubes immediately.



### 1.3 Blood processing and handling

#### 1.3.1 Centrifuge procedure

Collected venous blood will be centrifuged and the extracted plasma and/or serum will be pipetted into aliquots according to the blood collection protocol.

- Set up in a well-ventilated environment, on a horizontally levelled and rigid surface with adequate load-bearing capacity.
- As safety zone maintain a clear radius of at least 30 cm around the centrifuge. Do not place any dangerous substances within this security zone.
- Open the centrifuge door by pressing the open button.
- Place the remaining tubes containing blood into appropriate sized adapters.
- Place the tubes containing water in opposite adapters, where they should mirror the placement of the tubes holding blood.
- Never place both tubes housing water and blood into the same adapters but should be placed in different adapters for even weight distribution.
- Place the adapters carefully and gently into the rotor buckets
- Seal the buckets with the lids and close the centrifuge.
- Use only with rotors which have been loaded properly.
- Make sure the rotor is locked properly into place before operating the centrifuge.
- Never overload the rotor.
- Never start the centrifuge when the centrifuge door is open.
- Do not lean on the centrifuge.
- Do not place anything on top of the centrifuge during a run.
- Gently close the centrifuge door. The centrifuge door mechanism will click and lock in place.
- Turn on the centrifuge by pressing the start button.
- Select the required speed and time from preprogrammed setting or manually using the arrow keys (3000xg for 10 mins for each tube).

Once the centrifuge has completely stopped spinning wait for an audible sound and then open the centrifuge. Remove the tubes from the centrifuge and place them in a tube rack.

#### 1.3.2 Handling of collected blood

Three different types of test tubes will be used per study participant to collect venous blood. The collected blood will be designated for whole blood, or plasma and serum separation. One 8ml EDTA tube (with added anticoagulant) will be used to collect whole blood for analysis, one 6ml heparin tube will be used for plasma extraction, and one 8.5ml SST tube will be used for serum extraction. Tubes will be labelled with study timepoint (T1, T2 or T3), participant ID, and type of sample. All information regarding blood collection tubes is presented in Table 1.

**Table 1.** Volume of blood in different test tubes

Test tube	Blood volume	Designated for:
EDTA tube	6 ml	Whole blood
Heparin gel tube	6 ml	Heparin plasma extraction
SST tube	8.5 ml	Serum extraction
<b>Total blood:</b>	22.5ml	



- The whole blood sample (6ml) collected in the EDTA tube will be stored at -80°C, as indicated in Table 2.

**Table 2.** Volumes and use of EDTA whole blood sample.

Whole blood aliquot no.	EDTA volume	Designated for the analysis of:
1	6 ml	HbA1c

- The blood (8.5ml) collected in the SST tube will be left to separate at room temperature for 20 mins and then centrifuged at 3000 rpm for 10 min. The extracted (heparin) plasma will be pipetted into 4 aliquots of 1 ml (considering a 50% efficiency of centrifugation in plasma extraction). One aliquot of 1ml will be used for determining glucose, insulin, lipids, LFT and hsCRP, while the 3 aliquots of 1ml each will be stored at -80°C, as indicated in Table 3.

**Table 3.** Volumes and use of SST plasma aliquots.

Plasma aliquot no.	EDTA plasma volume	Designated for the analysis of:
1	1000 µl	Glucose, insulin, lipids, LFT, hsCRP
		<b>Designated for:</b>
2	1000 µl	Storage at -80°C
3	1000 µl	Storage at -80°C
4	1000 µl	Storage at -80°C

- The blood (6 ml) collected in the heparin tube will be centrifuged at 3000 rpm for 10 min and the extracted plasma will be pipetted into 3 aliquots of 600 µl (considering a 50% efficiency of centrifugation in plasma extraction). One aliquot of 600 µl will be used for determining cytokine concentrations, while the remaining 3 aliquots of 500 µl each will be stored at -80°C, as indicated in Table 4.

**Table 4.** Volumes and use of heparin plasma aliquots.

Plasma aliquot no.	Heparin plasma volume	Designated for the analysis of:
1	1ml	Cytokines (IL-1β, IL-6, IL-8, IL-10, and TNF)
		<b>Designated for:</b>
2	1ml	Storage at -80°C
3	1ml	Storage at -80°C
4	1ml	Storage at -80°C

**NOTE:** It is essential that ONLY NON-HAZARDOUS waste be placed in the wastepaper/ general rubbish bins. Pipette tips should be disposed in sharps containers, whereas laboratory and associated waste directly involved in specimen processing (i.e blood collection tubes, gloves etc) must be disposed in biological waste bags.

**1.4 Blood storage**

Eppendorf tubes or screw cap tubes must be clearly labelled with identification, media used and date, placed in a freezer well rack and should not be stored for long periods on a bench, but must be transferred with an ice esky box to a dedicated storage area (i.e. refrigerator, cold room or cupboard) as soon as possible.

Laboratory coats must be removed and hung up before leaving laboratory areas and should be laundered once a week. Hands must be washed with an antibacterial agent BEFORE leaving laboratory (Hibiclens/Microshield or equivalent, followed by extensive rinsing).




Figure 1. Flow of participants through the trial. DXA, Dual X-ray Absorptiometry; KOOS, Knee injury and Osteoarthritis Outcome Score

\*Optional qualitative interview for process evaluation at 6 months

529x695mm (96 x 96 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	ACTRN12622000440729
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	21
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	21
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	21
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	4-5
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
<b>Methods: Participants, interventions, and outcomes</b>			

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6-7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-13, Table 2, Supplementary File 1
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Table 2
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8-13, Table 2
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	13
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	13-18, Table 3
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	19
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7-8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7-8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7-8
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7-8

17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	NA
-----	--	----

### Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	18
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	19
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	19
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	19

### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	18
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	19-20
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA

### Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	20
--------------------------	----	---	----

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	20
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	20
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Supplementary File 1
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	20
	31b	Authorship eligibility guidelines and any intended use of professional writers	NA
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary File 1
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	Supplementary File 2

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-Non Commercial-No Derivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.



# BMJ Open

## The effectiveness of an anti-inflammatory diet versus low-fat diet for knee osteoarthritis: the FEAST randomised controlled trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-079374.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Jan-2024
Complete List of Authors:	Law, Lynette; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Heerey, Joshua; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Devlin, Brooke; University of Queensland, School of Human Movement and Nutrition Sciences Brukner, Peter; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Kemp, Joanne; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Attanayake, Amanda; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Hulett, Mark; La Trobe University, Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science De Livera, Alysha; La Trobe University, Department of Mathematics and Statistics; The University of Melbourne, School of Population and Global Health Mosler, Andrea; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Morris, Hayden; Melbourne Knee Centre White, Nathan; Melbourne Knee Centre Culvenor, Adam; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	Knee < ORTHOPAEDIC & TRAUMA SURGERY, Chronic Disease, REHABILITATION MEDICINE, NUTRITION & DIETETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1     **The effectiveness of an anti-inflammatory diet versus low-**  
2     **fat diet for knee osteoarthritis: the FEAST randomised**  
3     **controlled trial protocol**  
4  
5     Lynette Law<sup>1</sup>, Joshua J Heerey<sup>1</sup>, Brooke L Devlin<sup>2</sup>, Peter Brukner<sup>1</sup>, Joanne L Kemp<sup>1</sup>, Amanda  
6     Attanayake<sup>1</sup>, Mark D Hulett<sup>3</sup>, Alysha De Livera<sup>4, 5, 6</sup>, Andrea B Mosler<sup>1</sup>, Hayden G Morris<sup>7</sup>,  
7     Nathan P White<sup>7</sup>, Adam G Culvenor<sup>1</sup>  
8  
9         1. La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health,  
10             Human Services and Sport, La Trobe University, Bundoora, Victoria, Australia  
11         2. School of Human Movement and Nutrition Sciences, University of Queensland,  
12             Brisbane, Australia  
13         3. Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science,  
14             La Trobe University, Bundoora, Victoria, Australia  
15         4. Department of Mathematics and Statistics, La Trobe University, Bundoora, Victoria,  
16             Australia  
17         5. School of Population and Global Health, The University of Melbourne, Victoria,  
18             Australia  
19         6. Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia  
20         7. Melbourne Knee Centre, Melbourne, Victoria, Australia.  
21  
22     **Corresponding Author:**  
23     Dr Adam Culvenor  
24     La Trobe Sport and Exercise Medicine Research Centre,  
25     La Trobe University,  
26     Kingsbury Drive, Bundoora, 3086, Victoria, Australia  
27     Phone: +61 9479 5116  
28     Email: a.culvenor@latrobe.edu.au  
29     **Word count:** 3,998

## ABSTRACT

**Introduction:** Chronic inflammation plays a key role in knee osteoarthritis pathophysiology and increases risk of comorbidities, yet most interventions do not typically target inflammation. Our study will investigate if an anti-inflammatory dietary program is superior to a standard care low-fat dietary program for improving knee pain, function and quality-of-life in people with knee osteoarthritis.

**Methods and analysis:** The FEAST (eFfect of an Anti-inflammatory diet for knee oSTeoarthritis) Study is a parallel-group, assessor-blinded, superiority randomised controlled trial. Following baseline assessment, 144 participants aged 45-85 years with symptomatic knee osteoarthritis will be randomly allocated to one of two treatment groups (1:1 ratio). Participants randomised to the anti-inflammatory dietary program will receive six dietary consultations over 12 weeks (2 in-person, 4 phone/videoconference) and additional educational and behaviour change resources. The consultations and resources emphasise nutrient-dense minimally processed anti-inflammatory foods and discourage pro-inflammatory processed foods. Participants randomised to the standard care low-fat dietary program will receive three dietary consultations over 12 weeks (2 in-person, 1 phone/videoconference) consisting of healthy eating advice and education based on the Australian Dietary Guidelines, reflecting usual care in Australia. Adherence will be assessed with 3-day food diaries. Outcomes are assessed at 12 weeks and 6 months. The primary outcome will be change from baseline to 12 weeks in the mean score on four Knee injury and Osteoarthritis Outcome Score (KOOS<sub>4</sub>) subscales: knee pain, symptoms, function in daily activities and knee-related quality-of-life. Secondary outcomes include change in individual KOOS subscale scores, patient-perceived improvement, health-related quality-of-life, body mass and composition using dual-energy X-ray absorptiometry, inflammatory (high-sensitivity C-Reactive Protein, Interleukins, Tumour Necrosis Factor- $\alpha$ ) and metabolic blood biomarkers (glucose, HbA1c, insulin, liver function, lipids), lower-limb function and physical activity.

**Ethics and Dissemination:** Approved by La Trobe University Human Ethics Committee. Results will be presented in peer-reviewed journals and at international conferences.

**Trial registration:** ACTRN12622000440729

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Inflammation, Low-carbohydrate, Anti-inflammatory, Pain, Osteoarthritis, Knee, Chronic disease, Rehabilitation, Diet

**STRENGTHS AND LIMITATIONS OF THIS STUDY**

- The anti-inflammatory dietary program was codeveloped and piloted with patients and clinicians, with the comparison low-fat dietary program representing usual care.
- Sufficiently powered trial evaluating change from baseline to 12 weeks (primary endpoint) and 6 months facilitating longer-term effectiveness evaluation of the anti-inflammatory dietary program.
- This trial will evaluate both self-reported and objective outcomes to understand potential mechanisms of symptomatic changes.
- While outcome assessors are blinded to group allocation, the health professionals delivering the interventions and participants are unable to be blinded to group allocation due to the type of interventions.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

## INTRODUCTION

Osteoarthritis (OA) is the most common rheumatic disease affecting approximately 15% of the population, with OA of the knee being most prevalent.(1, 2) Knee OA and its associated symptoms can be disabling and lead to substantial societal and healthcare costs.(3) In Australia alone, annual OA-related healthcare expenditure exceeds \$2.1 billion.(4) Although the main symptom of knee OA is pain, individuals with knee OA have an increased risk of other chronic diseases, including cardiovascular disease and diabetes.(5) As many as two-thirds of older adults with knee OA have more than one comorbidity.(6)

Clinical guidelines for knee OA recommend exercise-therapy and weight-loss as first-line management strategies due to their excellent safety profile and therapeutic effects similar to commonly used analgesics.(3, 7) However, the effectiveness of exercise-therapy has recently been questioned due to its lack of benefit over an open-label placebo,(8) and findings that one-third of people completing an exercise program do not achieve a clinically meaningful improvement in pain.(9, 10) Weight-loss programs in those who are overweight or obese typically consist of caloric restrictive diets, which are challenging to adhere to and sustain.(11) A meta-analysis highlighted that, within two years of a calorie-restrictive program, over half of initial weight lost was regained, and by 5 years, this figure jumped to >80%.(12)

Anti-inflammatory diets provide an alternative to calorie-restrictive approaches by targeting local and systemic inflammation, both contributors to OA disease onset, progression and symptom burden.(13-15) Anti-inflammatory diets are typically high in minimally processed, nutrient rich foods such as fruit, vegetables, spices and extra virgin olive oil, which are dense in nutrients such as polyphenols, carotenoids, fibre, monounsaturated and polyunsaturated fatty acids.(16-19) These nutrients can significantly reduce inflammation even in the absence of weight loss(20) via antioxidant and anti-inflammatory properties by neutralising free radicals and associated cell damage, as well as improved lipid profiles.(16, 17, 21) Omega-3 fatty acids, abundant in nuts, seeds and fish, are also a key part of anti-inflammatory dietary approaches and help to achieve a more desirable omega-6 to omega-3 ratio.(22) In contrast, omega-6 fatty acids can be converted into arachidonic acid, a precursor for proinflammatory eicosanoids.(23) An elevated omega-6:omega-3 ratio exacerbates oxidative stress, which

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

104 increases the risk and severity of chronic disease, including OA.(15) Due to their focus on real  
105 foods and consumption to satiety, anti-inflammatory diets are likely more sustainable than  
106 traditional calorie-restrictive approaches.(17)

107  
108 Anti-inflammatory diets have garnered much interest in recent years due to their  
109 effectiveness in alleviating symptoms and improving biomarkers for a variety of chronic  
110 diseases, including diabetes,(18) cardiovascular disease,(24) epilepsy(25) and rheumatoid  
111 arthritis.(26) Small studies investigating anti-inflammatory diets for knee OA have  
112 demonstrated feasibility and effectiveness in reducing symptoms and inflammation over 12-  
113 16 weeks.(15, 27, 28) To date, no fully powered randomised controlled trial (RCT) has  
114 evaluated the effectiveness of an anti-inflammatory diet in knee OA.

115  
116 The primary aim of this RCT is to estimate the average effect of an anti-inflammatory dietary  
117 program compared to a standard care low-fat dietary program on knee-related pain, function  
118 and quality of life in individuals with knee OA. We hypothesise that the anti-inflammatory  
119 dietary program will result in greater improvements in knee-related pain, function and quality  
120 of life after 12 weeks (primary endpoint) and 6 months (secondary endpoint) compared to  
121 the standard care low-fat dietary program. Secondary aims are to assess 12-week and 6-  
122 month effectiveness of the anti-inflammatory dietary program on: i) self-reported global  
123 rating of change and achievement of acceptable symptoms; ii) health-related quality of life;  
124 iii) body mass and composition using dual-energy X-ray absorptiometry (DXA); iv)  
125 inflammatory and metabolic blood biomarkers, global lower-limb function and physical  
126 activity.

127  
128 **METHODS AND ANALYSIS**

129 **Study Design**

130 This protocol describes a pragmatic, 2-arm, parallel-group assessor-blinded superiority RCT  
131 and will be reported according to the Standard Protocol Items: Recommendations for  
132 Interventional Trials (SPIRIT) statement.(29) Reporting of the completed RCT will conform to  
133 the Consolidated Standards of Reporting Trials (CONSORT) statement.(30) The FEAST trial will  
134 be conducted at a single site (La Trobe University) in Melbourne, Australia with the first

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool



participant randomised on August 31, 2022 and the final participant anticipated to be randomised in June 2024. The primary endpoint will be at 12 weeks, with additional follow-up at 6 months (further longer-term follow-up dependent on funding). The study was prospectively registered on the Australian and New Zealand Clinical Trial Registry (ACTRN 12622000440729).

### Patient and public involvement

Participants and clinicians co-designed the anti-inflammatory intervention, research questions and study methods. This input was gained from: i) qualitative interviews with participants from the pilot study as part of formal process evaluation strategies;(28) ii) participant and clinician focus groups providing feedback on study recruitment material and participant handbooks; and iii) discussion with experienced clinicians managing knee OA and dietary intervention strategies as part of FEAST development. Patients and clinicians will provide input into the dissemination of study results by assisting with the decision on what information to share and in what format.

### Participants

One hundred and forty adults 45-85 years old with chronic knee pain consistent with a clinical OA diagnosis using criteria from the National Institute for Health and Care Excellence, which does not require radiographic evidence,(31) will be enrolled (table 1).

**Table 1.** Eligibility criteria

Inclusion criteria	Exclusion criteria
Fulfil National Institute for Health and Care Excellence(31) clinical criteria for osteoarthritis:	Knee injection, injury or surgery in the past 3 months
<ul style="list-style-type: none"> <li>Activity-related joint pain with average knee pain severity <math>\geq 4</math> on 11-point numeric rating scale (NRS, where 0 = no pain, 10 = worst pain possible) in the past week;</li> <li>No morning stiffness or morning stiffness <math>\leq 30</math> min; and</li> <li>Age <math>\geq 45</math> years</li> </ul>	

Age ≤85 years – due to potential safety reasons and additional co-morbidities that may hinder capacity for dietary adherence	Had all eligible knee joints replaced by arthroplasty
History of knee pain on most days of the past month	Planning to have knee surgery in next six months
History of knee pain for at least 3 months	Already strictly following an anti-inflammatory diet (e.g., low carbohydrate, high-fat, paleo, Mediterranean) or strict exclusion diet (e.g., vegan)
Be willing and able to attend 3-4 phone consults and 12-week and 6-month follow-up assessments	Unable to follow anti-inflammatory diet (e.g., medically contraindicated, history of food allergy/hypersensitivity, family reasons)
Able to understand written and spoken English, and to give informed consent	Taking the following diabetic medication that affects blood sugar levels (i.e., insulin, SGLT 2 inhibitors, sulfonylureas) to mitigate the risk of hypoglycaemia/ketoacidosis
	Contraindications for DXA scans (e.g., pregnant, breastfeeding, planning pregnancy in next 6 months, >200kg body weight)
	>5kg weight fluctuation in past 3 months (i.e., unstable weight)
	Dietary intervention (by a qualified dietitian) in past 3 months
	A diagnosed psychiatric disorder (excluding anxiety and depression), eating disorder or past bariatric surgery

NRS, numeric rating scale; SGLT, sodium glucose co-transporter; DXA, dual-energy X-ray absorptiometry

Recruitment and screening procedure

Trial flow is outlined in figure 1. Participants will be recruited from our network of collaborating orthopaedic surgeons in Victoria, Australia. Consistent with our prior work in other musculoskeletal conditions,(32, 33) potentially eligible participants (i.e., individuals aged 45-85 years with a history of knee pain for which medical care was sought) will be sent a study information letter inviting them to contact the research team. Additional recruitment strategies will include advertisements in local newspapers, community/university magazines/posters, community market stalls and social media.

\*\*\*FIGURE ONE HERE\*\*\*\*\*

Potential participants will be screened for eligibility via telephone. Once eligibility is confirmed, participants will attend a study orientation session via videoconference to explain further study details (e.g., fasting requirements) and be orientated to the dietary assessment tool (3-day food diary). If both knees meet the inclusion criteria, the most symptomatic knee will be considered as the index knee.

### *Randomisation procedure, concealment of allocation and blinding*

Upon completion of baseline assessment, participants will be randomised to either the anti-inflammatory dietary program or standard care low-fat dietary program. Study treatments, but not study hypotheses, will be revealed to participants. A computer-generated randomisation schedule has been developed *a priori* by an independent statistician in random permuted blocks of 4-8 and stratified by sex and body mass index ( $\geq 30\text{kg.m}^{-2}$  vs  $<30\text{kg.m}^{-2}$ ). To ensure concealed allocation, the randomisation schedule will be stored electronically in the secure Research Electronic Data Capture (REDCap®) system and only accessible to an unblinded researcher once baseline measures have been obtained, who will communicate treatment allocation to the participant. Investigators conducting the follow-up assessments will be blinded to group allocation. As the primary outcome is self-reported, participants are considered assessors; therefore, they will be blinded to previous scores. The health professionals delivering the interventions will deliver the intervention for both groups. Specific protocols for both interventions (including consultation contents and format, and accompanying resources) have been developed, and the health professionals have received training to ensure equal credibility. Random observations of intervention delivery will be conducted by the principal investigators to ensure treatment delivery credibility and fidelity. An independent statistician, blinded to group allocation, will perform the primary RCT analysis.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Interventions**

The anti-inflammatory dietary program and standard care low-fat dietary program are summarised aligning to Template for Intervention Description and Replication (TIDieR) guidelines(34) (table 2). Participants in both intervention groups were not actively discouraged to lose weight, but weight loss was described as a potential outcome of the interventions. The same health professionals will deliver the intervention for both groups.

*Anti-inflammatory dietary program*

Participants allocated to the anti-inflammatory dietary program will receive specific anti-inflammatory dietary education and an individualised eating plan, as well as a suite of resources to support behaviour change. The anti-inflammatory dietary program will be delivered over 12 weeks by a qualified dietitian or by another health professional specially trained to deliver the intervention (e.g., physiotherapist).

Participants will be encouraged to follow a diet containing minimally-processed foods and vegetable oils, and higher amounts of healthy fats and nutrient-dense wholefoods known to fight inflammation (e.g., fresh fruits low in natural sugar such as berries, non-starchy vegetables, nuts and seeds, seafood, poultry, red meat, eggs, full-fat dairy). Healthy fats include monounsaturated and polyunsaturated fats with optimal omega-3: omega-6 ratios as found in seafood, nuts, and extra-virgin olive oil. Participants will be advised to limit processed foods, refined carbohydrates (e.g., pasta, bread, rice), confectionary and foods with added sugar. Participants will be encouraged to consume a normocaloric diet and to eat to satiety, with no specific percentage of total energy intake targets for carbohydrate, fat or protein.

An initial in-person consultation (~45 minutes) will occur immediately following group allocation to constructively review participant’s current dietary intake (using baseline 3-day food diary) and develop an individualised meal plan. Participants will be provided with a comprehensive explanation of anti-inflammatory dietary principles, its rationale (e.g., the role of inflammation in OA, link between foods and inflammation) and its potential benefits and side-effects, and address questions and/or concerns. The following educational and behaviour change resources will also be provided at the initial consultation to support

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
ErasmusHogeschool

adherence: i) bespoke information booklet providing anti-inflammatory eating information, example meal plans, and foods that are encouraged and foods to avoid (Supplementary file 1 and 2); ii) complimentary subscription to an anti-inflammatory program (Defeat Diabetes phone app/website), providing anti-inflammatory recipes, masterclasses, meal plans and educational articles; iii) complimentary links to recommended documentaries exploring the benefits of anti-inflammatory nutrition (i.e., Fat Fiction, Cereal Killers, That Sugar Film); and iv) complimentary copy of a book exploring benefits of anti-inflammatory approach (A Fat Lot of Good(35)).

Follow-up phone/videoconference consultations (~30 minutes) will be scheduled in weeks 2, 4, 6, and 9, with timing to be negotiated between each participant and the health professional delivering the intervention. A final in-person consultation will be delivered immediately following the completion of the 12-week assessment. These follow-up consultations will provide participants with ongoing support, education and accountability. A 3-day food diary, completed prior to each consultation (see outcomes/adherence section), will guide individualised feedback and support to adapt meal plans to optimise adherence.

244 **Table 2:** Overview of intervention delivery described according to the TiDieR guidelines

1. BRIEF NAME	Anti-inflammatory dietary program	Standard care low-fat dietary program
2. WHY	Anti-inflammatory diets targeting systemic inflammation assist in the prevention and management of various chronic diseases.(16) Small pilot studies have shown a positive effect of anti-inflammatory diets to improve knee-related symptoms in people with knee osteoarthritis.(28)	Healthy eating guidelines and dietary advice described in the standard care program booklet was based on Australian Dietary Guidelines (ADGs).(17)  Two-three dietetic consultations represent usual care for patients referred for dietary management in Australia.(37, 38)
3. WHAT (MATERIALS)	Participants receive an intervention handbook containing all study details, key anti-inflammatory eating principles, example meal plans, traffic light system of foods encouraged and discouraged, and education (e.g., common myths, tips for eating out, shopping tips); complimentary access to the Defeat Diabetes program app/website; complimentary links to three movies; and a complimentary copy of the book “A Fat Lot of Good”.(35)	Participants receive an educational handbook emphasising ADGs healthy eating principles and are provided links to the online resources from the Eat for Health website ( <a href="https://www.eatforhealth.gov.au/">https://www.eatforhealth.gov.au/</a> ).
4. WHAT (PROCEDURES)	Six consultations providing individualised guidance and support to follow an anti-inflammatory eating pattern, emphasising the consumption of fruits, non-starchy vegetables, fish, poultry, red meat, eggs, full-fat dairy, nuts, seeds, and extra virgin olive oil. Participants will be encouraged to avoid highly processed foods, refined carbohydrates, added sugar, and processed meats.	Three consultations providing general advice and education regarding healthy eating based on the ADGs. The principles focus on consumption of foods from the five food groups, while limiting intake of foods containing saturated fat, added salt, added sugars and alcohol.
5. WHO PROVIDED	A qualified dietitian or health professional specially trained to deliver all components.	A qualified dietitian or health professional specially trained to deliver all components.
6. HOW	Delivered with individual support for 12 weeks, after which, participants will be encouraged to sustain the anti-inflammatory diet unsupported up to 6 months. Consultations are one-to-one.	Delivered with standard healthy eating advice for 12 weeks, after which, participants will be encouraged to sustain the program unsupported up to 6 months. Consultations are one-to-one.
7. WHERE	In-person consultations will occur at La Trobe University Nutrition and Dietetics research laboratory. Additional	In-person consultations will occur at the La Trobe University Nutrition and Dietetics research



	consultations will occur via telephone/videoconference (e.g., Zoom). Participants will integrate the diet principles into their daily consumption of foods and beverages.	laboratory. Additional consultations will occur via telephone/videoconference (e.g., Zoom). Participants will integrate the diet principles into their daily consumption of foods and beverages.
<b>8. WHEN AND HOW MUCH</b>	<p>Two in-person consultations at baseline (~45 mins) and week 12 (~30 mins)</p> <p>Four phone/videoconference follow-up consultations (~30 mins) in week 2, 4, 6, and 9.</p> <p><b>Total active intervention delivery time:</b> ~3.5 hours</p> <p>Participants are provided with self-management resources to optimise adherence to the anti-inflammatory diet up to the 6-month follow-up.</p>	<p>Two in-person consultations at baseline (~45 mins) and week 12 (~30 mins)</p> <p>One phone/videoconference follow-up consultation (~30 mins) in week 6.</p> <p><b>Total active control delivery time:</b> ~1.5 hours</p> <p>Participants encouraged to sustain their diet up to 6-month follow-up.</p>
<b>9. TAILORING</b>	Individualised anti-inflammatory dietary advice, education, and support aligning with participant preferences and goals.	Advice based on the ADGs.
<b>10. MODIFICATIONS</b>	Any modifications will be reported.	
<b>11. HOW WELL (planned)</b>	Two-three professionals (qualified dietitian and other health professional) receive prior training in how to deliver and supervise the program. Fidelity is assessed through random auditing by members of the principal investigator team (AC or BD). Participant adherence to the anti-inflammatory diet is assessed through consultation attendance, regular 3-day food diaries and self-report.	Two-three professionals (qualified dietitian and health professional) receive prior training in how to deliver and supervise the program. Fidelity is assessed through random auditing by members of the principal investigator team (AC or BD). Participant adherence to the standard care low-fat diet is assessed through consultation attendance, regular 3-day food diaries and self-report.
<b>12. HOW WELL (actual)</b>	This will be reported in the primary paper.	

245 TIDieR, Template for Intervention Description and Replication; ADG, Australian Dietary Guidelines

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

246     *Standard care low-fat dietary program*

247     Participants allocated to the standard care low-fat dietary program will receive advice and  
248     education regarding healthy eating based on the Australian Dietary Guidelines.(39) These  
249     government-endorsed guidelines aim to optimise nutrition intake through adequate  
250     consumption of foods from the five core food groups (grains and cereals; fruit; vegetables and  
251     legumes; lean meats and poultry, fish, eggs, and tofu; reduced fat dairy or alternatives), while  
252     limiting intake of foods containing saturated fat, added salt, added sugars and alcohol. They are  
253     high-carbohydrate and low-fat focused – participants will be encouraged to include at least four  
254     serves of wholegrains daily (e.g., brown rice, pasta, bread, quinoa, oats) and to choose low-fat  
255     protein and dairy foods where possible.

257     The program will be delivered through individual consultations with the treating dietitian or other  
258     specially trained health professional – the first in-person consultation immediately following  
259     baseline assessment (~45 minutes), the second via phone/videoconference at 6 weeks (~30  
260     minutes) and the third in-person at 12-week follow-up with timing individualised as required.  
261     Two to three consultations represents usual care for patients referred for dietary management  
262     in Australia through the current public healthcare (Medicare) rebate system.(37, 38) During the  
263     initial in-person consultation, participants will be provided with a bespoke educational booklet  
264     and advice and education emphasising the Australian Dietary Guideline principles  
265     (<https://www.eatforhealth.gov.au/guidelines>) and informed of complementary and publicly  
266     available online resources from the Eat for Health website (<https://www.eatforhealth.gov.au/>).

268     The follow-up phone/videoconference consultation in week-6 and in-person follow-up in week-  
269     12 will provide participants with ongoing support, education and accountability. The 3-day food  
270     diary, completed prior to each consultation (see outcomes/adherence section), will guide  
271     feedback and support to adapt meal plans to optimise adherence. The treating health  
272     professionals delivering the two dietary programs will be based centrally at La Trobe University  
273     and will be trained by the senior study dietitian (BLD) until deemed competent in intervention  
274     delivery.

Irrespective of group allocation, participants can continue usual medical care and consult with their treating health professionals as necessary (e.g., general practitioner regarding medication changes).

### Data collection procedure

Data will be collected at baseline and 6 weeks, 12 weeks and 6 months after randomisation, with 12 weeks the *a priori* primary endpoint as this coincides with completion of supported interventions (table 3). Where possible, data will be collected and managed using a secure web-based software platform (REDCap®) hosted at La Trobe University,(40) which has equivalent measurement properties to paper-based completion.(41) This strategy was used in our pilot study(28) and other trials of musculoskeletal conditions.(42) Paper versions will also be available if preferred.

## OUTCOMES

### Baseline characteristics

Participant characteristics including age, sex, ethnicity, knee pain/surgery details, socioeconomic details (e.g., education level, employment status, living status), medical history and health literacy (assessed with the Rapid Estimate of Adult Literacy in Medicine (REALM)(43)) will be collected (table 3).

### Primary Outcome

The primary outcome is the change from baseline to 12 weeks in the mean score on four Knee injury and Osteoarthritis Outcome Score (KOOS<sub>4</sub>) subscales covering knee pain, symptoms, function in daily activities and knee-related quality of life. The KOOS is a 42-item patient-reported outcome measure assessing five separately scored subscales: Pain, Symptoms, Function in Sport and Recreation (Sport/Rec), Activities of Daily Living (ADL), and Quality of Life. The KOOS<sub>4</sub> and all KOOS subscale scores range from 0 (extreme problems) to 100 (no problems). The KOOS is a valid, responsive and reliable questionnaire, with KOOS<sub>4</sub> a primary outcome for other knee OA trials.(33, 44, 45)

1  
2 309  
3  
4 310  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 311  
312

**Table 3.** Overview of data collection

Variable	Baseline	6 weeks	12 weeks	6 months
Participant characteristics				
Age	X			
Sex	X			
Ethnicity	X			
Education level	X			
Health literacy (REALM)	X			
Employment status	X			
Smoking status	X			
Civil status, living situation	X			
Medical history, comorbidities	X			
Knee pain/injury/surgery history	X			
Objective Clinical Outcomes				
Height, weight, waist girth	X		X	X
30-second chair stand test	X		X	X
40 metre walk test	X		X	X
Body composition (DXA)	X		X	X
Blood inflammatory and metabolic biomarkers	X		X	X
Blood pressure	X		X	X
Patient-reported Outcomes				
KOOS subscales	X	X	X	X
Global rating of change		X	X	X
Desire for knee surgery	X	X	X	X
Medication use	X	X	X	X
Knee pain (current and worst in past week)	X	X	X	X
EQ-5D-5L^	X	X	X	X
Patient acceptable symptom state	X	X	X	X
Brief Pain Inventory	X		X	X
International Physical Activity Questionnaire	X		X	X
Kessler Psychological Distress Scale (K10)	X		X	X
3-day Food Diaries*	X	X	X	X
Adverse events		X	X	X

REALM, Rapid Estimate of Adult Literacy in Medicine; KOOS, Knee injury and Osteoarthritis Outcome Score; DXA, Dual-Energy X-ray absorptiometry

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

\*3-day food diaries are also assessed prior to anti-inflammatory dietary program consultations at 2, 4 and 9 weeks

<sup>^</sup>Assesses health-related quality of life across 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (0-100) of current overall health status.

## Secondary effectiveness outcomes

### *KOOS subscales*

To allow for clinical in-depth interpretation, scores for the five KOOS subscales will be reported individually (i.e., pain, symptoms, function in sports and recreational activities, activities of daily living, quality of life).(10, 45)

### *Global Rating of Change (GROC) and patient-acceptable state*

Self-perceived change in pain and function will be assessed using a 7-point Likert scale ranging from 'much worse' to 'much better' in response to the questions: "Overall, how has your knee pain changed since the start of the study?" and "Overall, how has your knee function changed since the start of the study?", respectively. Treatment success will be defined as a response of either 'better' or 'much better'. Satisfaction with current knee function using the self-reported Patient Acceptable Symptom State (PASS) question(46). Participants not satisfied with current knee function at follow-up assessments will be asked a second question to determine if they considered the treatment to have failed.(46)

### *Anthropometrics*

Height and weight will be assessed using a seca 217 stadiometer and seca 703 EMR-validated column scale (Hammer Steindamm, Hamburg, Germany), respectively. Waist circumference will be measured using a metal tape measure (Lufkin W606PM ¼ inch x 2m Executive Thinline Pocket Tape).

### *Global lower-limb function*

Two performance-based tests of lower-limb function recommended by the OA Research Society International (OARSI) will be conducted: the 30-second chair-stand test (number of chair-stands

1  
2 344 from a standardised height chair in 30 seconds) and 40-metre walk test (time to walk 40 metres  
3  
4 345 safely, using walking aids if required).(47)  
5  
6 346

7  
8 347 *Body composition*  
9

10 348 A whole-body DXA scan will be acquired using a Hologic Horizon® DXA scanner (Bedford, MA,  
11  
12 349 United States) to assess adiposity (visceral, peripheral) and lean mass.(48)  
13  
14 350

15  
16  
17 351 *Inflammatory and metabolic biomarkers*  
18

19 352 An array of blood inflammatory and metabolic biomarkers will be analysed from samples of blood  
20  
21 353 collected, including high sensitivity C-Reactive Protein (hsCRP), cytokines (IL-1β, IL-6, IL-8, IL-10,  
22  
23 354 TNF-α), blood glucose, HbA1c, serum insulin, liver function tests (including albumin), and lipids  
24  
25 355 (e.g., high density lipoprotein, triglycerides). Participants will be instructed to fast for at least 10  
26  
27 356 hours prior to blood collection and a single forearm venepuncture will take place to collect a total  
28  
29 357 of ≤30 mL blood. Plasma and serum samples will be centrifuged (3000ms, 10 minutes), and all  
30  
31 358 samples (plasma, serum, and whole blood) frozen at -80°C for later analysis (Supplementary File  
32  
33 359 3).  
34  
35 360

36 361 **Secondary safety outcomes**  
37

38 362 *Adverse events*  
39

40 363 Adverse events and serious adverse events will be recorded at 6-week, 12-week and 6-month  
41  
42 364 follow-up via open probe questioning to optimise collection of sufficient detail. Under the  
43  
44 365 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) harms  
45  
46 366 statement, an adverse event is defined as any undesirable experience causing participants to  
47  
48 367 seek medical treatment (e.g., general practitioner).(49) A serious adverse event is defined as any  
49  
50 368 undesirable event/illness/injury classified as having the potential to significantly compromise  
51  
52 369 clinical outcome or result in significant disability or incapacity, those requiring inpatient or  
53  
54 370 outpatient hospital care, to be life-threatening or result in death.  
55  
56 371

57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool



## Exploratory outcomes

### *Dietary Analysis*

Participants will record food and beverage intake over three days via the smartphone application *Australia Calorie Counter - Easy Diet Diary* (Xyris Software Pty Ltd) or on paper (personal preference). Easy Diet Diary is a commercial calorie counter and food diary that allows users to email recorded diaries to treating professionals. Once received by the treating health professional, the 3-day food diaries will be imported into, and analysed using, Foodworks® Premium Edition nutrient analysis software (Version 10, Brisbane, Australia 2019) and Australian food composition databases. Paper-based 3-day food diaries will be manually entered into FoodWorks®. Total energy intake, macronutrients, micronutrients and core food group analysis will be reported. Dietary analysis data will also be used to calculate the inflammatory potential of participants' diets (e.g., Dietary Inflammatory Index).(50)

### *Quality of life*

Health-related quality of life will be assessed with the EQ-5D-5L generic health index, which comprises five dimensions of health (mobility, self-care, usual activities, pain or discomfort, anxiety or depression) and a Visual Analogue Scale (VAS) of current overall health status.(51) Both validity and reliability has been demonstrated in arthritic populations.(52)

### *Knee pain and interference*

Self-reported knee pain (current, worst over past week, average over past week) will be assessed using a 100mm VAS (0=no pain, 100=worst pain imaginable). The degree to which knee pain interferes with participant's daily functioning will be assessed using the Brief Pain Inventory,(53) a tool with reliability and validity demonstrated in knee pain populations.(54, 55)

### *Change in analgesic medication use*

Change in analgesic medication use from baseline to 12-week and 6-month follow-up will be assessed with a 7-point Likert scale (much less to much more).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Physical activity*

Physical activity will be assessed using the International Physical Activity Questionnaire (IPAQ),(56) a standardised and valid questionnaire providing an estimate of physical activity and sedentary behaviour, which has been widely validated.(56-58) Respondents are asked to report time spent in physical activity across three intensities (walking, moderate, vigorous). Using the IPAQ scoring protocol,(59) total weekly physical activity can be estimated by weighting time spent in each activity intensity with its estimated metabolic equivalent (MET) energy expenditure.(60)

*Blood pressure*

A pair of seated blood pressure measurements will be obtained using an automated monitor (Omron Model HEM-7121). The blood pressure cuff is placed over the mid-upper arm with the participant seated.

*Self-perceived wellness*

Self-reported sleep quality, hunger, fatigue and energy levels will be assessed using a 100mm VAS (0=worst outcome, 100=best outcome).

*Intervention adherence*

Adherence will be assessed by a self-reported VAS (0=not at all adherent, 100=extremely adherent) and 5-point Likert scale at 6 weeks, 12 weeks and 6 months and evaluation of 3-day food diaries by consulting health professionals. Satisfactory adherence is defined as a self-report of both  $\geq 80$  on the VAS and 'Most days' or 'Every day' on the Likert scale, at both the 6-week and 12-week timepoints.

**DATA MANAGEMENT**

Most outcome data will be collected and managed electronically via REDCap© web-based software hosted at La Trobe University. Other data (e.g., DXA reports) will be stored electronically on the La Trobe University secure research drive. All electronic data will be de-identified (participant code) and exported for data analysis and saved in a password protected database on the La Trobe University research drive only accessible to the research team. Paper-based identifying documents (e.g., consent forms) will be securely stored in a locked filing cabinet

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

accessible only to members of the research team and separately from re-identifiable (i.e., coded) data.

Due to the minimal known risks associated with the interventions being evaluated, our study will not have a formal data monitoring committee and does not require an interim analysis. This is the same approach we have taken with other low risk RCTs.(42) Any unexpected serious adverse events or outcomes will be discussed by the trial management committee (authors of this protocol) and reported to the approving human research ethics committee for monitoring.

### Sample size calculation

This trial has been powered to detect a clinically significant between-group difference for the primary outcome of KOOS<sub>4</sub>. A recent RCT comparing an anti-inflammatory diet vs low-caloric diet in overweight women with knee OA observed an effect size (standardised mean difference) on self-reported pain and function of 1.0 (95% confidence interval 0.5 to 1.6).(61) Given inherent differences in the FEAST RCT (e.g., Australian Dietary Guideline control group, not specifically targeting overweight participants, inclusion of both women and men), we used the lower bound 95% confidence interval to provide a conservative estimate of the anticipated effect size (0.5). This estimated effect size is also a conservative estimate based on our single-arm anti-inflammatory diet pilot trial, which had an effect size of 0.68.(28) Recruiting 128 participants (equally distributed between two arms) would yield 80% power to observe such an effect or larger at a two-tailed Type I error of 0.05. This sample size estimation is also conservative since it is based on independent samples t-test. Using an ANCOVA model that includes the baseline value as a covariate and is pre-specified for the analysis should provide higher power for the same sample size.(62) To account for a potential 10% drop-out, we will recruit 144 participants. This sample size will also be sufficient to detect a minimal important change (MIC) in KOOS<sub>4</sub> estimated at 10 points in patients with knee OA (with a common between-subject standard deviation of 15).(63)

### Statistical analyses

Analysis will be performed according to the Estimands Framework(64) with a statistical analyst blinded to group allocation. All outcomes and analyses are prospectively categorised as primary, secondary or exploratory. For the primary hypothesis, a linear model with baseline value, sex and BMI ( $\geq 30$  vs  $< 30 \text{ kg.m}^{-2}$ ) as covariates and treatment condition as a fixed factor will evaluate the

1  
2 465 treatment effect on the primary outcome of KOOS<sub>4</sub> (mean score of four of the five subscales of  
3  
4 466 the KOOS) at 12 weeks. A linear mixed model utilising repeated measures at all time-points for  
5  
6 467 secondary hypotheses will allow non-biased estimates of treatment effect in the presence of any  
7  
8 468 potential missing cases, providing data are missing at random. A sensitivity analysis using pattern-  
9  
10 469 mixture model to investigate the deviation from the missingness-at-random assumption will be  
11 470 carried out.(65) For secondary binary outcomes (e.g., treatment success), mixed-effect logistic  
12  
13 471 regression models will be used to assess the effect of treatment. A subsequent analysis of  
14  
15 472 participants classified as adherent to the protocol will be performed.

16 473

17  
18 474 **Healthcare resource use**

19  
20 475 Healthcare resource utilisation (e.g., hospitalisations, medical imaging, healthcare visits,  
21  
22 476 medication use) will be assessed by participant self-report to estimate costs associated with the  
23  
24 477 trial programs (e.g., hospital admissions, medication use, clinician visits, imaging tests, out-of-  
25  
26 478 pocket expenses).

27 479

28  
29 480 **Process Evaluation**

30  
31 481 Semi-structured interviews will be conducted on a subset of consenting participants (until data  
32  
33 482 saturation reached) at 6 months. Interviews will explore experiences, knowledge and  
34  
35 483 understanding of interventions received including potential benefits; acceptability and perceived  
36  
37 484 effectiveness of the intervention; and reasons for adhering (or not) to the allocated diet.  
38  
39 485 Purposive sampling will be used to recruit interview participants based upon characteristics (anti-  
40  
41 486 inflammatory dietary program vs standard care low-fat dietary program, men vs women) and  
42  
43 487 outcomes of the trial (good outcome vs poor outcome). Interviews will be audio recorded,  
44  
45 488 transcribed and analysed using Framework Analysis,(66) a flexible technique allowing  
46  
47 489 researchers to identify, compare and contrast data according to inductively- and deductively-  
48  
49 490 derived themes. Data will be coded and an inductive thematic analysis will be applied until no  
49  
50 491 new themes emerge.

51 492

52  
53  
54 493 **ETHICS AND DISSEMINATION**

55  
56 494 This study complies with the Declaration of Helsinki and has received approval from La Trobe  
57  
58 495 University Human Ethics Committee (HEC-22044). Written informed consent will be obtained  
59  
60 496 from participants prior to enrolment (Supplementary File 4). Anti-inflammatory diets are  
497 associated with minimal and transient adverse events, thus there are minimal safety

considerations associated with this trial.

Study outcomes will be widely disseminated through a variety of sources. Results will be reported in peer-reviewed publications and presented at key national and international conferences. Only aggregate data will be reported. A lay summary report will be available for study participants. Any important protocol amendments will be reported to the approving ethics committee, registered at ANZCTR and communicated in the primary RCT paper. Any serious adverse events will be recorded and reported to the approving ethics committee.

Deidentified data will be made available upon reasonable request to the principal investigator (AGC) after publication (except where the sharing of data is prevented by privacy, confidentiality, or other ethical matters, or other contractual or legal obligations) according to La Trobe University Research Data Management Policy.

## DISCUSSION

The current RCT will be the first full-scale trial to evaluate the symptomatic, inflammatory, functional and body composition benefits of an anti-inflammatory dietary program compared to a standard care low-fat dietary program based on Australian Dietary Guidelines. While outcome assessors are blinded to group allocation, owing to the type of interventions (i.e., dietary advice) blinding of participants will not be possible. We also acknowledge that, like most RCTs, there is a risk that our recruitment strategy may result in a selected sample not representative of the general population. However, using similar recruitment strategies, our prior RCTs have resulted in a representative sample of the culturally and sociodemographically diverse Australian population that has similar characteristics to other international cohorts with the index musculoskeletal condition.(67)

The evaluation of a non-pharmacological anti-inflammatory dietary program to improve pain, symptoms, and quality of life for individuals with OA could have important individual and socio-economic benefits – decreased healthcare dollars spent on managing OA and reduced surgery waiting lists. Another benefit is that anti-inflammatory diets are also effective at combating metabolic syndrome, a key risk factor for chronic diseases, and thus the benefits from treating OA could stretch further to improving other medical co-morbidities.(68) This fully-powered RCT represents a crucial step towards the development of a sustainable and cost-effective therapy

1  
2 531 that can both supplement and complement existing treatment strategies to optimise OA  
3  
4 532 outcomes.  
5  
6 533  
7 534

8  
9 535 **AUTHOR CONTRIBUTIONS**

10  
11 536 AGC, BLD, PB and JLK conceived the study and obtained funding. AGC, BLD, PB, and JLK designed  
12 537 the study protocol with input from LL, JJH and ABM. ADL provided statistical expertise and will  
13  
14 538 conduct primary statistical analysis. MDH provided blood analysis expertise and will lead  
15  
16 539 inflammatory and metabolic marker analyses. HGM and NPW assisted with participant  
17  
18 540 recruitment from their clinical population with knee osteoarthritis. LL drafted the manuscript  
19  
20 541 with input from AGC, JJH, BLD, PB, JLK, AA, MDH, ADL, ABM, HGM and NPW. All authors and read  
21  
22 542 and approved the final manuscript.  
23  
24 543

25 544 **FUNDING**

26  
27 545 This trial is supported by the National Health and Medical Research Council (NHMRC) of Australia  
28  
29 546 through an Investigator Grant held by AGC (GNT2008523), an Investigator Grant held by JLK  
30 547 (APP2017844), and a philanthropic donation from PB.  
31  
32 548

34 549 **COMPETING INTERESTS STATEMENT**

35  
36 550 PB is the founder of Defeat Diabetes and author of “A Fat Lot of Good”. PB contributed to study  
37  
38 551 design but has no role in study execution, data management, analysis or the decision to publish.  
39  
40 552 The NHMRC has no role in study design and will not have any role in its execution, data  
41  
42 553 management, analysis and interpretation or on the decision to submit the results for publication.  
43  
44 554 JLK is an editor of the British Journal of Sports Medicine (British Medical Journal Group). AGC is  
45 555 an associate editor of British Journal of Sports Medicine (British Medical Journal Group). All other  
46  
47 556 authors have no competing interests.  
48  
49 557

50  
51 558 **ACKNOWLEDGEMENTS**

52  
53 559 We thank La Trobe University Medical Centre for assistance with blood collection, La Trobe  
54 560 Nutrition and Dietetics department for the use of the nutrition lab and DXA scanner, and  
55  
56 561 Melbourne Pathology for providing pathology collection kits and analysis of biomarkers from  
57  
58 562 blood specimens.  
59  
60 563

564 **FIGURE LEGENDS**

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool



**Figure 1.** Flow of participants through the trial. DXA, Dual X-ray Absorptiometry; KOOS, Knee injury and Osteoarthritis Outcome Score

\*Optional qualitative interview for process evaluation at 6 months

## SUPPLEMENTARY FILES

**Supplementary File 1.** Sample of the standard care low fat dietary program participant booklet

**Supplementary File 2.** Sample of the anti-inflammatory dietary program participant booklet

**Supplementary File 3.** Standard Operating Procedures for blood collection, processing and storage

**Supplementary File 4.** Patient information and consent form

## REFERENCES

1. Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. *EclinicalMedicine*. 2020;29-30:100587.
2. Duong V, Oo WM, Ding C, Culvenor AG, Hunter DJ. Evaluation and treatment of knee pain. *JAMA*. 2023;330:1568-80.
3. Weng Q, Goh S-L, Wu J, Persson MSM, Wei J, Sarmanova A, et al. Comparative efficacy of exercise therapy and oral non-steroidal anti-inflammatory drugs and paracetamol for knee or hip osteoarthritis: a network meta-analysis of randomised controlled trials. *British Journal of Sports Medicine*. 2023;bjsports-2022-105898.
4. Ackerman I, Bohensky M, Pratt C, Gorelik A, Liew D. Counting the Cost: Part 1 Healthcare costs. The current and future burden of arthritis 2016.
5. Williams A, Kamper SJ, Wiggers JH, O'Brien KM, Lee H, Wolfenden L, et al. Musculoskeletal conditions may increase the risk of chronic disease: a systematic review and meta-analysis of cohort studies. *BMC Med*. 2018;16(1):167.
6. Pihl K, Roos EM, Taylor RS, Grønne DT, Skou ST. Associations between comorbidities and immediate and one-year outcomes following supervised exercise therapy and patient education - A cohort study of 24,513 individuals with knee or hip osteoarthritis. *Osteoarthritis Cartilage*. 2021;29(1):39-49.
7. Juhl C, Christensen R, Roos EM, Zhang W, Lund H. Impact of exercise type and dose on pain and disability in knee osteoarthritis: a systematic review and meta-regression analysis of randomized controlled trials. *Arthritis Rheumatol*. 2014;66(3):622-36.
8. Henriksen M, Hansen JB, Klokke L, Bliddal H, Christensen R. Comparable effects of exercise and analgesics for pain secondary to knee osteoarthritis: a meta-analysis of trials included in Cochrane systematic reviews. *J Comp Eff Res*. 2016;5(4):417-31.
9. Barton CJ, Kemp JL, Roos EM, Skou ST, Dundules K, Pazzinatto MF, et al. Program evaluation of GLA:D® Australia: Physiotherapist training outcomes and effectiveness of implementation for people with knee osteoarthritis. *Osteoarthritis and Cartilage Open*. 2021;3(3):100175.
10. Roos EM, Grønne DT, Skou ST, Zywił MG, McGlasson R, Barton CJ, et al. Immediate outcomes following the GLA:D® program in Denmark, Canada and Australia. A longitudinal analysis including 28,370 patients with symptomatic knee or hip osteoarthritis. *Osteoarthritis Cartilage*. 2021;29(4):502-6.
11. Das SK, Gilhooly CH, Golden JK, Pittas AG, Fuss PJ, Cheatham RA, et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. *Am J Clin Nutr*. 2007;85(4):1023-30.

1  
2 610 12. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. *Med Clin*  
3 611 *North Am.* 2018;102(1):183-97.  
4 612 13. Ansari MY, Ahmad N, Haqqi TM. Oxidative stress and inflammation in osteoarthritis  
5 613 pathogenesis: Role of polyphenols. *Biomed Pharmacother.* 2020;129:110452.  
6 614 14. Goldring MB, Otero M. Inflammation in osteoarthritis. *Curr Opin Rheumatol.* 2011;23(5):471-8.  
7 615 15. Strath LJ, Jones CD, Philip George A, Lukens SL, Morrison SA, Soleymani T, et al. The Effect of  
8 616 Low-Carbohydrate and Low-Fat Diets on Pain in Individuals with Knee Osteoarthritis. *Pain Med.*  
9 617 2020;21(1):150-60.  
10 618 16. Galbete C, Kröger J, Jannasch F, Iqbal K, Schwingshackl L, Schwedhelm C, et al. Nordic diet,  
11 619 Mediterranean diet, and the risk of chronic diseases: the EPIC-Potsdam study. *BMC Medicine.*  
12 620 2018;16(1):99.  
13 621 17. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomed*  
14 622 *Pharmacother.* 2002;56(8):365-79.  
15 623 18. Esposito K, Maiorino MI, Bellastella G, Chiodini P, Panagiotakos D, Giugliano D. A journey into a  
16 624 Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. *BMJ Open.*  
17 625 2015;5(8):e008222.  
18 626 19. Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative Stress and Inflammation: What  
19 627 Polyphenols Can Do for Us? *Oxid Med Cell Longev.* 2016;2016:7432797.  
20 628 20. Neale EP, Batterham MJ, Tapsell LC. Consumption of a healthy dietary pattern results in  
21 629 significant reductions in C-reactive protein levels in adults: a meta-analysis. *Nutr Res.* 2016;36(5):391-  
22 630 401.  
23 631 21. Ciaffi J, Mitselman D, Mancarella L, Brusi V, Lisi L, Ruscitti P, et al. The Effect of Ketogenic Diet on  
24 632 Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review. *Frontiers in*  
25 633 *Medicine.* 2021;8.  
26 634 22. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical  
27 635 implications in cardiovascular prevention. *Biochem Pharmacol.* 2009;77(6):937-46.  
28 636 23. Ricker MA, Haas WC. Anti-Inflammatory Diet in Clinical Practice: A Review. *Nutr Clin Pract.*  
29 637 2017;32(3):318-25.  
30 638 24. Li J, Lee DH, Hu J, Tabung FK, Li Y, Bhupathiraju SN, et al. Dietary Inflammatory Potential and  
31 639 Risk of Cardiovascular Disease Among Men and Women in the U.S. *J Am Coll Cardiol.* 2020;76(19):2181-  
32 640 93.  
33 641 25. D'Andrea Meira I, Romão TT, Pires do Prado HJ, Krüger LT, Pires MEP, da Conceição PO. Ketogenic Diet and Epilepsy: What We Know So Far. *Front Neurosci.* 2019;13:5.  
34 642 26. Schönenberger KA, Schüpfer AC, Gloy VL, Hasler P, Stanga Z, Kaegi-Braun N, et al. Effect of Anti-  
35 643 Inflammatory Diets on Pain in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Nutrients.*  
36 644 2021;13(12).  
37 645 27. Dyer J, Davison G, Marcora SM, Mauger AR. Effect of a Mediterranean Type Diet on  
38 646 Inflammatory and Cartilage Degradation Biomarkers in Patients with Osteoarthritis. *J Nutr Health Aging.*  
39 647 2017;21(5):562-6.  
40 648 28. Cooper I, Brukner P, Devlin B, Reddy A, Fulton M, Kemp J, et al. An anti-inflammatory diet  
41 649 intervention for knee osteoarthritis: a feasibility study. *BMC Musculoskeletal Disorders.* 2022;23.  
42 650 29. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013  
43 651 explanation and elaboration: guidance for protocols of clinical trials. *BMJ : British Medical Journal.*  
44 652 2013;346:e7586.  
45 653 30. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010  
46 654 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ.*  
47 655 2010;340:c869.  
48 656 31. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance.  
49 657 Osteoarthritis: Care and Management in Adults. London: National Institute for Health and Care  
50 658 Excellence (UK)  
51 659  
52 660 Copyright © National Clinical Guideline Centre, 2014.; 2014.  
53 661 32. Culvenor AG, Collins NJ, Guermazi A, Cook JL, Vicenzino B, Khan KM, et al. Early knee  
54 662 osteoarthritis is evident one year following anterior cruciate ligament reconstruction: a magnetic  
55 663 resonance imaging evaluation. *Arthritis Rheumatol.* 2015;67(4):946-55.

33. Culvenor AG, Collins NJ, Guermazi A, Cook JL, Vicenzino B, Whitehead TS, et al. Early Patellofemoral Osteoarthritis Features One Year After Anterior Cruciate Ligament Reconstruction: Symptoms and Quality of Life at Three Years. *Arthritis Care Res (Hoboken)*. 2016;68(6):784-92.
34. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ : British Medical Journal*. 2014;348:g1687.
35. Brukner DP. *A Fat Lot of Good*. 1 ed: Penguin Australia Pty Ltd; 2018. 368 p.
36. Wingrove K, Lawrence MA, Russell C, McNaughton SA. Evidence Use in the Development of the Australian Dietary Guidelines: A Qualitative Study. *Nutrients*. 2021;13(11):3748.
37. Cant RP. Patterns of delivery of dietetic care in private practice for patients referred under Medicare Chronic Disease Management: results of a national survey. *Aust Health Rev*. 2010;34(2):197-203.
38. Spencer L, O'Shea MC, Ball L, Desbrow B, Leveritt M. Attendance, weight and waist circumference outcomes of patients with type 2 diabetes receiving Medicare-subsidised dietetic services. *Aust J Prim Health*. 2014;20(3):291-7.
39. Health N, Council MR. *Australian dietary guidelines*. Canberra (Australia): National Health and Medical Research Council. 2013.
40. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208.
41. Gudbergensen H, Bartels EM, Krusager P, Wæhrens EE, Christensen R, Danneskiold-Samsøe B, et al. Test-retest of computerized health status questionnaires frequently used in the monitoring of knee osteoarthritis: a randomized crossover trial. *BMC Musculoskeletal Disorders*. 2011;12(1):190.
42. Culvenor AG, West TJ, Bruder AM, Scholes MJ, Barton CJ, Roos EM, et al. Supervised exercise-therapy and Patient Education Rehabilitation (SUPER) versus minimal intervention for young adults at risk of knee osteoarthritis after ACL reconstruction: SUPER-Knee randomised controlled trial protocol. *BMJ Open*. 2023;13(1):e068279.
43. Davis TC, Crouch MA, Long SW, Jackson RH, Bates P, George RB, et al. Rapid assessment of literacy levels of adult primary care patients. *Fam Med*. 1991;23(6):433-5.
44. Skou ST, Roos EM, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, et al. A Randomized, Controlled Trial of Total Knee Replacement. *N Engl J Med*. 2015;373(17):1597-606.
45. Collins NJ, Prinsen CA, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. *Osteoarthritis Cartilage*. 2016;24(8):1317-29.
46. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis*. 2005;64(1):34-7.
47. Dobson F, Hinman RS, Roos EM, Abbott JH, Stratford P, Davis AM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. *Osteoarthritis and Cartilage*. 2013;21(8):1042-52.
48. Shepherd JA, Ng BK, Sommer MJ, Heymsfield SB. Body composition by DXA. *Bone*. 2017;104:101-5.
49. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. *Bmj*. 2016;352:i157.
50. Shivappa N, Steck SE, Hurley TG, Hussey JR, Hébert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. *Public Health Nutr*. 2014;17(8):1689-96.
51. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res*. 2013;22(7):1717-27.
52. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). *Br J Rheumatol*. 1997;36(5):551-9.
53. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singap*. 1994;23(2):129-38.
54. Mendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. *Eur J Pain*. 2006;10(4):353-61.

1  
2 719 55. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al. Around-the-Clock,  
3 720 Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain: Placebo-Controlled Trial and  
4 721 Long-term Evaluation. *Archives of Internal Medicine*. 2000;160(6):853-60.  
5 722 56. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International  
6 723 physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc*.  
7 724 2003;35(8):1381-95.  
8 725 57. Maddison R, Ni Mhurchu C, Jiang Y, Vander Hoorn S, Rodgers A, Lawes CM, et al. International  
9 726 Physical Activity Questionnaire (IPAQ) and New Zealand Physical Activity Questionnaire (NZPAQ): a  
10 727 doubly labelled water validation. *Int J Behav Nutr Phys Act*. 2007;4:62.  
11 728 58. Cleland C, Ferguson S, Ellis G, Hunter RF. Validity of the International Physical Activity  
12 729 Questionnaire (IPAQ) for assessing moderate-to-vigorous physical activity and sedentary behaviour of  
13 730 older adults in the United Kingdom. *BMC Medical Research Methodology*. 2018;18(1):176.  
14 731 59. Sjostrom M, Ainsworth BE, Bauman A, Bull FC, Hamilton-Craig CR, Sallis JF, editors. Guidelines  
15 732 for data processing analysis of the International Physical Activity Questionnaire (IPAQ) - Short and long  
16 733 forms2005.  
17 734 60. AINSWORTH BE, HASKELL WL, WHITT MC, IRWIN ML, SWARTZ AM, STRATH SJ, et al.  
18 735 Compendium of Physical Activities: an update of activity codes and MET intensities. *Medicine & Science*  
19 736 *in Sports & Exercise*. 2000;32(9):S498-S516.  
20 737 61. Dolatkhah N, Toopchizadeh V, Barmaki S, Salekzamani Y, Najjari A, Farshbaf-Khalili A, et al. The  
21 738 effect of an anti-inflammatory in comparison with a low caloric diet on physical and mental health in  
22 739 overweight and obese women with knee osteoarthritis: a randomized clinical trial. *Eur J Nutr*.  
23 740 2023;62(2):659-72.  
24 741 62. Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in  
25 742 randomized clinical trials. *J Clin Epidemiol*. 2007;60(12):1234-8.  
26 743 63. Silva MDC, Perriman DM, Fearon AM, Couldrick JM, Scarvell JM. Minimal important change and  
27 744 difference for knee osteoarthritis outcome measurement tools after non-surgical interventions: a  
28 745 systematic review. *BMJ Open*. 2023;13(5):e063026.  
29 746 64. Lynggaard H, Bell J, Löscher C, Besseghir A, Rantell K, Schoder V, et al. Principles and  
30 747 recommendations for incorporating estimands into clinical study protocol templates. *Trials*.  
31 748 2022;23(1):685.  
32 749 65. White IR, Kalaitzaki E, Thompson SG. Allowing for missing outcome data and incomplete uptake  
33 750 of randomised interventions, with application to an Internet-based alcohol trial. *Statistics in Medicine*.  
34 751 2011;30:3192-207.  
35 752 66. Ritchie J, Spencer L, editors. *Qualitative data analysis for applied policy research*2002.  
36 753 67. Culvenor AG, West TJ, Bruder AM, Scholes MJ, Barton CJ, Roos EM, et al. Recruitment and  
37 754 baseline characteristics of young adults at risk of early-onset knee osteoarthritis after ACL  
38 755 reconstruction in the SUPER-Knee trial. under review. 2023.  
39 756 68. Peiris CL, Culvenor AG. Metabolic syndrome and osteoarthritis: implications for the  
40 757 management of an increasingly common phenotype. *Osteoarthritis and Cartilage*. 2023;Online ahead of  
41 758 print.  
42 759  
43 760  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool




Figure 1. Flow of participants through the trial. DXA, Dual X-ray Absorptiometry; KOOS, Knee injury and Osteoarthritis Outcome Score

\*Optional qualitative interview for process evaluation at 6 months

529x695mm (96 x 96 DPI)



# FEAST

## SAMPLE FROM LOW-FAT PARTICIPANT BOOKLET



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool





Australian Government  
National Health and Medical Research Council  
Department of Health and Ageing

www.eatforhealth.gov.au

# Australian Guide to Healthy Eating

Enjoy a wide variety of nutritious foods from these five food groups every day.

Drink plenty of water.

Grain (cereal) foods, mostly wholegrain and/or high cereal fibre varieties

Vegetables and legumes/beans



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



Use small amounts

Only sometimes and in small amounts






## Vegetables and legumes

Vegetables, including legumes/beans are nutrient dense, low in kilojoules, and are a good source of minerals and vitamins (such as magnesium, vitamin C and folate), dietary fibre and a range of natural plant chemicals such as carotenoids. Legumes include chickpeas, kidney beans, and peas. Aim for 5 serves a day.

### What is a serve of vegetables\*?

A standard serve is about 75g (100–350kJ) or:

½ cup	cooked green or orange vegetables (for example, broccoli, spinach, carrots or pumpkin)
½ cup	cooked dried or canned beans, peas or lentils
1 cup	green leafy or raw salad vegetables
½ cup	sweet corn
½ medium	potato or other starchy vegetables (sweet potato, taro or cassava)
1 medium	tomato



\*With canned varieties, choose those with no added salt

## Fruit

A wide variety of fruit is grown and available in Australia. Choosing fruits in season provides **better value and better quality**. And just like with veggies, choosing different coloured fruits increases the variety of nutrients, which can enhance your health! Aim for **two serves** of fruit a day.

Try eating fruits from these different fruit categories:

- citrus fruit such as oranges, mandarins, and grapefruit
- pome fruits such as apples and pears
- stone fruit such as apricots, cherries, peaches, nectarines, and plums
- tropical fruit such as bananas, papaya, mangoes, pineapple, and melons
- berries


### What is a serve of fruit?

A standard serve is about 150g (350kJ) or:

1 medium	apple, banana, orange or pear
2 small	apricots, kiwi fruits or plums
1 cup	diced or canned fruit (no added sugar)

Or only occasionally:

125ml (½ cup)	fruit juice (no added sugar)
30g	dried fruit (for example, 4 dried apricot halves, 1½ tablespoons of sultanas)



- other fruits such as grapes and passionfruit

Enjoy more fruit by trying:

- chopped fruit to cereal, porridge, salad, or toast
- fruit as a convenient snack while out and about
- fruit-based desserts (baked apples, fruit crumbles, stewed/ poached fruit)
- adding fruit to pancakes, scones, pikelets, and low-fat muffins.



## Wholegrains

All types of grains are good sources of complex carbohydrates and some key vitamins and minerals. Grain foods are mostly made from wheat, oats, rice, rye, barley, millet, quinoa and corn.

Wholegrains are naturally high in fibre, helping you feel full and satisfied — which makes it easier to maintain a healthy body weight. Nutritionally, wholegrain and wholemeal foods are very similar.

### What is a serve of grain\* (cereal) food?

A standard serve is (500kJ) or:

1 slice (40g)	bread
½ medium (40g)	roll or flat bread
½ cup (75-120g)	cooked rice, pasta, noodles, barley, buckwheat, semolina, polenta, bulgur or quinoa
½ cup (120g)	cooked porridge
⅔ cup (30g)	wheat cereal flakes
¼ cup (30g)	muesli
3 (35g)	crispbreads
1 (60g)	crumpet
1 small (35g)	English muffin or scone



\*Grain (cereal) foods, mostly wholegrain and/or high cereal fibre varieties

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Aim for 4-6 serves of grain foods a day. Additional serves can be eaten depending on your activity level.

Enjoy more wholegrains by having:

- breakfasts that include whole-grain cereals, like oatmeal.
- wholemeal toast or wholemeal bagels for white-flour versions.
- low-fat muffins made with whole-grain flours.
- sandwiches using whole-grain breads or rolls.
- quinoa, brown rice, wild rice, barley or bulgur instead of white rice.
- wild rice or barley in soups, stews, casseroles and salads.
- rolled oats or crushed whole-wheat bran cereal in recipes instead of dry breadcrumbs.

Lean meat and poultry, fish, eggs, tofu, nuts and seeds

These are a critical part of having enough protein each day. They also provide other nutrients such as: iodine, iron, zinc, vitamins, especially B12, and essential fatty acids.


There's a lot to choose from:

- Lean meats - Beef, lamb, veal, pork, kangaroo
- Poultry - Chicken, turkey, duck, emu, goose, bush birds
- Fish and seafood - Fish, prawns, crab, lobster, mussels, oysters, scallops, clams
- Eggs
- Nuts and seeds - Almonds, pine nuts, walnut, macadamia, hazelnut, cashew, peanut, nut spreads, and pumpkin seeds
- Legumes/beans - All beans, lentils, chickpeas, split peas, tofu.

**How much is a serve of lean meat and poultry, fish, eggs, nuts and seeds, and legumes/beans\*?**

**A standard serve is (500–600kJ):**

65g	cooked lean red meats such as beef, lamb, veal, pork, goat or kangaroo (about 90-100g raw)
80g	cooked lean poultry such as chicken or turkey (100g raw)
100g	cooked fish fillet (about 115g raw) or one small can of fish
2 large (120g)	eggs
1 cup (150g)	cooked or canned legumes/beans such as lentils, chick peas or split peas
170g	tofu
30g	nuts, seeds, peanut or almond butter or tahini or other nut or seed paste



\*Choose those with no added salt



## Milk, yoghurt, cheese, and/or alternatives

Dairy products (and dairy alternatives) are rich in calcium, protein, and lots of nutrients. Dairy foods contribute to strong bones. Aim for **at least 2-3 serves daily**.

Examples of milk, yoghurt, cheese and/or alternatives include:

- Milks - All reduced fat or full cream milks, plain and flavoured, long life milks, fortified soy beverages
- Yoghurt - All yoghurts including reduced fat or full cream, plain and flavoured, soy yoghurt (calcium fortified)
- Cheese - All hard cheeses, reduced or full fat for example cheddar, Gouda, Swiss

**How much is a serve of milk\*, yoghurt\*, cheese\* and/or alternatives?**

**A standard serve is (500–600kJ):**

1 cup (250ml)	fresh, UHT long life, reconstituted powdered milk or buttermilk
½ cup (120ml)	evaporated milk
2 slices (40g)	or 4 x 3 x 2cm cube (40g) of hard cheese, such as cheddar
½ cup (120g)	ricotta cheese
¾ cup (200g)	yoghurt
1 cup (250ml)	soy, rice or other cereal drink with at least 100mg of added calcium per 100ml



**The following foods contain about the same amount of calcium as a serve of milk, yoghurt or cheese:**

100g	almonds with skin
60g	sardines, canned in water
½ cup (100g)	canned pink salmon with bones
100g	firm tofu (check the label as calcium levels vary)

\*Choose mostly reduced fat

# FEAST

# SAMPLE OF ANTI-INFLAMMATORY PARTICIPANT BOOKLET





# EXAMPLE WEEKLY MEAL PLANS

Here are examples of what a week might look like. Consider these plans as a guide to give you ideas, not something written in stone! Most of the recipes below can be found on the **Defeat Diabetes** app, or by simply searching on Google online.

Lots of other anti-inflammatory/low-carbohydrate ideas online at: <https://www.eatthebutter.org/dinner-ideas/>

## Week 1

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
<b>Breakfast</b>	Raspberry chia pot	Yoghurt with berries	Raspberry chia pot	Coconut crunch granola	Berry yoghurt smoothie	Scrambled eggs with spinach and avocado	Zucchini and feta fritters
<b>Snack</b>	Apple with peanut butter	Hummus and veggies	Apple with peanut butter	Handful of almonds with piece of dark chocolate	Hummus and veggies	Apple with peanut butter	Handful of walnuts
<b>Lunch</b>	Roast vegetable salad	Salad with can of tuna	Leftover prawn pad thai	Leftover burrito bowl	Salad with can of tuna	Salmon with cauliflower rice bowl	One pan spiced halloumi and eggplant
<b>Snack</b>	Handful of almonds with piece of dark chocolate	Almond meal blueberry muffin	Zucchini and feta fritter	Almond meal blueberry muffin	Handful of almonds with piece of dark chocolate	Yoghurt with berries	Almond meal blueberry muffin
<b>Dinner</b>	Garlic prawns with zoodles	Beef pad thai	15-minute burrito bowl	Miso barramundi with vegetables	Swedish meatballs	Baked portobello mushrooms with feta	Grilled lamb chops with roasted vegetables

Week 2

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
Breakfast	Coconut crunch granola	Berry smoothie	Scrambled eggs with spinach and avocado	Berry smoothie	Coconut crunch granola	Scrambled eggs with spinach and avocado	Shakshuka
Snack	Mini frittata	Pear	Apple with handful of almonds	Pear	Mini frittata	Handful of walnuts with piece of dark chocolate	Yoghurt with berries
Lunch	Salad with sliced steak	Easy Tuna Niçoise	Leftover stuffed capsicum	Leftover burger patty with salad	Leftover green curry with cauli rice	Cesar salad	Warm veggie salad with almonds
Snack	Slice of orange almond meal cake	Handful of walnuts with piece of dark chocolate	Mini frittata	Slice of orange almond meal cake	Apple with handful of almonds	Yoghurt with berries	Pear
Dinner	Salmon poke bowl	Stuffed capsicums	Smoky beef burger on mushroom buns	Green vegetable and prawn curry with cauli rice	Easy mushroom, lemon, and garlic chicken	Cauliflower pizza with pesto, sausage, and herbs	Grilled steak and roasted vegetables

Week 3

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
<b>Breakfast</b>	Breakfast egg muffins	Berry yoghurt smoothie	Breakfast egg muffins	Chia pudding pot	Berry yoghurt smoothie	Bacon and eggs with roasted tomatoes	Mexican breakfast scramble
<b>Snack</b>	Chia pudding pot	Beef jerky	Greek yoghurt with berries	Breakfast egg muffins	Handful of almonds with cheese stick	Apple with peanut butter	Strawberry power balls
<b>Lunch</b>	Zucchini and walnut salad	Leftover beef burrito bowl	Leftover salmon patties with salad	Greek salad	Leftover tagine	Chicken, broccoli and almond salad	Mushroom soup with crispy cheese croutons
<b>Snack</b>	Strawberry power balls	Handful of almonds with square of dark chocolate	Strawberry power balls	Handful of almonds with apple	Dark chocolate (avocado) mousse	Beef jerky	Dark chocolate (avocado) mousse
<b>Dinner</b>	15-minute beef burrito bowl	Salmon patties with feta sauce and beet salad	Chicken curry with cauliflower rice	Lamb and apricot tagine	Pan-seared barramundi with cauliflower mash	Zucchini lasagne	Grilled lamb chops with roasted vegetables

## Week 4

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
<b>Breakfast</b>	Coconut granola with milk	Blueberry almond protein smoothie	Vegetable cheese frittata	Blueberry almond protein smoothie	Coconut granola with milk	Tofu scramble	Almond flour pancakes

Snack	Roasted chickpeas	Slice of almond flour banana bread	Greek yoghurt with berries	Peanut butter balls	Beef jerky	Roasted chickpeas	Handful of walnuts
Lunch	Vegetable cheese frittata	Leftover roast vegetable salad with halloumi	Leftover broccoli and leek soup	Vegetable cheese frittata	Kale Caesar salad	Leftover stuffed capsicums	Creamy Tuscan soup
Snack	Slice of almond flour banana bread	Handful of almonds with dark chocolate	Roasted chickpeas	Slice of almond flour banana bread	Handful of almonds with dark chocolate	Greek yoghurt with berries	Peanut butter balls
Dinner	Roast vegetable salad with halloumi	Cheesy broccoli soup	Spicy tofu san choi bao	Vegetarian stuffed zucchini boats	Stuffed capsicums	Beetroot & halloumi salad with pomegranate	Spiced eggplant curry with cauliflower rice

FEAST Project

---

## Standard Operating Procedure

### Blood collection, processing, handling, and storage procedures

---

For peer review only

1.1 Purpose

The purpose of the current SOP is to provide step-by-step instructions on the exact procedures that the research team needs to follow for conducting venous blood collection for biochemical analysis at baseline and follow-up examination.

1.2 General procedures for venous blood collection

Venous blood samples will be obtained from each participant for biochemical analysis following a 12-hour overnight fast, at baseline (T1), 12 weeks (T2) and 6 months (T3) (figure 1)




Figure 1: Study design

The researcher will perform venepuncture to obtain no more than 30mL of blood.

1.2.1 Consumables and supplies required for performing venepuncture

The consumables and supplies that will be used for performing the venepuncture in the study are the following:

- Disposable Latex gloves must be worn by the researcher and anyone else assisting with blood collection.
- Alcohol swab will be used to clean the venepuncture site.
- Winged steel needles appropriate for adults with an extension tube (a butterfly) will be used. The butterfly will have either a syringe or an evacuated tube with an adaptorSterile gauze pads will.....
- Adhesive hypo allergic bandages (plasters or Band-Aids) will be applied to the puncture site to minimize the risk of infection.
- Plastic Bag for Waste will be used to dispose all of the biohazardous waste generated as well as a sharps biocan to dispose of all needles.

1.2.2 Steps in obtaining venous blood from the participant

The steps for obtaining venous blood samples from the study participants are provided below:

Step 1: Complete general preparation.

- Find an indoor site to encourage privacy during blood collection. The site should have a table or other piece of furniture with a flat surface where you can lay out all consumables/ supplies. An examination bed should be readily available if the respondent feels faint and needs to lie down.
- Ensure that each subject has completed a 10-hour fast.



- Wash and dry hands, put on gloves before initiating blood collection from the participant.
- Take out a clean absorbent paper sheet and spread it over a flat surface to lay out consumable and supplies.

**Step 2:** Prepare the participant for the venepuncture.

- The individual should be seated comfortably in a chair with arm extended on the slanting armrest to form a straight line from the shoulder to the wrist. The arm and elbow should be supported firmly by the armrest and should not be bent at the elbow.
- Ask each volunteer if they have a history of fainting. If so, ensure that the blood sample is only drawn whilst the subject is lying down on a bed.
- Describe to the participant exactly what will be done during the collection of the blood sample.

**Step 3:** Prepare the venepuncture site.

- Apply (tighten) tourniquet.
- Ask the participant to close his/her hand so that the veins will become more prominent and thus easier to enter. Vigorous hand exercise or "pumping" should be avoided.
- Select the vein site. Palpate and trace the path of veins several times with the index finger. If superficial veins are not readily apparent, blood can be forced into the vein by gently massaging the arm from wrist to elbow. Several sharp taps at the vein site with index and second finger will cause the vein to dilate.
- Loosen tourniquet.
- The venepuncture site must be cleansed once with an alcohol swab to prevent any chemical or microbiologic contamination of either the patient or the specimen.
- Check equipment, tube selection and thread needle (or butterfly) securely onto tube holder (barrel).
- Re-apply the tourniquet and relocated vein position and direction. A tourniquet allows the veins to fill with blood, thus making the veins more prominent and easier to enter. Do not leave the tourniquet on for longer than 1 minute otherwise it may result in either hemoconcentration or variation in blood test values.
- Remove needle cover and check bevel is orientated uppermost.

**Step 4:** Blood drawing

- Puncture the skin 3–5 mm away from the vein; this allows good access without pushing the vein away.
- If the needle enters alongside the vein rather than into it, withdraw the needle slightly without removing it completely, and angle it into the vessel.
- Insert the tube into the holder and commence filling the tubes.
- Draw blood slowly and steadily.
- Release the tourniquet as soon as blood flow is established. Tourniquet release allows the blood circulation to return to normal and also reduces bleeding at the venipuncture site.
- Remove the tube from the holder and invert (8-10 times) to mix the blood with tube additives. Place blood samples on ice if required..
- Place a cotton wool above the venepuncture site, withdraw the needle and apply pressure.
- Dispose of needle in a sharps container.
- Check site and apply an adhesive bandage.
- Label all tubes immediately.



1.3 Blood processing and handling

1.3.1 Centrifuge procedure

Collected venous blood will be centrifuged and the extracted plasma and/or serum will be pipetted into aliquots according to the blood collection protocol.

- Set up in a well-ventilated environment, on a horizontally levelled and rigid surface with adequate load-bearing capacity.
- As safety zone maintain a clear radius of at least 30 cm around the centrifuge. Do not place any dangerous substances within this security zone.
- Open the centrifuge door by pressing the open button.
- Place the remaining tubes containing blood into appropriate sized adapters.
- Place the tubes containing water in opposite adapters, where they should mirror the placement of the tubes holding blood.
- Never place both tubes housing water and blood into the same adapters but should be placed in different adapters for even weight distribution.
- Place the adapters carefully and gently into the rotor buckets
- Seal the buckets with the lids and close the centrifuge.
- Use only with rotors which have been loaded properly.
- Make sure the rotor is locked properly into place before operating the centrifuge.
- Never overload the rotor.
- Never start the centrifuge when the centrifuge door is open.
- Do not lean on the centrifuge.
- Do not place anything on top of the centrifuge during a run.
- Gently close the centrifuge door. The centrifuge door mechanism will click and lock in place.
- Turn on the centrifuge by pressing the start button.
- Select the required speed and time from preprogrammed setting or manually using the arrow keys (3000xg for 10 mins for each tube).

Once the centrifuge has completely stopped spinning wait for an audible sound and then open the centrifuge. Remove the tubes from the centrifuge and place them in a tube rack.

1.3.2 Handling of collected blood

Three different types of test tubes will be used per study participant to collect venous blood. The collected blood will be designated for whole blood, or plasma and serum separation. One 8ml EDTA tube (with added anticoagulant) will be used to collect whole blood for analysis, one 6ml heparin tube will be used for plasma extraction, and one 8.5ml SST tube will be used for serum extraction. Tubes will be labelled with study timepoint (T1, T2 or T3), participant ID, and type of sample. All information regarding blood collection tubes is presented in Table 1.

Table 1. Volume of blood in different test tubes

Test tube	Blood volume	Designated for:
EDTA tube	6 ml	Whole blood
Heparin gel tube	6 ml	Heparin plasma extraction
SST tube	8.5 ml	Serum extraction
Total blood:	22.5ml	

- The whole blood sample (6ml) collected in the EDTA tube will be stored at -80°C, as indicated in Table 2.

**Table 2.** Volumes and use of EDTA whole blood sample.

Whole blood aliquot no.	EDTA volume	Designated for the analysis of:
1	6 ml	HbA1c

- The blood (8.5ml) collected in the SST tube will be left to separate at room temperature for 20 mins and then centrifuged at 3000 rpm for 10 min. The extracted (heparin) plasma will be pipetted into 4 aliquots of 1 ml (considering a 50% efficiency of centrifugation in plasma extraction). One aliquot of 1ml will be used for determining glucose, insulin, lipids, LFT and hsCRP, while the 3 aliquots of 1ml each will be stored at -80°C, as indicated in Table 3.

**Table 3.** Volumes and use of SST plasma aliquots.

Plasma aliquot no.	EDTA plasma volume	Designated for the analysis of:
1	1000 µl	Glucose, insulin, lipids, LFT, hsCRP
		<b>Designated for:</b>
2	1000 µl	Storage at -80°C
3	1000 µl	Storage at -80°C
4	1000 µl	Storage at -80°C

- The blood (6 ml) collected in the heparin tube will be centrifuged at 3000 rpm for 10 min and the extracted plasma will be pipetted into 3 aliquots of 600 µl (considering a 50% efficiency of centrifugation in plasma extraction). One aliquot of 600 µl will be used for determining cytokine concentrations, while the remaining 3 aliquots of 500 µl each will be stored at -80°C, as indicated in Table 4.

**Table 4.** Volumes and use of heparin plasma aliquots.

Plasma aliquot no.	Heparin plasma volume	Designated for the analysis of:
1	1ml	Cytokines (IL-1β, IL-6, IL-8, IL-10, and TNF)
		<b>Designated for:</b>
2	1ml	Storage at -80°C
3	1ml	Storage at -80°C
4	1ml	Storage at -80°C

**NOTE:** It is essential that ONLY NON-HAZARDOUS waste be placed in the wastepaper/ general rubbish bins. Pipette tips should be disposed in sharps containers, whereas laboratory and associated waste directly involved in specimen processing (i.e blood collection tubes, gloves etc) must be disposed in biological waste bags.

#### 1.4 Blood storage

Eppendorf tubes or screw cap tubes must be clearly labelled with identification, media used and date, placed in a freezer well rack and should not be stored for long periods on a bench, but must be transferred with an ice esky box to a dedicated storage area (i.e. refrigerator, cold room or cupboard) as soon as possible.

Laboratory coats must be removed and hung up before leaving laboratory areas and should be laundered once a week. Hands must be washed with an antibacterial agent BEFORE leaving laboratory (Hibiclens/Microshield or equivalent, followed by extensive rinsing).



**Participant Information Sheet/Consent Form**  
**Interventional study - Adult providing own consent**

<b>Title</b>	Optimising outcomes for people with knee pain through food: FEAST randomised controlled trial
<b>Short Title</b>	The FEAST trial
<b>Ethics Reference Number</b>	HEC22044
<b>Project Sponsor</b>	La Trobe University
<b>Coordinating Principal Investigator/ Principal Investigator</b>	Dr Adam Culvenor (School of Allied Health, Human Services and Sport (SAHHSS), La Trobe University)
<b>Associate Investigator(s)</b>	Dr Brooke Devlin (School of Human Movement and Nutrition Sciences, University of Queensland) Prof. Peter Brukner (SAHHSS, La Trobe University) Ass. Prof. Joanne Kemp (SAHHSS, La Trobe University) Prof. Kay Crossley (SAHHSS, La Trobe University) Dr Andrea Mosler (SAHHSS, La Trobe University) Dr Josh Heerey (SAHHSS, La Trobe University) Ms Lynette Law (PhD student, SAHHSS, La Trobe University) Ms Amanda Attanayake (SAHHSS, La Trobe University)
<b>Location</b>	La Trobe University

**Part 1      What does my participation involve?**

**1      Introduction**

You are invited to take part in this research project because you have knee pain. This research project aims to assess the effectiveness of two different programs provided through advice and education by a qualified dietitian to improve your knee pain, function and quality of life.

This information sheet tells you about the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want to take part in the project. Please read this information carefully. Ask questions about anything that you don't understand or want to know more about. Before deciding whether or not to take part, you might want to talk about it with a relative, friend or your local doctor.

**Your participation is voluntary**

Participation in this research is completely voluntary and there will be no cost to you. If you don't wish to take part, you don't have to. If you decide you want to take part, you will be given a copy of this Participant Information Sheet and asked to sign the consent section. By signing it you are telling us that you:

- Understand what you have read
- Consent to take part in the research project
- Consent to have the tests and treatments that are described
- Consent to the use of your personal and health information as described.

You will be given a copy of this Participation Information Sheet and Consent Form to keep.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool

## 2 What is the purpose of this research?

As you may be aware, knee pain is very common and is often associated with knee osteoarthritis. Osteoarthritis is the most common form of arthritis and is a leading cause of disability in Australia. Currently, there is no cure for osteoarthritis, therefore it is important to investigate treatments that can improve the main symptoms associated with osteoarthritis: pain, swelling, stiffness and movement difficulties. We will recruit 140 adults who have knee pain.

This study is being conducted by researchers at La Trobe University and is partly funded by the National Health and Medical Research Council (NHMRC) of Australia and Dr Peter Brukner. All assessments and consultations will be at **no cost** to you.

## 3 Who can participate?

You can participate in this study if you meet all the following:

- Between 45-85 years of age and understand written and spoken English
- Activity-related knee pain on most days of the past month
- Knee pain for at least 3 months
- No morning knee stiffness, or morning stiffness that lasts less than 30mins
- Willing to complete the assigned 12-week eating program and attend all appointments (detailed below)

You are not eligible and cannot participate in this study if you meet any of the following:

- Knee pain not primarily due to osteoarthritis (e.g., fibromyalgia, referred pain)
- Bilateral knee replacement
- Already strictly following a specific diet (e.g., low-carb, paleo, Mediterranean, Vegan)
- Received treatment from a dietitian, or knee injection, in the past 3 months
- Experienced  $\geq 5$ kg weight loss in the past 3 months or body weight  $\geq 200$ kg
- Planning to have knee surgery in the next 6 months
- Pregnant or breastfeeding
- History of psychiatric or eating disorder (excluding anxiety/depression) or bariatric surgery

## 4 What does participation in this research involve?

This study will be conducted over 6 months in total (see flowchart on next page).

### ***Pre-baseline (online/phone) appointment***

You will be asked to attend a 30-minute Zoom/telephone appointment prior to your first face-to-face appointment. At this appointment, we will discuss the consent form, outline the fasting process needed to complete your blood test and DEXA scan, and answer any questions you might have. We will also explain how to complete a 3-day food diary, which will be done using a smart phone application or paper-based food diary (personal preference).

### ***Baseline (first) appointment***

This appointment will be arranged at a convenient time for you at La Trobe University, Bundoora and will take approximately 2 hours. You will be asked to not eat/drink anything or conduct any exercise in the morning of your appointment (i.e., fasting for 12-hours) for the purpose of a blood test. At the appointment, we will assess your:

- Height, weight, waist circumference and blood pressure
- Body composition measured via a Dual-energy X-ray Absorptiometry Scan (DEXA).  
This involves laying on the scanner bed for ~7 mins. The machine uses small doses ( $<1\%$  yearly dose) of radiation to assess tissue density (how much muscle and adipose tissue you have). The total effective dose of radiation has been calculated by a Medical Physicist (see risks below). Light clothing with no metal (e.g., zips, clips, underwire) should be worn (gown provided if needed). All measures will be taken by trained



- researchers who hold Victorian Government radiation licenses and comply to the Code of Practice set out by the Australian Radiation Protection and Nuclear Safety Agency.
- Blood test: A trained researcher qualified to take blood will collect a small amount of blood (~25 mL, equivalent to ~4 teaspoons) from a forearm vein to assess inflammation levels.
  - Questionnaires assessing your pain, activity level and quality of life and food intake
  - Functional tests: i) how many times you can stand from a chair in 30 secs; and ii) how fast you can walk 40 metres.

We will provide a snack/drink as soon as you complete the DEXA and blood tests.

**Random assignment to one of two different treatments**

At the end of the first appointment at La Trobe University, you will be randomly assigned (50:50 chance, like a coin toss) to receive a program (from qualified dietitians) to either:


- i) minimise processed foods that are known to promote inflammation and optimise foods shown to reduce inflammation; or
- ii) minimise foods that are known to be high in fat content.

This means neither you nor the researchers will be able to choose which group you are assigned to. We do not know which treatment is best; to find out we need to compare the two programs. Although the two programs involve modifying some types of food that you eat, you can eat as much as you like of these foods. **You do not need to restrict the amount of food that you eat.**

Irrespective of which group you are assigned to, you will receive specific education and advice from an Accredited Practising Dietitian (APD) in a dietary consultation at the start of the study (at the end of your first appointment at La Trobe University). Your dietitian will also work with you to develop a personalised management plan to support you throughout the study. You will be asked to follow the program for 12 weeks (but you can continue for as long as you like). We will ask you to record your food intake for 3 days at up to six different times throughout the study.

**Support phone calls**

To support you throughout the study and answer any questions you have, we will arrange up to four follow-up consultations to be conducted over the phone/online during the 12 weeks. This phone call will take approximately 15-20 minutes. At these times, we will also ask you to complete some of the same questionnaires online (via a secure link provided by e-mail).



**Figure 1. Flowchart of study assessments**

**Follow-up appointments**

So that we can assess the results of the program you have been assigned, we will ask you to return for face-to-face appointments at La Trobe University at **12 weeks and 6 months after your first appointment.** These follow-up appointments will be like the first appointment where

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool



we will do all the same tests and questionnaires. You will need to fast (not eat/drink anything) the morning of your appointment for the blood test. You will have another dietary consultation with the study dietitian who will provide support for you to continue with the program you have been assigned. You should allow about 2 hours for these appointments. To assess longer-term results, we will ask you to complete the same online questionnaires at 1 and 2 years after your first appointment. The total time commitment for participating will be approximately 6-8 hours.

There are no additional costs associated with participating in this research project. All medical care and tests (i.e., dietitian consultations, DEXA scan, blood tests) required as part of the research project will be provided free of charge. The results of the DEXA scan and blood tests will not be used to diagnose health conditions, but only to evaluate the effects of the intervention. We will provide you with your individual results when the DEXA and blood analyses are completed at the end of the study. Your travel costs to attend the assessments will be reimbursed up to \$100.

At the end of the first 12 weeks, or after 6-12 months, we may also ask if you are willing to have a separate interview with one of the study researchers (this interview is optional and you can take part in the study without needing to complete the interview). The purpose of this interview is to seek feedback on the study treatments, satisfaction with the process received and whether there are any suggestions for improvement. The interview will take approximately 30 minutes, but you can cease the interview at any time. To ensure responses are correctly interpreted, responses to questions will be audio recorded and transcribed. Audio recording transcriptions will be completed by 'Transcription Australia' on their secure, encrypted Australian-based software. Although voice in your audio recording could lead to your identification, this file will not be used during analysis. Instead, a re-identifiable transcription, which you will have the opportunity to check for accuracy, will be used for analysis. Re-identifiable means that we will use a code number and not your name on data collected to ensure your anonymity. Following the completion of analysis of this transcription, the audio file associated with your interview will be deleted. After analysis, overall findings and conclusions from all interviews will also be sent to you, to allow an opportunity to make any further comments. We will seek around 40 participants to be interviewed. It is your decision or not whether you wish to be interviewed.

## 5 What are the alternatives to participation?

You do not have to take part in this research project to receive treatment for your knee. Other options are available; these include seeing a physiotherapist or dietitian (e.g., private or public health centre). The research team will discuss these options with you before you decide to take part in this project. You can also discuss the options with your doctor, dietitian or physiotherapist.

## 6 What are the possible benefits of taking part?

We cannot guarantee or promise that you will receive any benefits from this research. However, possible benefits may include improvement of pain, function, quality of life, physical activity, and confidence in your knee. You may gain valuable insight into how to manage your food intake and specific anti-inflammatory and low-fat foods, nutrients and eating habits. The expected benefit to society is the development of a drug-free and non-invasive treatment option to help manage pain and disability associated with osteoarthritis. This will give doctors and patients alternative ways to manage knee pain, which in turn may lead to improvements in the quality of life for patients.

## 7 What are the possible risks and disadvantages of taking part?

With any medical treatment there are: (i) risks we know about; (ii) risks we don't know about; and (iii) risks we don't expect. We have listed the risks we know about below. You may have none, some or all the effects listed below, and they may be mild, moderate or severe. If you have any of these side effects, or are worried about them, talk with the study coordinator.

Possible Side Effect	How often is it likely to occur?	How severe might it be?	How long might it last?
Emotional distress due to involvement in research and completion of questionnaires	Rarely; although can occur when completing study questionnaires	Minimal	While completing the study questionnaires
Emotional distress due to diet assessment	Rarely; although can occur when assessing food intake prior to, or during, appointments	Minimal	While completing the food diary or assessment
Discomfort due to body measurements	Can occur while measurements are done by your dietitian or researcher	Minimal Mild	During appointment only
Discomfort due to blood test	Rarely; while blood is being collected	Mild	Bruising or swelling may last 1-3 days
Exposure to ionising radiation	1x 7-minute scan at initial, 12-week and 6-month appointment	Minimal	Effect too small to measure
Tiredness/change in bowel patterns with change in diet	Any change in diet can make you feel tired or have different bowel patterns	Minimal	1-2 weeks
Contraction of COVID-19	Can occur during the face-to-face assessments	Minimal Moderate	1-2 weeks

If you become upset or distressed because of your participation in the research, the study coordinator together with the qualified dietitian will assist you with appropriate support. We can also provide you information about services you can access to seek help for emotional distress.

**Risks associated with completing study questionnaires and diet assessment**

Completing questionnaires about your knee pain, function, quality of life and dietary intake may cause emotional distress. If you begin to feel upset or distressed when completing your questionnaires or dietary assessment, please let a member of the research team know. We will provide you with the appropriate support, including a document outlining services you can access to help with your emotional distress.

**Risks associated with blood test**

Having a blood sample taken may cause some discomfort or bruising. On very rare occasions, the blood vessel may swell, or blood may clot in the blood vessel, or the spot from which blood is taken could become inflamed. Some people may feel light-headed when having blood taken and may occasionally faint. Very rarely, there could be a minor infection or bleeding. A qualified person will take a very small amount of your blood (max 30mL each appointment (normal blood donation is 500mL)) using stringent infection control procedures. If you notice increased redness, swelling or other signs of infection in the days following your assessment, tell us immediately.

**Risks associated with eating low-inflammatory foods or low-fat foods**

As you adjust to the eating program you are assigned to, you may experience feelings of tiredness and/or changes in bowel habits and patterns. The researchers will assess your diet and ensure you are meeting your energy and nutrient needs throughout the study intervention. This eating program may be different than your normal diet and therefore influence your usual weekly shopping bill and expenses. As part of the consultations, you will be provided with some advice on how to follow the diet on a budget if required to ensure there is minimal financial burden.

**Exposure to ionising radiation**

If you choose to take part in this research, you will undergo three 7-minute DEXA scans (first, 12-week and 6-month assessments). DEXA scans are a non-invasive, fast and simple procedure. This research study involves exposure to a very small amount of radiation from a DEXA scan that you would not normally receive. As part of everyday living, everyone is exposed to naturally occurring background radiation and receives a dose of about 2 millisieverts (mSv) each year. The effective dose you will receive from all of these DEXA scans is approximately 0.03 mSv. At these

dose levels, no harmful effects of radiation have been demonstrated as any effect is too small to measure. The risk is believed to be minimal.

The scans we are taking are for research purposes and are not intended to be used like scans taken for a full clinical examination or to be used to help diagnose, treat or manage a particular condition. The whole-body DEXA scan may identify participants with a low bone mineral density. However, a whole body DEXA scan is not the established method for detecting low bone mineral density. Therefore, as a precaution if you are identified as having a low bone mineral density you will be encouraged to make an appointment with your General Practitioner to discuss the results.

Have you been involved in any other research studies that involve radiation? If so, please tell us. Please keep information contained within this Patient Information Sheet about your exposure to radiation in this study, including the radiation dose, for at least 5 years. You will be required to provide this dose to researchers of any future research projects involving exposure to radiation.

### **Contraction of COVID-19**

You may be at risk of contracting COVID-19 during one of the face-to-face appointments at La Trobe University. Prior to attending La Trobe University, you will be screened for signs and symptoms of COVID-19 by a member of the research team. You will also need to be fully vaccinated (or hold a valid medical exemption) to be able to attend La Trobe University for your assessments. The research team will put in place the appropriate control measures to reduce the risk of COVID 19 transmission. The risk is believed to be minimal.

## **8 What if I withdraw from this research project?**

You are under no obligation to continue with the research study. You may change your mind at any time about participating in the research. People withdraw from studies for various reasons, and you do not need to provide a reason.

You can withdraw from the study at any time by completing and signing the 'Participant Withdrawal of Consent Form'. This form is provided at the end of this document and is to be completed by you and supplied to the research team if you choose to withdraw at a later date.

If you withdraw from the study, you will be able to choose whether the study will destroy or retain the information it has collected about you. Information about you that has already been analysed (i.e., once you have been allocated to either program), may not be able to be destroyed to ensure accurate and unbiased study reporting. Personal details collected, such as your name and contact details, can be destroyed at any time upon study withdrawal.

## **9 What happens when the research project ends?**

At the completion of the research project, you may continue to use the resources provided and to follow the eating program principles if you choose to. If requested, we will provide you with your individual results including your body composition (DEXA) assessment and whole study results. We, or other researchers, may also use coded information (so that you cannot be identified) collected for this research study in future related studies. If you consent (tick the box on the consent form) to be contacted for future related research, we will store your contact details (name, address, phone number, email) on the secure La Trobe University research drive, only accessible to members of the research team, and may contact you about future related research projects.

## **Part 2 How is the research project being conducted?**

### **10 What will happen to information about me?**

By signing the consent form you agree to the relevant research staff collecting and using personal information about you for the research project. Any information obtained in connection with this research project that can identify you will remain confidential and securely stored. It will be disclosed only with your permission, or in compliance with the law.

**Storage, retention and destruction**

The anonymity of your participation is assured with our procedure, in which a code number (not your name) will identify you. Data will be kept securely at La Trobe University in a locked filing cabinet and password protected research computer. Identifiable data will be stored for 15 years, then destroyed (electronic records deleted, paper-files shredded). Data will be strictly handled confidentially under guidelines set out by the National Health and Medical Research Council. The principal investigator (Dr Adam Culvenor) is responsible for maintaining this confidentiality.

In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you have the right to request access to your information collected and stored by the research team. You also have the right to request that any information with which you disagree be corrected.

The results of this project may be published and/or presented in a variety of forums and used by research students to obtain a research degree. In any publication, presentation or data files shared with other researchers, information will be provided in such a way that you cannot be identified, except with your permission.

**11 Who is organising and funding the research?**

This research project is being conducted by Dr Adam Culvenor and a team of researchers. It has been funded by the NHMRC (GNT2008523) and Dr Peter Brukner. Dr Peter Brukner is also an investigator on the project and has written a book and developed an app that will be used as part of the study. He will not be involved in data collection, analysis or the decision to publish results. No member of the research team will receive a personal financial benefit from your involvement in this research project (other than their ordinary wages).

**12 Who has reviewed the research project?**

All research in Australia involving humans is reviewed by an independent group of people called a Human Research Ethics Committee (HREC). The ethical aspects of this research project have been approved by the HREC of La Trobe University Human Ethics Committee.

This project will be carried out according to the *National Statement on Ethical Conduct in Human Research (2018)*. This statement has been developed to protect the interests of people who agree to participate in human research studies.

**13 Further information and who to contact**

For all enquiries, you can contact the Clinical Trial Manager, during business hours:  
Dr Adam Culvenor, Senior Research Fellow in Physiotherapy, La Trobe University  
Telephone: 03 9479 5116; E-mail: a.culvenor@latrobe.edu.au

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

Reviewing HREC: La Trobe University Human Research Ethics Committee  
Complaints Contact: Senior Human Ethics Officer, Ethics and Integrity, Research Office  
Telephone: 03 9479 1443 E-mail: humanethics@latrobe.edu.au

\* Please quote the application reference number HEC22044





## Consent Form - Adult providing own consent

**Title** Optimising outcomes for people with knee pain through food: FEAST randomised controlled trial

**Short Title** The FEAST trial

**Ethics Reference Number** HEC22044

**Project Sponsor** La Trobe University

**Coordinating Principal Investigator/  
Principal Investigator** Dr Adam Culvenor (La Trobe University)

**Associate Investigator(s)** Dr Brooke Devlin (University of Queensland)  
Prof. Peter Brukner (La Trobe University)  
Ass. Prof. Joanne Kemp (La Trobe University)  
Prof. Kay Crossley (La Trobe University)  
Dr Andrea Mosler (La Trobe University)  
Dr Josh Heerey (La Trobe University)  
Ms Lynette Law (PhD student, La Trobe University)  
Ms Amanda Attanayake (SAHHSS, La Trobe University)

**Location** La Trobe University

### Consent Agreement

I have read the Participant Information Sheet and I understand the purposes, procedures and risks of the research described in the project.

I understand that data files may be shared with other researchers, and that information will be provided in such a way that I cannot be identified, except with my permission.

I have had an opportunity to ask questions and I am satisfied with the answers I have received. I freely agree to participate in this research project as described and understand that I am free to withdraw at any time during the study without affecting my future health care.

I understand that, if I decide to discontinue the study treatment, I may be asked to attend follow-up visits to allow collection of information regarding my health status. I agree that data gathered for the study may be published provided my name or other identifying information is not used.

- ☐ I wish... / ☐ do not wish... to receive results of the study
- ☐ I consent... / ☐ do not consent... to be contacted for future related research
- ☐ I consent... / ☐ do not consent... to have my interview responses audio-recorded/transcribed.
- ☐ I consent... / ☐ do not consent... to have my samples/data used in future research

I understand that I will be given a signed copy of this document to keep.

Name of Participant (please print) \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

### Declaration by Researcher<sup>†</sup>

I have given a verbal explanation of the research project, its procedures and risks and I believe that the participant has understood that explanation.

Name of Researcher<sup>†</sup> (please print) \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

<sup>†</sup> An appropriately qualified member of the research team must provide the explanation of, and information concerning, the research project.



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	ACTRN12622000440729
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	21
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	21
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	21
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	4-5
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
<b>Methods: Participants, interventions, and outcomes</b>			



Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6-7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-13, Table 2, Supplementary File 1
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Table 2
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8-13, Table 2
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	13
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	13-18, Table 3
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	19
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7-8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7-8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7-8
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7-8

17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	NA
-----	--	----

#### Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	18
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	19
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	19
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	19

#### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	18
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	19-20
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA

#### Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	20
--------------------------	----	---	----

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	20
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	20
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Supplementary File 1
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	20
	31b	Authorship eligibility guidelines and any intended use of professional writers	NA
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary File 1
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	Supplementary File 2

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-Non Commercial-No Derivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## The effectiveness of an anti-inflammatory diet versus low-fat diet for knee osteoarthritis: the FEAST randomised controlled trial protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-079374.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Mar-2024
Complete List of Authors:	Law, Lynette; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Heerey, Joshua; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Devlin, Brooke; University of Queensland, School of Human Movement and Nutrition Sciences Brukner, Peter; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Kemp, Joanne; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Attanayake, Amanda; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Hullet, Mark; La Trobe University, Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science De Livera, Alysha; La Trobe University, Department of Mathematics and Statistics; The University of Melbourne, School of Population and Global Health Mosler, Andrea; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre Morris, Hayden; Melbourne Knee Centre White, Nathan; Melbourne Knee Centre Culvenor, Adam; La Trobe University, La Trobe Sport and Exercise Medicine Research Centre
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	Knee < ORTHOPAEDIC & TRAUMA SURGERY, Chronic Disease, REHABILITATION MEDICINE, NUTRITION & DIETETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

# The effectiveness of an anti-inflammatory diet versus low-fat diet for knee osteoarthritis: the FEAST randomised controlled trial protocol

Lynette Law<sup>1</sup>, Joshua J Heerey<sup>1</sup>, Brooke L Devlin<sup>2</sup>, Peter Brukner<sup>1</sup>, Joanne L Kemp<sup>1</sup>, Amanda Attanayake<sup>1</sup>, Mark D Hulett<sup>3</sup>, Alysha De Livera<sup>4, 5, 6</sup>, Andrea B Mosler<sup>1</sup>, Hayden G Morris<sup>7</sup>, Nathan P White<sup>7</sup>, Adam G Culvenor<sup>1</sup>

1. La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, Victoria, Australia
2. School of Human Movement and Nutrition Sciences, University of Queensland, Brisbane, Australia
3. Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, Australia
4. Department of Mathematics and Statistics, La Trobe University, Bundoora, Victoria, Australia
5. School of Population and Global Health, The University of Melbourne, Victoria, Australia
6. Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia
7. Melbourne Knee Centre, Melbourne, Victoria, Australia.

**Corresponding Author:**  
Dr Adam Culvenor  
La Trobe Sport and Exercise Medicine Research Centre,  
La Trobe University,  
Kingsbury Drive, Bundoora, 3086, Victoria, Australia  
Phone: +61 9479 5116  
Email: a.culvenor@latrobe.edu.au

**Word count:** 3,998

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Erasmus Hogeschool

Page 1 of 27

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

## ABSTRACT

**Introduction:** Chronic inflammation plays a key role in knee osteoarthritis pathophysiology and increases risk of comorbidities, yet most interventions do not typically target inflammation. Our study will investigate if an anti-inflammatory dietary program is superior to a standard care low-fat dietary program for improving knee pain, function and quality-of-life in people with knee osteoarthritis.

**Methods and analysis:** The FEAST (eFfect of an Anti-inflammatory diet for knee oSTeoarthritis) Study is a parallel-group, assessor-blinded, superiority randomised controlled trial. Following baseline assessment, 144 participants aged 45-85 years with symptomatic knee osteoarthritis will be randomly allocated to one of two treatment groups (1:1 ratio). Participants randomised to the anti-inflammatory dietary program will receive six dietary consultations over 12 weeks (2 in-person, 4 phone/videoconference) and additional educational and behaviour change resources. The consultations and resources emphasise nutrient-dense minimally processed anti-inflammatory foods and discourage pro-inflammatory processed foods. Participants randomised to the standard care low-fat dietary program will receive three dietary consultations over 12 weeks (2 in-person, 1 phone/videoconference) consisting of healthy eating advice and education based on the Australian Dietary Guidelines, reflecting usual care in Australia. Adherence will be assessed with 3-day food diaries. Outcomes are assessed at 12 weeks and 6 months. The primary outcome will be change from baseline to 12 weeks in the mean score on four Knee injury and Osteoarthritis Outcome Score (KOOS<sub>4</sub>) subscales: knee pain, symptoms, function in daily activities and knee-related quality-of-life. Secondary outcomes include change in individual KOOS subscale scores, patient-perceived improvement, health-related quality-of-life, body mass and composition using dual-energy X-ray absorptiometry, inflammatory (high-sensitivity C-Reactive Protein, Interleukins, Tumour Necrosis Factor- $\alpha$ ) and metabolic blood biomarkers (glucose, HbA1c, insulin, liver function, lipids), lower-limb function and physical activity.

**Ethics and Dissemination:** Approved by La Trobe University Human Ethics Committee. Results will be presented in peer-reviewed journals and at international conferences.

**Trial registration:** ACTRN12622000440729



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Inflammation, Low-carbohydrate, Anti-inflammatory, Pain, Osteoarthritis, Knee, Chronic disease, Rehabilitation, Diet

**STRENGTHS AND LIMITATIONS OF THIS STUDY**

- The anti-inflammatory dietary program was codeveloped and piloted with patients and clinicians, with the comparison low-fat dietary program representing usual care.
- Sufficiently powered trial evaluating change from baseline to 12 weeks (primary endpoint) and 6 months facilitating longer-term effectiveness evaluation of the anti-inflammatory dietary program.
- This trial will evaluate both self-reported and objective outcomes to understand potential mechanisms of symptomatic changes.
- While outcome assessors are blinded to group allocation, the health professionals delivering the interventions and participants are unable to be blinded to group allocation due to the type of interventions.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

## INTRODUCTION

Osteoarthritis (OA) is the most common rheumatic disease affecting approximately 15% of the population, with OA of the knee being most prevalent.(1, 2) Knee OA and its associated symptoms can be disabling and lead to substantial societal and healthcare costs.(3) In Australia alone, annual OA-related healthcare expenditure exceeds \$2.1 billion.(4) Although the main symptom of knee OA is pain, individuals with knee OA have an increased risk of other chronic diseases, including cardiovascular disease and diabetes.(5) As many as two-thirds of older adults with knee OA have more than one comorbidity.(6)

Clinical guidelines for knee OA recommend exercise-therapy and weight-loss as first-line management strategies due to their excellent safety profile and therapeutic effects similar to commonly used analgesics.(3, 7) However, the effectiveness of exercise-therapy has recently been questioned due to its lack of benefit over an open-label placebo,(8) and findings that one-third of people completing an exercise program do not achieve a clinically meaningful improvement in pain.(9, 10) Weight-loss programs in those who are overweight or obese typically consist of caloric restrictive diets, which are challenging to adhere to and sustain.(11) A meta-analysis highlighted that, within two years of a calorie-restrictive program, over half of initial weight lost was regained, and by 5 years, this figure jumped to >80%.(12)

Anti-inflammatory diets provide an alternative to calorie-restrictive approaches by targeting local and systemic inflammation, both contributors to OA disease onset, progression and symptom burden.(13-15) Anti-inflammatory diets are typically high in minimally processed, nutrient rich foods such as fruit, vegetables, spices and extra virgin olive oil, which are dense in nutrients such as polyphenols, carotenoids, fibre, monounsaturated and polyunsaturated fatty acids.(16-19) These nutrients can significantly reduce inflammation even in the absence of weight loss(20) via antioxidant and anti-inflammatory properties by neutralising free radicals and associated cell damage, as well as improved lipid profiles.(16, 17, 21) Omega-3 fatty acids, abundant in nuts, seeds and fish, are also a key part of anti-inflammatory dietary approaches and help to achieve a more desirable omega-6 to omega-3 ratio.(22) In contrast, omega-6 fatty acids can be converted into arachidonic acid, a precursor for proinflammatory eicosanoids.(23) An elevated omega-6:omega-3 ratio exacerbates oxidative stress, which

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

104 increases the risk and severity of chronic disease, including OA.(15) Due to their focus on real  
105 foods and consumption to satiety, anti-inflammatory diets are likely more sustainable than  
106 traditional calorie-restrictive approaches.(17)

107  
108 Anti-inflammatory diets have garnered much interest in recent years due to their  
109 effectiveness in alleviating symptoms and improving biomarkers for a variety of chronic  
110 diseases, including diabetes,(18) cardiovascular disease,(24) epilepsy(25) and rheumatoid  
111 arthritis.(26) Small studies investigating anti-inflammatory diets for knee OA have  
112 demonstrated feasibility and effectiveness in reducing symptoms and inflammation over 12-  
113 16 weeks.(15, 27, 28) To date, no fully powered randomised controlled trial (RCT) has  
114 evaluated the effectiveness of an anti-inflammatory diet in knee OA.

115  
116 The primary aim of this RCT is to estimate the average effect of an anti-inflammatory dietary  
117 program compared to a standard care low-fat dietary program on knee-related pain, function  
118 and quality of life in individuals with knee OA. We hypothesise that the anti-inflammatory  
119 dietary program will result in greater improvements in knee-related pain, function and quality  
120 of life after 12 weeks (primary endpoint) and 6 months (secondary endpoint) compared to  
121 the standard care low-fat dietary program. Secondary aims are to assess 12-week and 6-  
122 month effectiveness of the anti-inflammatory dietary program on: i) self-reported global  
123 rating of change and achievement of acceptable symptoms; ii) health-related quality of life;  
124 iii) body mass and composition using dual-energy X-ray absorptiometry (DXA); iv)  
125 inflammatory and metabolic blood biomarkers, global lower-limb function and physical  
126 activity.

127  
128 **METHODS AND ANALYSIS**

129 **Study Design**

130 This protocol describes a pragmatic, 2-arm, parallel-group assessor-blinded superiority RCT  
131 and will be reported according to the Standard Protocol Items: Recommendations for  
132 Interventional Trials (SPIRIT) statement.(29) Reporting of the completed RCT will conform to  
133 the Consolidated Standards of Reporting Trials (CONSORT) statement.(30) The FEAST trial will  
134 be conducted at a single site (La Trobe University) in Melbourne, Australia with the first

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

participant randomised on August 31, 2022 and the final participant anticipated to be randomised in June 2024. The primary endpoint will be at 12 weeks, with additional follow-up at 6 months (further longer-term follow-up dependent on funding). The study was prospectively registered on the Australian and New Zealand Clinical Trial Registry (ACTRN 12622000440729).

### Patient and public involvement

Participants and clinicians co-designed the anti-inflammatory intervention, research questions and study methods. This input was gained from: i) qualitative interviews with participants from the pilot study as part of formal process evaluation strategies;(28) ii) participant and clinician focus groups providing feedback on study recruitment material and participant handbooks; and iii) discussion with experienced clinicians managing knee OA and dietary intervention strategies as part of FEAST development. Patients and clinicians will provide input into the dissemination of study results by assisting with the decision on what information to share and in what format.

### Participants

One hundred and forty adults 45-85 years old with chronic knee pain consistent with a clinical OA diagnosis using criteria from the National Institute for Health and Care Excellence, which does not require radiographic evidence,(31) will be enrolled (table 1).

**Table 1.** Eligibility criteria

Inclusion criteria	Exclusion criteria
Fulfil National Institute for Health and Care Excellence(31) clinical criteria for osteoarthritis:	Another reason than OA for knee symptoms (e.g., tumour, fibromyalgia)
<ul style="list-style-type: none"> <li>Activity-related joint pain with average knee pain severity <math>\geq 4</math> on 11-point numeric rating scale (NRS, where 0 = no pain, 10 = worst pain possible) in the past week;</li> <li>No morning stiffness or morning stiffness <math>\leq 30</math> min; and</li> <li>Age <math>\geq 45</math> years</li> </ul>	

Age ≤85 years – due to potential safety reasons and additional co-morbidities that may hinder capacity for dietary adherence	Planning to have knee surgery in next 6 months
History of knee pain on most days of the past month	Already strictly following an anti-inflammatory diet (e.g., low carbohydrate, high-fat, paleo, Mediterranean)
History of knee pain for at least 3 months	Following a habitual diet that excludes animal products (e.g., vegan)
Be willing and able to attend 3-4 phone consults and 12-week and 6-month follow-up assessments	Unable to follow anti-inflammatory diet (e.g., medically contraindicated, history of food allergy/hypersensitivity, family reasons)
Able to understand written and spoken English, and to give informed consent	Taking the following diabetic medication that affects blood sugar levels (i.e., insulin, SGLT 2 inhibitors, sulfonylureas) to mitigate the risk of hypoglycaemia/ketoacidosis
	Contraindications for DXA scans (e.g., pregnant, breastfeeding, planning pregnancy in next 6 months, >200kg body weight)
	>5kg weight fluctuation in past 3 months (i.e., unstable weight)
	Unable to understand written and spoken English
	Knee injection, injury or surgery in the past 3 months
	A diagnosed psychiatric disorder (excluding anxiety and depression)
	History of eating disorder or bariatric surgery
	Had all eligible knee joints replaced by arthroplasty

NRS, numeric rating scale; SGLT, sodium glucose co-transporter; DXA, dual-energy X-ray absorptiometry

Recruitment and screening procedure

Trial flow is outlined in figure 1. Participants will be recruited from our network of collaborating orthopaedic surgeons in Victoria, Australia. Consistent with our prior work in other musculoskeletal conditions,(32, 33) potentially eligible participants (i.e., individuals aged 45-85 years with a history of knee pain for which medical care was sought) will be sent a study information letter inviting them to contact the research team. Additional recruitment

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

strategies will include advertisements in local newspapers, community/university magazines/posters, community market stalls and social media.

\*\*\*FIGURE ONE HERE\*\*\*

Potential participants will be screened for eligibility via telephone. Once eligibility is confirmed, participants will attend a study orientation session via videoconference to explain further study details (e.g., fasting requirements) and be orientated to the dietary assessment tool (3-day food diary). If both knees meet the inclusion criteria, the most symptomatic knee will be considered as the index knee.

### *Randomisation procedure, concealment of allocation and blinding*

Upon completion of baseline assessment, participants will be randomised to either the anti-inflammatory dietary program or standard care low-fat dietary program. Study treatments, but not study hypotheses, will be revealed to participants. A computer-generated randomisation schedule has been developed *a priori* by an independent statistician in random permuted blocks of 4-8 and stratified by sex and body mass index ( $\geq 30\text{kg.m}^{-2}$  vs  $<30\text{kg.m}^{-2}$ ). To ensure concealed allocation, the randomisation schedule will be stored electronically in the secure Research Electronic Data Capture (REDCap®) system and only accessible to an unblinded researcher once baseline measures have been obtained, who will communicate treatment allocation to the participant. Investigators conducting the follow-up assessments will be blinded to group allocation. As the primary outcome is self-reported, participants are considered assessors; therefore, they will be blinded to previous scores. The health professionals delivering the interventions will deliver the intervention for both groups. Specific protocols for both interventions (including consultation contents and format, and accompanying resources) have been developed, and the health professionals have received training to ensure equal credibility. Random observations of intervention delivery will be conducted by the principal investigators to ensure treatment delivery credibility and fidelity. An independent statistician, blinded to group allocation, will perform the primary RCT analysis.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Interventions**

The anti-inflammatory dietary program and standard care low-fat dietary program are summarised aligning to Template for Intervention Description and Replication (TIDieR) guidelines(34) (table 2). Participants in both intervention groups were not actively discouraged to lose weight, but weight loss was described as a potential outcome of the interventions. The same health professionals will deliver the intervention for both groups.

*Anti-inflammatory dietary program*

Participants allocated to the anti-inflammatory dietary program will receive specific anti-inflammatory dietary education and an individualised eating plan, as well as a suite of resources to support behaviour change. The anti-inflammatory dietary program will be delivered over 12 weeks by a qualified dietitian or by another health professional specially trained to deliver the intervention (e.g., physiotherapist).

Participants will be encouraged to follow a diet containing minimally-processed foods and vegetable oils, and higher amounts of healthy fats and nutrient-dense wholefoods known to fight inflammation (e.g., fresh fruits low in natural sugar such as berries, non-starchy vegetables, nuts and seeds, seafood, poultry, red meat, eggs, full-fat dairy). Healthy fats include monounsaturated and polyunsaturated fats with optimal omega-3: omega-6 ratios as found in seafood, nuts, and extra-virgin olive oil. Participants will be advised to limit processed foods, refined carbohydrates (e.g., pasta, bread, rice), confectionary and foods with added sugar. Participants will be encouraged to consume a normocaloric diet and to eat to satiety, with no specific percentage of total energy intake targets for carbohydrate, fat or protein.

An initial in-person consultation (~45 minutes) will occur immediately following group allocation to constructively review participant’s current dietary intake (using baseline 3-day food diary) and develop an individualised meal plan. Participants will be provided with a comprehensive explanation of anti-inflammatory dietary principles, its rationale (e.g., the role of inflammation in OA, link between foods and inflammation) and its potential benefits and side-effects, and address questions and/or concerns. The following educational and behaviour change resources will also be provided at the initial consultation to support

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
ErasmusHogeschool

228 adherence: i) bespoke information booklet providing anti-inflammatory eating information,  
229 example meal plans, and foods that are encouraged and foods to avoid (Supplementary file 1  
230 and 2); ii) complimentary subscription to an anti-inflammatory program (Defeat Diabetes  
231 phone app/website), providing anti-inflammatory recipes, masterclasses, meal plans and  
232 educational articles; iii) complimentary links to recommended documentaries exploring the  
233 benefits of anti-inflammatory nutrition (i.e., Fat Fiction, Cereal Killers, That Sugar Film); and  
234 iv) complimentary copy of a book exploring benefits of anti-inflammatory approach (A Fat Lot  
235 of Good(35)).

236  
237 Follow-up phone/videoconference consultations (~30 minutes) will be scheduled in weeks 2,  
238 4, 6, and 9, with timing to be negotiated between each participant and the health professional  
239 delivering the intervention. A final in-person consultation will be delivered immediately  
240 following the completion of the 12-week assessment. These follow-up consultations will  
241 provide participants with ongoing support, education and accountability. A 3-day food diary,  
242 completed prior to each consultation (see outcomes/adherence section), will guide  
243 individualised feedback and support to adapt meal plans to optimise adherence.

244 **Table 2:** Overview of intervention delivery described according to the TiDieR guidelines

1. BRIEF NAME	Anti-inflammatory dietary program	Standard care low-fat dietary program
2. WHY	Anti-inflammatory diets targeting systemic inflammation assist in the prevention and management of various chronic diseases.(16) Small pilot studies have shown a positive effect of anti-inflammatory diets to improve knee-related symptoms in people with knee osteoarthritis.(28)	Healthy eating guidelines and dietary advice described in the standard care program booklet was based on Australian Dietary Guidelines (ADGs).(17)  Two-three dietetic consultations represent usual care for patients referred for dietary management in Australia.(37, 38)
3. WHAT (MATERIALS)	Participants receive an intervention handbook containing all study details, key anti-inflammatory eating principles, example meal plans, traffic light system of foods encouraged and discouraged, and education (e.g., common myths, tips for eating out, shopping tips); complimentary access to the Defeat Diabetes program app/website; complimentary links to three movies; and a complimentary copy of the book “A Fat Lot of Good”.(35)	Participants receive an educational handbook emphasising ADGs healthy eating principles and are provided links to the online resources from the Eat for Health website ( <a href="https://www.eatforhealth.gov.au/">https://www.eatforhealth.gov.au/</a> ).
4. WHAT (PROCEDURES)	Six consultations providing individualised guidance and support to follow an anti-inflammatory eating pattern, emphasising the consumption of fruits, non-starchy vegetables, fish, poultry, red meat, eggs, full-fat dairy, nuts, seeds, and extra virgin olive oil. Participants will be encouraged to avoid highly processed foods, refined carbohydrates, added sugar, and processed meats.	Three consultations providing general advice and education regarding healthy eating based on the ADGs. The principles focus on consumption of foods from the five food groups, while limiting intake of foods containing saturated fat, added salt, added sugars and alcohol.
5. WHO PROVIDED	A qualified dietitian or health professional specially trained to deliver all components.	A qualified dietitian or health professional specially trained to deliver all components.
6. HOW	Delivered with individual support for 12 weeks, after which, participants will be encouraged to sustain the anti-inflammatory diet unsupported up to 6 months. Consultations are one-to-one.	Delivered with standard healthy eating advice for 12 weeks, after which, participants will be encouraged to sustain the program unsupported up to 6 months. Consultations are one-to-one.
7. WHERE	In-person consultations will occur at La Trobe University Nutrition and Dietetics research laboratory. Additional	In-person consultations will occur at the La Trobe University Nutrition and Dietetics research

	consultations will occur via telephone/videoconference (e.g., Zoom). Participants will integrate the diet principles into their daily consumption of foods and beverages.	laboratory. Additional consultations will occur via telephone/videoconference (e.g., Zoom). Participants will integrate the diet principles into their daily consumption of foods and beverages.
<b>8. WHEN AND HOW MUCH</b>	Two in-person consultations at baseline (~45 mins) and week 12 (~30 mins) Four phone/videoconference follow-up consultations (~30 mins) in week 2, 4, 6, and 9. <b>Total active intervention delivery time:</b> ~3.5 hours  Participants are provided with self-management resources to optimise adherence to the anti-inflammatory diet up to the 6-month follow-up.	Two in-person consultations at baseline (~45 mins) and week 12 (~30 mins) One phone/videoconference follow-up consultation (~30 mins) in week 6. <b>Total active control delivery time:</b> ~1.5 hours  Participants encouraged to sustain their diet up to 6-month follow-up.
<b>9. TAILORING</b>	Individualised anti-inflammatory dietary advice, education, and support aligning with participant preferences and goals.	Advice based on the ADGs.
<b>10. MODIFICATIONS</b>	Any modifications will be reported.	
<b>11. HOW WELL (planned)</b>	Two-three professionals (qualified dietitian and other health professional) receive prior training in how to deliver and supervise the program. Fidelity is assessed through random auditing by members of the principal investigator team (AC or BD). Participant adherence to the anti-inflammatory diet is assessed through consultation attendance, regular 3-day food diaries and self-report.	Two-three professionals (qualified dietitian and health professional) receive prior training in how to deliver and supervise the program. Fidelity is assessed through random auditing by members of the principal investigator team (AC or BD). Participant adherence to the standard care low-fat diet is assessed through consultation attendance, regular 3-day food diaries and self-report.
<b>12. HOW WELL (actual)</b>	This will be reported in the primary paper.	

245 TIDieR, Template for Intervention Description and Replication; ADG, Australian Dietary Guidelines

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

246     *Standard care low-fat dietary program*

247     Participants allocated to the standard care low-fat dietary program will receive advice and  
248     education regarding healthy eating based on the Australian Dietary Guidelines.(39) These  
249     government-endorsed guidelines aim to optimise nutrition intake through adequate  
250     consumption of foods from the five core food groups (grains and cereals; fruit; vegetables and  
251     legumes; lean meats and poultry, fish, eggs, and tofu; reduced fat dairy or alternatives), while  
252     limiting intake of foods containing saturated fat, added salt, added sugars and alcohol. They are  
253     high-carbohydrate and low-fat focused – participants will be encouraged to include at least four  
254     serves of wholegrains daily (e.g., brown rice, pasta, bread, quinoa, oats) and to choose low-fat  
255     protein and dairy foods where possible.

257     The program will be delivered through individual consultations with the treating dietitian or other  
258     specially trained health professional – the first in-person consultation immediately following  
259     baseline assessment (~45 minutes), the second via phone/videoconference at 6 weeks (~30  
260     minutes) and the third in-person at 12-week follow-up with timing individualised as required.  
261     Two to three consultations represents usual care for patients referred for dietary management  
262     in Australia through the current public healthcare (Medicare) rebate system.(37, 38) During the  
263     initial in-person consultation, participants will be provided with a bespoke educational booklet  
264     and advice and education emphasising the Australian Dietary Guideline principles  
265     (<https://www.eatforhealth.gov.au/guidelines>) and informed of complementary and publicly  
266     available online resources from the Eat for Health website (<https://www.eatforhealth.gov.au/>).

268     The follow-up phone/videoconference consultation in week-6 and in-person follow-up in week-  
269     12 will provide participants with ongoing support, education and accountability. The 3-day food  
270     diary, completed prior to each consultation (see outcomes/adherence section), will guide  
271     feedback and support to adapt meal plans to optimise adherence. The treating health  
272     professionals delivering the two dietary programs will be based centrally at La Trobe University  
273     and will be trained by the senior study dietitian (BLD) until deemed competent in intervention  
274     delivery.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

Irrespective of group allocation, participants can continue usual medical care and consult with their treating health professionals as necessary (e.g., general practitioner regarding medication changes).

### Data collection procedure

Data will be collected at baseline and 6 weeks, 12 weeks and 6 months after randomisation, with 12 weeks the *a priori* primary endpoint as this coincides with completion of supported interventions (table 3). Where possible, data will be collected and managed using a secure web-based software platform (REDCap®) hosted at La Trobe University,(40) which has equivalent measurement properties to paper-based completion.(41) This strategy was used in our pilot study(28) and other trials of musculoskeletal conditions.(42) Paper versions will also be available if preferred.

## OUTCOMES

### Baseline characteristics

Participant characteristics including age, sex, ethnicity, knee pain/surgery details, socioeconomic details (e.g., education level, employment status, living status), medical history and health literacy (assessed with the Rapid Estimate of Adult Literacy in Medicine (REALM)(43)) will be collected (table 3).

### Primary Outcome

The primary outcome is the change from baseline to 12 weeks in the mean score on four Knee injury and Osteoarthritis Outcome Score (KOOS<sub>4</sub>) subscales covering knee pain, symptoms, function in daily activities and knee-related quality of life. The KOOS is a 42-item patient-reported outcome measure assessing five separately scored subscales: Pain, Symptoms, Function in Sport and Recreation (Sport/Rec), Activities of Daily Living (ADL), and Quality of Life. The KOOS<sub>4</sub> and all KOOS subscale scores range from 0 (extreme problems) to 100 (no problems). The KOOS is a valid, responsive and reliable questionnaire, with KOOS<sub>4</sub> a primary outcome for other knee OA trials.(33, 44, 45)



1  
2 309  
3  
4 310  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 311  
312

**Table 3.** Overview of data collection

Variable	Baseline	6 weeks	12 weeks	6 months
Participant characteristics				
Age	X			
Sex	X			
Ethnicity	X			
Education level	X			
Health literacy (REALM)	X			
Employment status	X			
Smoking status	X			
Civil status, living situation	X			
Medical history, comorbidities	X			
Knee pain/injury/surgery history	X			
Objective Clinical Outcomes				
Height, weight, waist girth	X		X	X
30-second chair stand test	X		X	X
40 metre walk test	X		X	X
Body composition (DXA)	X		X	X
Blood inflammatory and metabolic biomarkers	X		X	X
Blood pressure	X		X	X
Patient-reported Outcomes				
KOOS subscales	X	X	X	X
Global rating of change		X	X	X
Desire for knee surgery	X	X	X	X
Medication use	X	X	X	X
Knee pain (current and worst in past week)	X	X	X	X
EQ-5D-5L^	X	X	X	X
Patient acceptable symptom state	X	X	X	X
Brief Pain Inventory	X		X	X
International Physical Activity Questionnaire	X		X	X
Kessler Psychological Distress Scale (K10)	X		X	X
3-day Food Diaries*	X	X	X	X
Adverse events		X	X	X

REALM, Rapid Estimate of Adult Literacy in Medicine; KOOS, Knee injury and Osteoarthritis Outcome Score; DXA, Dual-Energy X-ray absorptiometry

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

\*3-day food diaries are also assessed prior to anti-inflammatory dietary program consultations at 2, 4 and 9 weeks

<sup>^</sup>Assesses health-related quality of life across 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale (0-100) of current overall health status.

## Secondary effectiveness outcomes

### *KOOS subscales*

To allow for clinical in-depth interpretation, scores for the five KOOS subscales will be reported individually (i.e., pain, symptoms, function in sports and recreational activities, activities of daily living, quality of life).(10, 45)

### *Global Rating of Change (GROC) and patient-acceptable state*

Self-perceived change in pain and function will be assessed using a 7-point Likert scale ranging from 'much worse' to 'much better' in response to the questions: "Overall, how has your knee pain changed since the start of the study?" and "Overall, how has your knee function changed since the start of the study?", respectively. Treatment success will be defined as a response of either 'better' or 'much better'. Satisfaction with current knee function using the self-reported Patient Acceptable Symptom State (PASS) question(46). Participants not satisfied with current knee function at follow-up assessments will be asked a second question to determine if they considered the treatment to have failed.(46)

### *Anthropometrics*

Height and weight will be assessed using a seca 217 stadiometer and seca 703 EMR-validated column scale (Hammer Steindamm, Hamburg, Germany), respectively. Waist circumference will be measured using a metal tape measure (Lufkin W606PM ¼ inch x 2m Executive Thinline Pocket Tape).

### *Global lower-limb function*

Two performance-based tests of lower-limb function recommended by the OA Research Society International (OARSI) will be conducted: the 30-second chair-stand test (number of chair-stands

1  
2 344 from a standardised height chair in 30 seconds) and 40-metre walk test (time to walk 40 metres  
3  
4 345 safely, using walking aids if required).(47)  
5  
6 346

7  
8 347 *Body composition*  
9

10 348 A whole-body DXA scan will be acquired using a Hologic Horizon® DXA scanner (Bedford, MA,  
11  
12 349 United States) to assess adiposity (visceral, peripheral) and lean mass.(48)  
13  
14 350

15  
16  
17 351 *Inflammatory and metabolic biomarkers*  
18

19 352 An array of blood inflammatory and metabolic biomarkers will be analysed from samples of blood  
20  
21 353 collected, including high sensitivity C-Reactive Protein (hsCRP), cytokines (IL-1 $\beta$ , IL-6, IL-8, IL-10,  
22  
23 354 TNF- $\alpha$ ), blood glucose, HbA1c, serum insulin, liver function tests (including albumin), and lipids  
24  
25 355 (e.g., high density lipoprotein, triglycerides). Participants will be instructed to fast for at least 10  
26  
27 356 hours prior to blood collection and a single forearm venepuncture will take place to collect a total  
28  
29 357 of  $\leq 30$  mL blood. Plasma and serum samples will be centrifuged (3000ms, 10 minutes), and all  
30  
31 358 samples (plasma, serum, and whole blood) frozen at -80°C for later analysis (Supplementary File  
32  
33 359 3).  
34 360

35  
36 361 **Secondary safety outcomes**  
37

38 362 *Adverse events*  
39

40 363 Adverse events and serious adverse events will be recorded at 6-week, 12-week and 6-month  
41  
42 364 follow-up via open probe questioning to optimise collection of sufficient detail. Under the  
43  
44 365 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) harms  
45  
46 366 statement, an adverse event is defined as any undesirable experience causing participants to  
47  
48 367 seek medical treatment (e.g., general practitioner).(49) A serious adverse event is defined as any  
49  
50 368 undesirable event/illness/injury classified as having the potential to significantly compromise  
51  
52 369 clinical outcome or result in significant disability or incapacity, those requiring inpatient or  
53  
54 370 outpatient hospital care, to be life-threatening or result in death.  
55 371

56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
ErasmusHogeschool

## Exploratory outcomes

### *Dietary Analysis*

Participants will record food and beverage intake over three days via the smartphone application *Australia Calorie Counter - Easy Diet Diary* (Xyris Software Pty Ltd) or on paper (personal preference). Easy Diet Diary is a commercial calorie counter and food diary that allows users to email recorded diaries to treating professionals. Once received by the treating health professional, the 3-day food diaries will be imported into, and analysed using, Foodworks® Premium Edition nutrient analysis software (Version 10, Brisbane, Australia 2019) and Australian food composition databases. Paper-based 3-day food diaries will be manually entered into FoodWorks®. Total energy intake, macronutrients, micronutrients and core food group analysis will be reported. Dietary analysis data will also be used to calculate the inflammatory potential of participants' diets (e.g., Dietary Inflammatory Index).(50)

### *Quality of life*

Health-related quality of life will be assessed with the EQ-5D-5L generic health index, which comprises five dimensions of health (mobility, self-care, usual activities, pain or discomfort, anxiety or depression) and a Visual Analogue Scale (VAS) of current overall health status.(51) Both validity and reliability has been demonstrated in arthritic populations.(52)

### *Knee pain and interference*

Self-reported knee pain (current, worst over past week, average over past week) will be assessed using a 100mm VAS (0=no pain, 100=worst pain imaginable). The degree to which knee pain interferes with participant's daily functioning will be assessed using the Brief Pain Inventory,(53) a tool with reliability and validity demonstrated in knee pain populations.(54, 55)

### *Change in analgesic medication use*

Change in analgesic medication use from baseline to 12-week and 6-month follow-up will be assessed with a 7-point Likert scale (much less to much more).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*Physical activity*

Physical activity will be assessed using the International Physical Activity Questionnaire (IPAQ),(56) a standardised and valid questionnaire providing an estimate of physical activity and sedentary behaviour, which has been widely validated.(56-58) Respondents are asked to report time spent in physical activity across three intensities (walking, moderate, vigorous). Using the IPAQ scoring protocol,(59) total weekly physical activity can be estimated by weighting time spent in each activity intensity with its estimated metabolic equivalent (MET) energy expenditure.(60)

*Blood pressure*

A pair of seated blood pressure measurements will be obtained using an automated monitor (Omron Model HEM-7121). The blood pressure cuff is placed over the mid-upper arm with the participant seated.

*Self-perceived wellness*

Self-reported sleep quality, hunger, fatigue and energy levels will be assessed using a 100mm VAS (0=worst outcome, 100=best outcome).

*Intervention adherence*

Adherence will be assessed by a self-reported VAS (0=not at all adherent, 100=extremely adherent) and 5-point Likert scale at 6 weeks, 12 weeks and 6 months and evaluation of 3-day food diaries by consulting health professionals. Satisfactory adherence is defined as a self-report of both  $\geq 80$  on the VAS and 'Most days' or 'Every day' on the Likert scale, at both the 6-week and 12-week timepoints.

**DATA MANAGEMENT**

Most outcome data will be collected and managed electronically via REDCap© web-based software hosted at La Trobe University. Other data (e.g., DXA reports) will be stored electronically on the La Trobe University secure research drive. All electronic data will be de-identified (participant code) and exported for data analysis and saved in a password protected database on the La Trobe University research drive only accessible to the research team. Paper-based identifying documents (e.g., consent forms) will be securely stored in a locked filing cabinet

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

accessible only to members of the research team and separately from re-identifiable (i.e., coded) data.

Due to the minimal known risks associated with the interventions being evaluated, our study will not have a formal data monitoring committee and does not require an interim analysis. This is the same approach we have taken with other low risk RCTs.(42) Any unexpected serious adverse events or outcomes will be discussed by the trial management committee (authors of this protocol) and reported to the approving human research ethics committee for monitoring.

### Sample size calculation

This trial has been powered to detect a clinically significant between-group difference for the primary outcome of KOOS<sub>4</sub>. A recent RCT comparing an anti-inflammatory diet vs low-caloric diet in overweight women with knee OA observed an effect size (standardised mean difference) on self-reported pain and function of 1.0 (95% confidence interval 0.5 to 1.6).(61) Given inherent differences in the FEAST RCT (e.g., Australian Dietary Guideline control group, not specifically targeting overweight participants, inclusion of both women and men), we used the lower bound 95% confidence interval to provide a conservative estimate of the anticipated effect size (0.5). This estimated effect size is also a conservative estimate based on our single-arm anti-inflammatory diet pilot trial, which had an effect size of 0.68.(28) Recruiting 128 participants (equally distributed between two arms) would yield 80% power to observe such an effect or larger at a two-tailed Type I error of 0.05. This sample size estimation is also conservative since it is based on independent samples t-test. Using an ANCOVA model that includes the baseline value as a covariate and is pre-specified for the analysis should provide higher power for the same sample size.(62) To account for a potential 10% drop-out, we will recruit 144 participants. This sample size will also be sufficient to detect a minimal important change (MIC) in KOOS<sub>4</sub> estimated at 10 points in patients with knee OA (with a common between-subject standard deviation of 15).(63)

### Statistical analyses

Analysis will be performed according to the Estimands Framework(64) with a statistical analyst blinded to group allocation. All outcomes and analyses are prospectively categorised as primary, secondary or exploratory. For the primary hypothesis, a linear model with baseline value, sex and BMI ( $\geq 30$  vs  $< 30 \text{ kg.m}^{-2}$ ) as covariates and treatment condition as a fixed factor will evaluate the



1  
2 465 treatment effect on the primary outcome of KOOS<sub>4</sub> (mean score of four of the five subscales of  
3  
4 466 the KOOS) at 12 weeks. A linear mixed model utilising repeated measures at all time-points for  
5  
6 467 secondary hypotheses will allow non-biased estimates of treatment effect in the presence of any  
7  
8 468 potential missing cases, providing data are missing at random. A sensitivity analysis using pattern-  
9  
10 469 mixture model to investigate the deviation from the missingness-at-random assumption will be  
11  
12 470 carried out.<sup>(65)</sup> For secondary binary outcomes (e.g., treatment success), mixed-effect logistic  
13  
14 471 regression models will be used to assess the effect of treatment. A subsequent analysis of  
15  
16 472 participants classified as adherent to the protocol will be performed. Following publication of the  
17  
18 473 primary trial results, we will also perform a formal mediation analysis to estimate direct and  
19  
20 474 indirect (e.g., through weight and inflammation change) effects.  
21

22 476 **Healthcare resource use**

23  
24 477 Healthcare resource utilisation (e.g., hospitalisations, medical imaging, healthcare visits,  
25  
26 478 medication use) will be assessed by participant self-report to estimate costs associated with the  
27  
28 479 trial programs (e.g., hospital admissions, medication use, clinician visits, imaging tests, out-of-  
29  
30 480 pocket expenses).  
31

32  
33 482 **Process Evaluation**

34  
35 483 Semi-structured interviews will be conducted on a subset of consenting participants (until data  
36  
37 484 saturation reached) at 6 months. Interviews will explore experiences, knowledge and  
38  
39 485 understanding of interventions received including potential benefits; acceptability and perceived  
40  
41 486 effectiveness of the intervention; and reasons for adhering (or not) to the allocated diet.  
42  
43 487 Purposive sampling will be used to recruit interview participants based upon characteristics (anti-  
44  
45 488 inflammatory dietary program vs standard care low-fat dietary program, men vs women) and  
46  
47 489 outcomes of the trial (good outcome vs poor outcome). Interviews will be audio recorded,  
48  
49 490 transcribed and analysed using Framework Analysis,<sup>(66)</sup> a flexible technique allowing  
49  
50 491 researchers to identify, compare and contrast data according to inductively- and deductively-  
51  
52 492 derived themes. Data will be coded and an inductive thematic analysis will be applied until no  
53  
54 493 new themes emerge.  
55

56  
57  
58 495 **ETHICS AND DISSEMINATION**

59  
60 496 This study complies with the Declaration of Helsinki and has received approval from La Trobe  
497  
University Human Ethics Committee (HEC-22044). Written informed consent will be obtained

from participants prior to enrolment (Supplementary File 4). Anti-inflammatory diets are associated with minimal and transient adverse events, thus there are minimal safety considerations associated with this trial.

Study outcomes will be widely disseminated through a variety of sources. Results will be reported in peer-reviewed publications and presented at key national and international conferences. Only aggregate data will be reported. A lay summary report will be available for study participants. Any important protocol amendments will be reported to the approving ethics committee, registered at ANZCTR and communicated in the primary RCT paper. Any serious adverse events will be recorded and reported to the approving ethics committee.

Deidentified data will be made available upon reasonable request to the principal investigator (AGC) after publication (except where the sharing of data is prevented by privacy, confidentiality, or other ethical matters, or other contractual or legal obligations) according to La Trobe University Research Data Management Policy.

## DISCUSSION

The current RCT will be the first full-scale trial to evaluate the symptomatic, inflammatory, functional and body composition benefits of an anti-inflammatory dietary program compared to a standard care low-fat dietary program based on Australian Dietary Guidelines. While outcome assessors are blinded to group allocation, owing to the type of interventions (i.e., dietary advice) blinding of participants will not be possible. We also acknowledge that, like most RCTs, there is a risk that our recruitment strategy may result in a selected sample not representative of the general population. However, using similar recruitment strategies, our prior RCTs have resulted in a representative sample of the culturally and sociodemographically diverse Australian population that has similar characteristics to other international cohorts with the index musculoskeletal condition.<sup>(67)</sup>

The evaluation of a non-pharmacological anti-inflammatory dietary program to improve pain, symptoms, and quality of life for individuals with OA could have important individual and socio-economic benefits – decreased healthcare dollars spent on managing OA and reduced surgery waiting lists. Another benefit is that anti-inflammatory diets are also effective at combating metabolic syndrome, a key risk factor for chronic diseases, and thus the benefits from treating OA could stretch further to improving other medical co-morbidities.<sup>(68)</sup> This fully-powered RCT

1  
2 532 represents a crucial step towards the development of a sustainable and cost-effective therapy  
3  
4 533 that can both supplement and complement existing treatment strategies to optimise OA  
5  
6 534 outcomes.

7 535  
8  
9 536  
10  
11 537 **AUTHOR CONTRIBUTIONS**  
12 538 AGC, BLD, PB and JLK conceived the study and obtained funding. AGC, BLD, PB, and JLK designed  
13  
14 539 the study protocol with input from LL, JJH and ABM. ADL provided statistical expertise and will  
15  
16 540 conduct primary statistical analysis. MDH provided blood analysis expertise and will lead  
17  
18 541 inflammatory and metabolic marker analyses. HGM and NPW assisted with participant  
19  
20 542 recruitment from their clinical population with knee osteoarthritis. LL drafted the manuscript  
21  
22 543 with input from AGC, JJH, BLD, PB, JLK, AA, MDH, ADL, ABM, HGM and NPW. All authors and read  
23  
24 544 and approved the final manuscript.

25 545  
26  
27 546 **FUNDING**  
28  
29 547 This trial is supported by the National Health and Medical Research Council (NHMRC) of Australia  
30  
31 548 through an Investigator Grant held by AGC (GNT2008523), an Investigator Grant held by JLK  
32  
33 549 (APP2017844), and a philanthropic donation from PB.

34 550  
35  
36 551 **COMPETING INTERESTS STATEMENT**  
37  
38 552 PB is the founder of Defeat Diabetes and author of “A Fat Lot of Good”. PB contributed to study  
39  
40 553 design but has no role in study execution, data management, analysis or the decision to publish.  
41  
42 554 The NHMRC has no role in study design and will not have any role in its execution, data  
43  
44 555 management, analysis and interpretation or on the decision to submit the results for publication.  
45  
46 556 JLK is an editor of the British Journal of Sports Medicine (British Medical Journal Group). AGC is  
47  
48 557 an associate editor of British Journal of Sports Medicine (British Medical Journal Group). All other  
49  
50 558 authors have no competing interests.

51 559  
52  
53 560 **ACKNOWLEDGEMENTS**  
54 561 We thank La Trobe University Medical Centre for assistance with blood collection, La Trobe  
55  
56 562 Nutrition and Dietetics department for the use of the nutrition lab and DXA scanner, and  
57  
58 563 Melbourne Pathology for providing pathology collection kits and analysis of biomarkers from  
59  
60 564 blood specimens.

565

## FIGURE LEGENDS

**Figure 1.** Flow of participants through the trial. DXA, Dual X-ray Absorptiometry; KOOS, Knee injury and Osteoarthritis Outcome Score

\*Optional qualitative interview for process evaluation at 6 months

## SUPPLEMENTARY FILES

**Supplementary File 1.** Sample of the standard care low fat dietary program participant booklet

**Supplementary File 2.** Sample of the anti-inflammatory dietary program participant booklet

**Supplementary File 3.** Standard Operating Procedures for blood collection, processing and storage

**Supplementary File 4.** Patient information and consent form

## REFERENCES

1. Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. *EClinicalMedicine*. 2020;29-30:100587.
2. Duong V, Oo WM, Ding C, Culvenor AG, Hunter DJ. Evaluation and treatment of knee pain. *JAMA*. 2023;330:1568-80.
3. Weng Q, Goh S-L, Wu J, Persson MSM, Wei J, Sarmanova A, et al. Comparative efficacy of exercise therapy and oral non-steroidal anti-inflammatory drugs and paracetamol for knee or hip osteoarthritis: a network meta-analysis of randomised controlled trials. *British Journal of Sports Medicine*. 2023;bjsports-2022-105898.
4. Ackerman I, Bohensky M, Pratt C, Gorelik A, Liew D. Counting the Cost: Part 1 Healthcare costs. The current and future burden of arthritis 2016.
5. Williams A, Kamper SJ, Wiggers JH, O'Brien KM, Lee H, Wolfenden L, et al. Musculoskeletal conditions may increase the risk of chronic disease: a systematic review and meta-analysis of cohort studies. *BMC Med*. 2018;16(1):167.
6. Pihl K, Roos EM, Taylor RS, Grønne DT, Skou ST. Associations between comorbidities and immediate and one-year outcomes following supervised exercise therapy and patient education - A cohort study of 24,513 individuals with knee or hip osteoarthritis. *Osteoarthritis Cartilage*. 2021;29(1):39-49.
7. Juhl C, Christensen R, Roos EM, Zhang W, Lund H. Impact of exercise type and dose on pain and disability in knee osteoarthritis: a systematic review and meta-regression analysis of randomized controlled trials. *Arthritis Rheumatol*. 2014;66(3):622-36.
8. Henriksen M, Hansen JB, Klokke L, Bliddal H, Christensen R. Comparable effects of exercise and analgesics for pain secondary to knee osteoarthritis: a meta-analysis of trials included in Cochrane systematic reviews. *J Comp Eff Res*. 2016;5(4):417-31.
9. Barton CJ, Kemp JL, Roos EM, Skou ST, Dundules K, Pazzinatto MF, et al. Program evaluation of GLA:D® Australia: Physiotherapist training outcomes and effectiveness of implementation for people with knee osteoarthritis. *Osteoarthritis and Cartilage Open*. 2021;3(3):100175.
10. Roos EM, Grønne DT, Skou ST, Zywił MG, McGlasson R, Barton CJ, et al. Immediate outcomes following the GLA:D® program in Denmark, Canada and Australia. A longitudinal analysis including 28,370 patients with symptomatic knee or hip osteoarthritis. *Osteoarthritis Cartilage*. 2021;29(4):502-6.

1  
2 609 11. Das SK, Gilhooly CH, Golden JK, Pittas AG, Fuss PJ, Cheatham RA, et al. Long-term effects of 2  
3 610 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and  
4 611 metabolism in CALERIE: a 1-y randomized controlled trial. *Am J Clin Nutr.* 2007;85(4):1023-30.  
5 612 12. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. *Med Clin*  
6 613 *North Am.* 2018;102(1):183-97.  
7 614 13. Ansari MY, Ahmad N, Haqqi TM. Oxidative stress and inflammation in osteoarthritis  
8 615 pathogenesis: Role of polyphenols. *Biomed Pharmacother.* 2020;129:110452.  
9 616 14. Goldring MB, Otero M. Inflammation in osteoarthritis. *Curr Opin Rheumatol.* 2011;23(5):471-8.  
10 617 15. Strath LJ, Jones CD, Philip George A, Lukens SL, Morrison SA, Soleymani T, et al. The Effect of  
11 618 Low-Carbohydrate and Low-Fat Diets on Pain in Individuals with Knee Osteoarthritis. *Pain Med.*  
12 619 2020;21(1):150-60.  
13 620 16. Galbete C, Kröger J, Jannasch F, Iqbal K, Schwingshackl L, Schwedhelm C, et al. Nordic diet,  
14 621 Mediterranean diet, and the risk of chronic diseases: the EPIC-Potsdam study. *BMC Medicine.*  
15 622 2018;16(1):99.  
16 623 17. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomed*  
17 624 *Pharmacother.* 2002;56(8):365-79.  
18 625 18. Esposito K, Maiorino MI, Bellastella G, Chiodini P, Panagiotakos D, Giugliano D. A journey into a  
19 626 Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. *BMJ Open.*  
20 627 2015;5(8):e008222.  
21 628 19. Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative Stress and Inflammation: What  
22 629 Polyphenols Can Do for Us? *Oxid Med Cell Longev.* 2016;2016:7432797.  
23 630 20. Neale EP, Batterham MJ, Tapsell LC. Consumption of a healthy dietary pattern results in  
24 631 significant reductions in C-reactive protein levels in adults: a meta-analysis. *Nutr Res.* 2016;36(5):391-  
25 632 401.  
26 633 21. Ciaffi J, Mitselman D, Mancarella L, Brusi V, Lisi L, Ruscitti P, et al. The Effect of Ketogenic Diet on  
27 634 Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review. *Frontiers in*  
28 635 *Medicine.* 2021;8.  
29 636 22. Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical  
30 637 implications in cardiovascular prevention. *Biochem Pharmacol.* 2009;77(6):937-46.  
31 638 23. Ricker MA, Haas WC. Anti-Inflammatory Diet in Clinical Practice: A Review. *Nutr Clin Pract.*  
32 639 2017;32(3):318-25.  
33 640 24. Li J, Lee DH, Hu J, Tabung FK, Li Y, Bhupathiraju SN, et al. Dietary Inflammatory Potential and  
34 641 Risk of Cardiovascular Disease Among Men and Women in the U.S. *J Am Coll Cardiol.* 2020;76(19):2181-  
35 642 93.  
36 643 25. D'Andrea Meira I, Romão TT, Pires do Prado HJ, Krüger LT, Pires MEP, da Conceição PO.  
37 644 Ketogenic Diet and Epilepsy: What We Know So Far. *Front Neurosci.* 2019;13:5.  
38 645 26. Schönenberger KA, Schüpfer AC, Gloy VL, Hasler P, Stanga Z, Kaegi-Braun N, et al. Effect of Anti-  
39 646 Inflammatory Diets on Pain in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. *Nutrients.*  
40 647 2021;13(12).  
41 648 27. Dyer J, Davison G, Marcora SM, Mauger AR. Effect of a Mediterranean Type Diet on  
42 649 Inflammatory and Cartilage Degradation Biomarkers in Patients with Osteoarthritis. *J Nutr Health Aging.*  
43 650 2017;21(5):562-6.  
44 651 28. Cooper I, Brukner P, Devlin B, Reddy A, Fulton M, Kemp J, et al. An anti-inflammatory diet  
45 652 intervention for knee osteoarthritis: a feasibility study. *BMC Musculoskeletal Disorders.* 2022;23.  
46 653 29. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013  
47 654 explanation and elaboration: guidance for protocols of clinical trials. *BMJ : British Medical Journal.*  
48 655 2013;346:e7586.  
49 656 30. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010  
50 657 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ.*  
51 658 2010;340:c869.  
52 659 31. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance.  
53 660 Osteoarthritis: Care and Management in Adults. London: National Institute for Health and Care  
54 661 Excellence (UK)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
ErasmusHogeschool



32. Culvenor AG, Collins NJ, Guermazi A, Cook JL, Vicenzino B, Khan KM, et al. Early knee osteoarthritis is evident one year following anterior cruciate ligament reconstruction: a magnetic resonance imaging evaluation. *Arthritis Rheumatol*. 2015;67(4):946-55.
33. Culvenor AG, Collins NJ, Guermazi A, Cook JL, Vicenzino B, Whitehead TS, et al. Early Patellofemoral Osteoarthritis Features One Year After Anterior Cruciate Ligament Reconstruction: Symptoms and Quality of Life at Three Years. *Arthritis Care Res (Hoboken)*. 2016;68(6):784-92.
34. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ : British Medical Journal*. 2014;348:g1687.
35. Brukner DP. *A Fat Lot of Good*. 1 ed: Penguin Australia Pty Ltd; 2018. 368 p.
36. Wingrove K, Lawrence MA, Russell C, McNaughton SA. Evidence Use in the Development of the Australian Dietary Guidelines: A Qualitative Study. *Nutrients*. 2021;13(11):3748.
37. Cant RP. Patterns of delivery of dietetic care in private practice for patients referred under Medicare Chronic Disease Management: results of a national survey. *Aust Health Rev*. 2010;34(2):197-203.
38. Spencer L, O'Shea MC, Ball L, Desbrow B, Leveritt M. Attendance, weight and waist circumference outcomes of patients with type 2 diabetes receiving Medicare-subsidised dietetic services. *Aust J Prim Health*. 2014;20(3):291-7.
39. Health N, Council MR. Australian dietary guidelines. Canberra (Australia): National Health and Medical Research Council. 2013.
40. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform*. 2019;95:103208.
41. Gudbergensen H, Bartels EM, Krusager P, Wæhrens EE, Christensen R, Danneskiold-Samsøe B, et al. Test-retest of computerized health status questionnaires frequently used in the monitoring of knee osteoarthritis: a randomized crossover trial. *BMC Musculoskeletal Disorders*. 2011;12(1):190.
42. Culvenor AG, West TJ, Bruder AM, Scholes MJ, Barton CJ, Roos EM, et al. Supervised exercise-therapy and Patient Education Rehabilitation (SUPER) versus minimal intervention for young adults at risk of knee osteoarthritis after ACL reconstruction: SUPER-Knee randomised controlled trial protocol. *BMJ Open*. 2023;13(1):e068279.
43. Davis TC, Crouch MA, Long SW, Jackson RH, Bates P, George RB, et al. Rapid assessment of literacy levels of adult primary care patients. *Fam Med*. 1991;23(6):433-5.
44. Skou ST, Roos EM, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, et al. A Randomized, Controlled Trial of Total Knee Replacement. *N Engl J Med*. 2015;373(17):1597-606.
45. Collins NJ, Prinsen CA, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. *Osteoarthritis Cartilage*. 2016;24(8):1317-29.
46. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. *Ann Rheum Dis*. 2005;64(1):34-7.
47. Dobson F, Hinman RS, Roos EM, Abbott JH, Stratford P, Davis AM, et al. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. *Osteoarthritis and Cartilage*. 2013;21(8):1042-52.
48. Shepherd JA, Ng BK, Sommer MJ, Heymsfield SB. Body composition by DXA. *Bone*. 2017;104:101-5.
49. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. *Bmj*. 2016;352:i157.
50. Shivappa N, Steck SE, Hurley TG, Hussey JR, Hébert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. *Public Health Nutr*. 2014;17(8):1689-96.
51. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *Qual Life Res*. 2013;22(7):1717-27.
52. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). *Br J Rheumatol*. 1997;36(5):551-9.



1  
2 717 53. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med*  
3 718 *Singap.* 1994;23(2):129-38.  
4 719 54. Mendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain  
5 720 Inventory short form in patients with osteoarthritis. *Eur J Pain.* 2006;10(4):353-61.  
6 721 55. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, et al. Around-the-Clock,  
7 722 Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain: Placebo-Controlled Trial and  
8 723 Long-term Evaluation. *Archives of Internal Medicine.* 2000;160(6):853-60.  
9 724 56. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International  
10 725 physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc.*  
11 726 2003;35(8):1381-95.  
12 727 57. Maddison R, Ni Mhurchu C, Jiang Y, Vander Hoorn S, Rodgers A, Lawes CM, et al. International  
13 728 Physical Activity Questionnaire (IPAQ) and New Zealand Physical Activity Questionnaire (NZPAQ): a  
14 729 doubly labelled water validation. *Int J Behav Nutr Phys Act.* 2007;4:62.  
15 730 58. Cleland C, Ferguson S, Ellis G, Hunter RF. Validity of the International Physical Activity  
16 731 Questionnaire (IPAQ) for assessing moderate-to-vigorous physical activity and sedentary behaviour of  
17 732 older adults in the United Kingdom. *BMC Medical Research Methodology.* 2018;18(1):176.  
18 733 59. Sjostrom M, Ainsworth BE, Bauman A, Bull FC, Hamilton-Craig CR, Sallis JF, editors. Guidelines  
19 734 for data processing analysis of the International Physical Activity Questionnaire (IPAQ) - Short and long  
20 735 forms2005.  
21 736 60. AINSWORTH BE, HASKELL WL, WHITT MC, IRWIN ML, SWARTZ AM, STRATH SJ, et al.  
22 737 Compendium of Physical Activities: an update of activity codes and MET intensities. *Medicine & Science*  
23 738 *in Sports & Exercise.* 2000;32(9):S498-S516.  
24 739 61. Dolatkah N, Toopchizadeh V, Barmaki S, Salekzamani Y, Najjari A, Farshbaf-Khalili A, et al. The  
25 740 effect of an anti-inflammatory in comparison with a low caloric diet on physical and mental health in  
26 741 overweight and obese women with knee osteoarthritis: a randomized clinical trial. *Eur J Nutr.*  
27 742 2023;62(2):659-72.  
28 743 62. Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of covariance in  
29 744 randomized clinical trials. *J Clin Epidemiol.* 2007;60(12):1234-8.  
30 745 63. Silva MDC, Perriman DM, Fearon AM, Couldrick JM, Scarvell JM. Minimal important change and  
31 746 difference for knee osteoarthritis outcome measurement tools after non-surgical interventions: a  
32 747 systematic review. *BMJ Open.* 2023;13(5):e063026.  
33 748 64. Lynggaard H, Bell J, Lösch C, Besseghir A, Rantell K, Schoder V, et al. Principles and  
34 749 recommendations for incorporating estimands into clinical study protocol templates. *Trials.*  
35 750 2022;23(1):685.  
36 751 65. White IR, Kalaitzaki E, Thompson SG. Allowing for missing outcome data and incomplete uptake  
37 752 of randomised interventions, with application to an Internet-based alcohol trial. *Statistics in Medicine.*  
38 753 2011;30:3192-207.  
39 754 66. Ritchie J, Spencer L, editors. Qualitative data analysis for applied policy research2002.  
40 755 67. Culvenor AG, West TJ, Bruder AM, Scholes MJ, Barton CJ, Roos EM, et al. Recruitment and  
41 756 baseline characteristics of young adults at risk of early-onset knee osteoarthritis after ACL  
42 757 reconstruction in the SUPER-Knee trial. under review. 2023.  
43 758 68. Peiris CL, Culvenor AG. Metabolic syndrome and osteoarthritis: implications for the  
44 759 management of an increasingly common phenotype. *Osteoarthritis and Cartilage.* 2023;Online ahead of  
45 760 print.  
46 761  
47 762

51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool




Figure 1. Flow of participants through the trial. DXA, Dual X-ray Absorptiometry; KOOS, Knee injury and Osteoarthritis Outcome Score

\*Optional qualitative interview for process evaluation at 6 months

529x695mm (96 x 96 DPI)

# FEAST

## SAMPLE FROM LOW-FAT PARTICIPANT BOOKLET



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool





Australian Government  
National Health and Medical Research Council  
Department of Health and Ageing

www.eatforhealth.gov.au

# Australian Guide to Healthy Eating

Enjoy a wide variety of nutritious foods from these five food groups every day.

Drink plenty of water.

Grain (cereal) foods, mostly wholegrain and/or high cereal fibre varieties

Vegetables and legumes/beans



Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



Use small amounts

Only sometimes and in small amounts






## Vegetables and legumes

Vegetables, including legumes/beans are nutrient dense, low in kilojoules, and are a good source of minerals and vitamins (such as magnesium, vitamin C and folate), dietary fibre and a range of natural plant chemicals such as carotenoids. Legumes include chickpeas, kidney beans, and peas. Aim for 5 serves a day.

### What is a serve of vegetables\*?

A standard serve is about 75g (100–350kJ) or:

½ cup	cooked green or orange vegetables (for example, broccoli, spinach, carrots or pumpkin)
½ cup	cooked dried or canned beans, peas or lentils
1 cup	green leafy or raw salad vegetables
½ cup	sweet corn
½ medium	potato or other starchy vegetables (sweet potato, taro or cassava)
1 medium	tomato



\*With canned varieties, choose those with no added salt

## Fruit

A wide variety of fruit is grown and available in Australia. Choosing fruits in season provides **better value and better quality**. And just like with veggies, choosing different coloured fruits increases the variety of nutrients, which can enhance your health! Aim for **two serves** of fruit a day.

Try eating fruits from these different fruit categories:

- citrus fruit such as oranges, mandarins, and grapefruit
- pome fruits such as apples and pears
- stone fruit such as apricots, cherries, peaches, nectarines, and plums
- tropical fruit such as bananas, papaya, mangoes, pineapple, and melons
- berries


### What is a serve of fruit?

A standard serve is about 150g (350kJ) or:

1 medium	apple, banana, orange or pear
2 small	apricots, kiwi fruits or plums
1 cup	diced or canned fruit (no added sugar)

Or only occasionally:

125ml (½ cup)	fruit juice (no added sugar)
30g	dried fruit (for example, 4 dried apricot halves, 1½ tablespoons of sultanas)



- other fruits such as grapes and passionfruit

Enjoy more fruit by trying:

- chopped fruit to cereal, porridge, salad, or toast
- fruit as a convenient snack while out and about
- fruit-based desserts (baked apples, fruit crumbles, stewed/ poached fruit)
- adding fruit to pancakes, scones, pikelets, and low-fat muffins.



## Wholegrains

All types of grains are good sources of complex carbohydrates and some key vitamins and minerals. Grain foods are mostly made from wheat, oats, rice, rye, barley, millet, quinoa and corn.

Wholegrains are naturally high in fibre, helping you feel full and satisfied — which makes it easier to maintain a healthy body weight. Nutritionally, wholegrain and wholemeal foods are very similar.

### What is a serve of grain\* (cereal) food?

A standard serve is (500kJ) or:

1 slice (40g)	bread
½ medium (40g)	roll or flat bread
½ cup (75-120g)	cooked rice, pasta, noodles, barley, buckwheat, semolina, polenta, bulgur or quinoa
½ cup (120g)	cooked porridge
⅔ cup (30g)	wheat cereal flakes
¼ cup (30g)	muesli
3 (35g)	crispbreads
1 (60g)	crumpet
1 small (35g)	English muffin or scone



\*Grain (cereal) foods, mostly wholegrain and/or high cereal fibre varieties

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



Aim for 4-6 serves of grain foods a day. Additional serves can be eaten depending on your activity level.

Enjoy more wholegrains by having:

- breakfasts that include whole-grain cereals, like oatmeal.
- wholemeal toast or wholemeal bagels for white-flour versions.
- low-fat muffins made with whole-grain flours.
- sandwiches using whole-grain breads or rolls.
- quinoa, brown rice, wild rice, barley or bulgur instead of white rice.
- wild rice or barley in soups, stews, casseroles and salads.
- rolled oats or crushed whole-wheat bran cereal in recipes instead of dry breadcrumbs.

Lean meat and poultry, fish, eggs, tofu, nuts and seeds

These are a critical part of having enough protein each day. They also provide other nutrients such as: iodine, iron, zinc, vitamins, especially B12, and essential fatty acids.


There’s a lot to choose from:

- Lean meats - Beef, lamb, veal, pork, kangaroo
- Poultry - Chicken, turkey, duck, emu, goose, bush birds
- Fish and seafood - Fish, prawns, crab, lobster, mussels, oysters, scallops, clams
- Eggs
- Nuts and seeds - Almonds, pine nuts, walnut, macadamia, hazelnut, cashew, peanut, nut spreads, and pumpkin seeds
- Legumes/beans - All beans, lentils, chickpeas, split peas, tofu.

**How much is a serve of lean meat and poultry, fish, eggs, nuts and seeds, and legumes/beans\*?**

**A standard serve is (500–600kJ):**

65g	cooked lean red meats such as beef, lamb, veal, pork, goat or kangaroo (about 90-100g raw)
80g	cooked lean poultry such as chicken or turkey (100g raw)
100g	cooked fish fillet (about 115g raw) or one small can of fish
2 large (120g)	eggs
1 cup (150g)	cooked or canned legumes/beans such as lentils, chick peas or split peas
170g	tofu
30g	nuts, seeds, peanut or almond butter or tahini or other nut or seed paste



\*Choose those with no added salt

## Milk, yoghurt, cheese, and/or alternatives

Dairy products (and dairy alternatives) are rich in calcium, protein, and lots of nutrients. Dairy foods contribute to strong bones. Aim for **at least 2-3 serves daily**.

Examples of milk, yoghurt, cheese and/or alternatives include:

- Milks - All reduced fat or full cream milks, plain and flavoured, long life milks, fortified soy beverages
- Yoghurt - All yoghurts including reduced fat or full cream, plain and flavoured, soy yoghurt (calcium fortified)
- Cheese - All hard cheeses, reduced or full fat for example cheddar, Gouda, Swiss

**How much is a serve of milk\*, yoghurt\*, cheese\* and/or alternatives?**

**A standard serve is (500–600kJ):**

1 cup (250ml)	fresh, UHT long life, reconstituted powdered milk or buttermilk
½ cup (120ml)	evaporated milk
2 slices (40g)	or 4 x 3 x 2cm cube (40g) of hard cheese, such as cheddar
½ cup (120g)	ricotta cheese
¾ cup (200g)	yoghurt
1 cup (250ml)	soy, rice or other cereal drink with at least 100mg of added calcium per 100ml



**The following foods contain about the same amount of calcium as a serve of milk, yoghurt or cheese:**

100g	almonds with skin
60g	sardines, canned in water
½ cup (100g)	canned pink salmon with bones
100g	firm tofu (check the label as calcium levels vary)

*\*Choose mostly reduced fat*

# FEAST

# SAMPLE OF ANTI-INFLAMMATORY PARTICIPANT BOOKLET



# EXAMPLE WEEKLY MEAL PLANS

Here are examples of what a week might look like. Consider these plans as a guide to give you ideas, not something written in stone! Most of the recipes below can be found on the **Defeat Diabetes** app, or by simply searching on Google online.

Lots of other anti-inflammatory/low-carbohydrate ideas online at: <https://www.eatthebutter.org/dinner-ideas/>

## Week 1

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
<b>Breakfast</b>	Raspberry chia pot	Yoghurt with berries	Raspberry chia pot	Coconut crunch granola	Berry yoghurt smoothie	Scrambled eggs with spinach and avocado	Zucchini and feta fritters
<b>Snack</b>	Apple with peanut butter	Hummus and veggies	Apple with peanut butter	Handful of almonds with piece of dark chocolate	Hummus and veggies	Apple with peanut butter	Handful of walnuts
<b>Lunch</b>	Roast vegetable salad	Salad with can of tuna	Leftover prawn pad thai	Leftover burrito bowl	Salad with can of tuna	Salmon with cauliflower rice bowl	One pan spiced halloumi and eggplant
<b>Snack</b>	Handful of almonds with piece of dark chocolate	Almond meal blueberry muffin	Zucchini and feta fritter	Almond meal blueberry muffin	Handful of almonds with piece of dark chocolate	Yoghurt with berries	Almond meal blueberry muffin
<b>Dinner</b>	Garlic prawns with zoodles	Beef pad thai	15-minute burrito bowl	Miso barramundi with vegetables	Swedish meatballs	Baked portobello mushrooms with feta	Grilled lamb chops with roasted vegetables



Week 2

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
Breakfast	Coconut crunch granola	Berry smoothie	Scrambled eggs with spinach and avocado	Berry smoothie	Coconut crunch granola	Scrambled eggs with spinach and avocado	Shakshuka
Snack	Mini frittata	Pear	Apple with handful of almonds	Pear	Mini frittata	Handful of walnuts with piece of dark chocolate	Yoghurt with berries
Lunch	Salad with sliced steak	Easy Tuna Niçoise	Leftover stuffed capsicum	Leftover burger patty with salad	Leftover green curry with cauli rice	Cesar salad	Warm veggie salad with almonds
Snack	Slice of orange almond meal cake	Handful of walnuts with piece of dark chocolate	Mini frittata	Slice of orange almond meal cake	Apple with handful of almonds	Yoghurt with berries	Pear
Dinner	Salmon poke bowl	Stuffed capsicums	Smoky beef burger on mushroom buns	Green vegetable and prawn curry with cauli rice	Easy mushroom, lemon, and garlic chicken	Cauliflower pizza with pesto, sausage, and herbs	Grilled steak and roasted vegetables

Week 3



	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
<b>Breakfast</b>	Breakfast egg muffins	Berry yoghurt smoothie	Breakfast egg muffins	Chia pudding pot	Berry yoghurt smoothie	Bacon and eggs with roasted tomatoes	Mexican breakfast scramble
<b>Snack</b>	Chia pudding pot	Beef jerky	Greek yoghurt with berries	Breakfast egg muffins	Handful of almonds with cheese stick	Apple with peanut butter	Strawberry power balls
<b>Lunch</b>	Zucchini and walnut salad	Leftover beef burrito bowl	Leftover salmon patties with salad	Greek salad	Leftover tagine	Chicken, broccoli and almond salad	Mushroom soup with crispy cheese croutons
<b>Snack</b>	Strawberry power balls	Handful of almonds with square of dark chocolate	Strawberry power balls	Handful of almonds with apple	Dark chocolate (avocado) mousse	Beef jerky	Dark chocolate (avocado) mousse
<b>Dinner</b>	15-minute beef burrito bowl	Salmon patties with feta sauce and beet salad	Chicken curry with cauliflower rice	Lamb and apricot tagine	Pan-seared barramundi with cauliflower mash	Zucchini lasagne	Grilled lamb chops with roasted vegetables

## Week 4

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday	Sunday
<b>Breakfast</b>	Coconut granola with milk	Blueberry almond protein smoothie	Vegetable cheese frittata	Blueberry almond protein smoothie	Coconut granola with milk	Tofu scramble	Almond flour pancakes

Snack	Roasted chickpeas	Slice of almond flour banana bread	Greek yoghurt with berries	Peanut butter balls	Beef jerky	Roasted chickpeas	Handful of walnuts
Lunch	Vegetable cheese frittata	Leftover roast vegetable salad with halloumi	Leftover broccoli and leek soup	Vegetable cheese frittata	Kale Caesar salad	Leftover stuffed capsicums	Creamy Tuscan soup
Snack	Slice of almond flour banana bread	Handful of almonds with dark chocolate	Roasted chickpeas	Slice of almond flour banana bread	Handful of almonds with dark chocolate	Greek yoghurt with berries	Peanut butter balls
Dinner	Roast vegetable salad with halloumi	Cheesy broccoli soup	Spicy tofu san choi bao	Vegetarian stuffed zucchini boats	Stuffed capsicums	Beetroot & halloumi salad with pomegranate	Spiced eggplant curry with cauliflower rice

FEAST v 2.0  
17.08.2023

FEAST Project

---

## Standard Operating Procedure

### Blood collection, processing, handling, and storage procedures

---

For peer review only

1.1 Purpose

The purpose of the current SOP is to provide step-by-step instructions on the exact procedures that the research team needs to follow for conducting venous blood collection for biochemical analysis at baseline and follow-up examination.

1.2 General procedures for venous blood collection

Venous blood samples will be obtained from each participant for biochemical analysis following a 12-hour overnight fast, at baseline (T1), 12 weeks (T2) and 6 months (T3) (figure 1)




Figure 1: Study design

The researcher will perform venepuncture to obtain no more than 30mL of blood.

1.2.1 Consumables and supplies required for performing venepuncture

The consumables and supplies that will be used for performing the venepuncture in the study are the following:

- Disposable Latex gloves must be worn by the researcher and anyone else assisting with blood collection.
- Alcohol swab will be used to clean the venepuncture site.
- Winged steel needles appropriate for adults with an extension tube (a butterfly) will be used. The butterfly will have either a syringe or an evacuated tube with an adaptorSterile gauze pads will.....
- Adhesive hypo allergic bandages (plasters or Band-Aids) will be applied to the puncture site to minimize the risk of infection.
- Plastic Bag for Waste will be used to dispose all of the biohazardous waste generated as well as a sharps biocan to dispose of all needles.

1.2.2 Steps in obtaining venous blood from the participant

The steps for obtaining venous blood samples from the study participants are provided below:

**Step 1:** Complete general preparation.

- Find an indoor site to encourage privacy during blood collection. The site should have a table or other piece of furniture with a flat surface where you can lay out all consumables/ supplies. An examination bed should be readily available if the respondent feels faint and needs to lie down.
- Ensure that each subject has completed a 10-hour fast.

- Wash and dry hands, put on gloves before initiating blood collection from the participant.
- Take out a clean absorbent paper sheet and spread it over a flat surface to lay out consumable and supplies.

**Step 2:** Prepare the participant for the venepuncture.

- The individual should be seated comfortably in a chair with arm extended on the slanting armrest to form a straight line from the shoulder to the wrist. The arm and elbow should be supported firmly by the armrest and should not be bent at the elbow.
- Ask each volunteer if they have a history of fainting. If so, ensure that the blood sample is only drawn whilst the subject is lying down on a bed.
- Describe to the participant exactly what will be done during the collection of the blood sample.

**Step 3:** Prepare the venepuncture site.

- Apply (tighten) tourniquet.
- Ask the participant to close his/her hand so that the veins will become more prominent and thus easier to enter. Vigorous hand exercise or "pumping" should be avoided.
- Select the vein site. Palpate and trace the path of veins several times with the index finger. If superficial veins are not readily apparent, blood can be forced into the vein by gently massaging the arm from wrist to elbow. Several sharp taps at the vein site with index and second finger will cause the vein to dilate.
- Loosen tourniquet.
- The venepuncture site must be cleansed once with an alcohol swab to prevent any chemical or microbiologic contamination of either the patient or the specimen.
- Check equipment, tube selection and thread needle (or butterfly) securely onto tube holder (barrel).
- Re-apply the tourniquet and relocated vein position and direction. A tourniquet allows the veins to fill with blood, thus making the veins more prominent and easier to enter. Do not leave the tourniquet on for longer than 1 minute otherwise it may result in either hemoconcentration or variation in blood test values.
- Remove needle cover and check bevel is orientated uppermost.

**Step 4:** Blood drawing

- Puncture the skin 3–5 mm away from the vein; this allows good access without pushing the vein away.
- If the needle enters alongside the vein rather than into it, withdraw the needle slightly without removing it completely, and angle it into the vessel.
- Insert the tube into the holder and commence filling the tubes.
- Draw blood slowly and steadily.
- Release the tourniquet as soon as blood flow is established. Tourniquet release allows the blood circulation to return to normal and also reduces bleeding at the venipuncture site.
- Remove the tube from the holder and invert (8–10 times) to mix the blood with tube additives. Place blood samples on ice if required..
- Place a cotton wool above the venepuncture site, withdraw the needle and apply pressure.
- Dispose of needle in a sharps container.
- Check site and apply an adhesive bandage.
- Label all tubes immediately.





1.3 Blood processing and handling

1.3.1 Centrifuge procedure

Collected venous blood will be centrifuged and the extracted plasma and/or serum will be pipetted into aliquots according to the blood collection protocol.

- Set up in a well-ventilated environment, on a horizontally levelled and rigid surface with adequate load-bearing capacity.
- As safety zone maintain a clear radius of at least 30 cm around the centrifuge. Do not place any dangerous substances within this security zone.
- Open the centrifuge door by pressing the open button.
- Place the remaining tubes containing blood into appropriate sized adapters.
- Place the tubes containing water in opposite adapters, where they should mirror the placement of the tubes holding blood.
- Never place both tubes housing water and blood into the same adapters but should be placed in different adapters for even weight distribution.
- Place the adapters carefully and gently into the rotor buckets
- Seal the buckets with the lids and close the centrifuge.
- Use only with rotors which have been loaded properly.
- Make sure the rotor is locked properly into place before operating the centrifuge.
- Never overload the rotor.
- Never start the centrifuge when the centrifuge door is open.
- Do not lean on the centrifuge.
- Do not place anything on top of the centrifuge during a run.
- Gently close the centrifuge door. The centrifuge door mechanism will click and lock in place.
- Turn on the centrifuge by pressing the start button.
- Select the required speed and time from preprogrammed setting or manually using the arrow keys (3000xg for 10 mins for each tube).

Once the centrifuge has completely stopped spinning wait for an audible sound and then open the centrifuge. Remove the tubes from the centrifuge and place them in a tube rack.

1.3.2 Handling of collected blood

Three different types of test tubes will be used per study participant to collect venous blood. The collected blood will be designated for whole blood, or plasma and serum separation. One 8ml EDTA tube (with added anticoagulant) will be used to collect whole blood for analysis, one 6ml heparin tube will be used for plasma extraction, and one 8.5ml SST tube will be used for serum extraction. Tubes will be labelled with study timepoint (T1, T2 or T3), participant ID, and type of sample. All information regarding blood collection tubes is presented in Table 1.

Table 1. Volume of blood in different test tubes

Test tube	Blood volume	Designated for:
EDTA tube	6 ml	Whole blood
Heparin gel tube	6 ml	Heparin plasma extraction
SST tube	8.5 ml	Serum extraction
Total blood:	22.5ml	

- The whole blood sample (6ml) collected in the EDTA tube will be stored at -80°C, as indicated in Table 2.

**Table 2.** Volumes and use of EDTA whole blood sample.

Whole blood aliquot no.	EDTA volume	Designated for the analysis of:
1	6 ml	HbA1c

- The blood (8.5ml) collected in the SST tube will be left to separate at room temperature for 20 mins and then centrifuged at 3000 rpm for 10 min. The extracted (heparin) plasma will be pipetted into 4 aliquots of 1 ml (considering a 50% efficiency of centrifugation in plasma extraction). One aliquot of 1ml will be used for determining glucose, insulin, lipids, LFT and hsCRP, while the 3 aliquots of 1ml each will be stored at -80°C, as indicated in Table 3.

**Table 3.** Volumes and use of SST plasma aliquots.

Plasma aliquot no.	EDTA plasma volume	Designated for the analysis of:
1	1000 µl	Glucose, insulin, lipids, LFT, hsCRP
		<b>Designated for:</b>
2	1000 µl	Storage at -80°C
3	1000 µl	Storage at -80°C
4	1000 µl	Storage at -80°C

- The blood (6 ml) collected in the heparin tube will be centrifuged at 3000 rpm for 10 min and the extracted plasma will be pipetted into 3 aliquots of 600 µl (considering a 50% efficiency of centrifugation in plasma extraction). One aliquot of 600 µl will be used for determining cytokine concentrations, while the remaining 3 aliquots of 500 µl each will be stored at -80°C, as indicated in Table 4.

**Table 4.** Volumes and use of heparin plasma aliquots.

Plasma aliquot no.	Heparin plasma volume	Designated for the analysis of:
1	1ml	Cytokines (IL-1β, IL-6, IL-8, IL-10, and TNF)
		<b>Designated for:</b>
2	1ml	Storage at -80°C
3	1ml	Storage at -80°C
4	1ml	Storage at -80°C

**NOTE:** It is essential that ONLY NON-HAZARDOUS waste be placed in the wastepaper/ general rubbish bins. Pipette tips should be disposed in sharps containers, whereas laboratory and associated waste directly involved in specimen processing (i.e blood collection tubes, gloves etc) must be disposed in biological waste bags.

#### 1.4 Blood storage

Eppendorf tubes or screw cap tubes must be clearly labelled with identification, media used and date, placed in a freezer well rack and should not be stored for long periods on a bench, but must be transferred with an ice esky box to a dedicated storage area (i.e. refrigerator, cold room or cupboard) as soon as possible.

Laboratory coats must be removed and hung up before leaving laboratory areas and should be laundered once a week. Hands must be washed with an antibacterial agent BEFORE leaving laboratory (Hibiclens/Microshield or equivalent, followed by extensive rinsing).



Participant Information Sheet/Consent Form  
Interventional study - Adult providing own consent

Title	Optimising outcomes for people with knee pain through food: FEAST randomised controlled trial
Short Title	The FEAST trial
Ethics Reference Number	HEC22044
Project Sponsor	La Trobe University
Coordinating Principal Investigator/ Principal Investigator	Dr Adam Culvenor (School of Allied Health, Human Services and Sport (SAHHSS), La Trobe University)
Associate Investigator(s)	Dr Brooke Devlin (School of Human Movement and Nutrition Sciences, University of Queensland)
	Prof. Peter Brukner (SAHHSS, La Trobe University)
	Ass. Prof. Joanne Kemp (SAHHSS, La Trobe University)
	Prof. Kay Crossley (SAHHSS, La Trobe University)
	Dr Andrea Mosler (SAHHSS, La Trobe University)
	Dr Josh Heerey (SAHHSS, La Trobe University)
	Ms Lynette Law (PhD student, SAHHSS, La Trobe University)
	Ms Amanda Attanayake (SAHHSS, La Trobe University)
Location	La Trobe University

Part 1 What does my participation involve?

1 Introduction

You are invited to take part in this research project because you have knee pain. This research project aims to assess the effectiveness of two different programs provided through advice and education by a qualified dietitian to improve your knee pain, function and quality of life.

This information sheet tells you about the research project. It explains the tests and treatments involved. Knowing what is involved will help you decide if you want to take part in the project. Please read this information carefully. Ask questions about anything that you don't understand or want to know more about. Before deciding whether or not to take part, you might want to talk about it with a relative, friend or your local doctor.

Your participation is voluntary

Participation in this research is completely voluntary and there will be no cost to you. If you don't wish to take part, you don't have to. If you decide you want to take part, you will be given a copy of this Participant Information Sheet and asked to sign the consent section. By signing it you are telling us that you:

- Understand what you have read
- Consent to take part in the research project
- Consent to have the tests and treatments that are described
- Consent to the use of your personal and health information as described.

You will be given a copy of this Participation Information Sheet and Consent Form to keep.

## 2 What is the purpose of this research?

As you may be aware, knee pain is very common and is often associated with knee osteoarthritis. Osteoarthritis is the most common form of arthritis and is a leading cause of disability in Australia. Currently, there is no cure for osteoarthritis, therefore it is important to investigate treatments that can improve the main symptoms associated with osteoarthritis: pain, swelling, stiffness and movement difficulties. We will recruit 140 adults who have knee pain.

This study is being conducted by researchers at La Trobe University and is partly funded by the National Health and Medical Research Council (NHMRC) of Australia and Dr Peter Brukner. All assessments and consultations will be at **no cost** to you.

## 3 Who can participate?

You can participate in this study if you meet all the following:

- Between 45-85 years of age and understand written and spoken English
- Activity-related knee pain on most days of the past month
- Knee pain for at least 3 months
- No morning knee stiffness, or morning stiffness that lasts less than 30mins
- Willing to complete the assigned 12-week eating program and attend all appointments (detailed below)

You are not eligible and cannot participate in this study if you meet any of the following:

- Knee pain not primarily due to osteoarthritis (e.g., fibromyalgia, referred pain)
- Bilateral knee replacement
- Already strictly following a specific diet (e.g., low-carb, paleo, Mediterranean, Vegan)
- Received treatment from a dietitian, or knee injection, in the past 3 months
- Experienced  $\geq 5\text{kg}$  weight loss in the past 3 months or body weight  $\geq 200\text{kg}$
- Planning to have knee surgery in the next 6 months
- Pregnant or breastfeeding
- History of psychiatric or eating disorder (excluding anxiety/depression) or bariatric surgery

## 4 What does participation in this research involve?

This study will be conducted over 6 months in total (see flowchart on next page).

### **Pre-baseline (online/phone) appointment**

You will be asked to attend a 30-minute Zoom/telephone appointment prior to your first face-to-face appointment. At this appointment, we will discuss the consent form, outline the fasting process needed to complete your blood test and DEXA scan, and answer any questions you might have. We will also explain how to complete a 3-day food diary, which will be done using a smart phone application or paper-based food diary (personal preference).

### **Baseline (first) appointment**

This appointment will be arranged at a convenient time for you at La Trobe University, Bundoora and will take approximately 2 hours. You will be asked to not eat/drink anything or conduct any exercise in the morning of your appointment (i.e., fasting for 12-hours) for the purpose of a blood test. At the appointment, we will assess your:

- Height, weight, waist circumference and blood pressure
- Body composition measured via a Dual-energy X-ray Absorptiometry Scan (DEXA).  
This involves laying on the scanner bed for ~7 mins. The machine uses small doses ( $<1\%$  yearly dose) of radiation to assess tissue density (how much muscle and adipose tissue you have). The total effective dose of radiation has been calculated by a Medical Physicist (see risks below). Light clothing with no metal (e.g., zips, clips, underwire) should be worn (gown provided if needed). All measures will be taken by trained

- researchers who hold Victorian Government radiation licenses and comply to the Code of Practice set out by the Australian Radiation Protection and Nuclear Safety Agency.
- Blood test: A trained researcher qualified to take blood will collect a small amount of blood (~25 mL, equivalent to ~4 teaspoons) from a forearm vein to assess inflammation levels.
  - Questionnaires assessing your pain, activity level and quality of life and food intake
  - Functional tests: i) how many times you can stand from a chair in 30 secs; and ii) how fast you can walk 40 metres.

We will provide a snack/drink as soon as you complete the DEXA and blood tests.

**Random assignment to one of two different treatments**

At the end of the first appointment at La Trobe University, you will be randomly assigned (50:50 chance, like a coin toss) to receive a program (from qualified dietitians) to either:

- i) minimise processed foods that are known to promote inflammation and optimise foods shown to reduce inflammation; or
- ii) minimise foods that are known to be high in fat content.

This means neither you nor the researchers will be able to choose which group you are assigned to. We do not know which treatment is best; to find out we need to compare the two programs. Although the two programs involve modifying some types of food that you eat, you can eat as much as you like of these foods. **You do not need to restrict the amount of food that you eat.**

Irrespective of which group you are assigned to, you will receive specific education and advice from an Accredited Practising Dietitian (APD) in a dietary consultation at the start of the study (at the end of your first appointment at La Trobe University). Your dietitian will also work with you to develop a personalised management plan to support you throughout the study. You will be asked to follow the program for 12 weeks (but you can continue for as long as you like). We will ask you to record your food intake for 3 days at up to six different times throughout the study.

**Support phone calls**

To support you throughout the study and answer any questions you have, we will arrange up to four follow-up consultations to be conducted over the phone/online during the 12 weeks. This phone call will take approximately 15-20 minutes. At these times, we will also ask you to complete some of the same questionnaires online (via a secure link provided by e-mail).




Figure 1. Flowchart of study assessments

**Follow-up appointments**

So that we can assess the results of the program you have been assigned, we will ask you to return for face-to-face appointments at La Trobe University at **12 weeks and 6 months after your first appointment.** These follow-up appointments will be like the first appointment where

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool



we will do all the same tests and questionnaires. You will need to fast (not eat/drink anything) the morning of your appointment for the blood test. You will have another dietary consultation with the study dietitian who will provide support for you to continue with the program you have been assigned. You should allow about 2 hours for these appointments. To assess longer-term results, we will ask you to complete the same online questionnaires at 1 and 2 years after your first appointment. The total time commitment for participating will be approximately 6-8 hours.

There are no additional costs associated with participating in this research project. All medical care and tests (i.e., dietitian consultations, DEXA scan, blood tests) required as part of the research project will be provided free of charge. The results of the DEXA scan and blood tests will not be used to diagnose health conditions, but only to evaluate the effects of the intervention. We will provide you with your individual results when the DEXA and blood analyses are completed at the end of the study. Your travel costs to attend the assessments will be reimbursed up to \$100.

At the end of the first 12 weeks, or after 6-12 months, we may also ask if you are willing to have a separate interview with one of the study researchers (this interview is optional and you can take part in the study without needing to complete the interview). The purpose of this interview is to seek feedback on the study treatments, satisfaction with the process received and whether there are any suggestions for improvement. The interview will take approximately 30 minutes, but you can cease the interview at any time. To ensure responses are correctly interpreted, responses to questions will be audio recorded and transcribed. Audio recording transcriptions will be completed by 'Transcription Australia' on their secure, encrypted Australian-based software. Although voice in your audio recording could lead to your identification, this file will not be used during analysis. Instead, a re-identifiable transcription, which you will have the opportunity to check for accuracy, will be used for analysis. Re-identifiable means that we will use a code number and not your name on data collected to ensure your anonymity. Following the completion of analysis of this transcription, the audio file associated with your interview will be deleted. After analysis, overall findings and conclusions from all interviews will also be sent to you, to allow an opportunity to make any further comments. We will seek around 40 participants to be interviewed. It is your decision or not whether you wish to be interviewed.

## 5 What are the alternatives to participation?

You do not have to take part in this research project to receive treatment for your knee. Other options are available; these include seeing a physiotherapist or dietitian (e.g., private or public health centre). The research team will discuss these options with you before you decide to take part in this project. You can also discuss the options with your doctor, dietitian or physiotherapist.

## 6 What are the possible benefits of taking part?

We cannot guarantee or promise that you will receive any benefits from this research. However, possible benefits may include improvement of pain, function, quality of life, physical activity, and confidence in your knee. You may gain valuable insight into how to manage your food intake and specific anti-inflammatory and low-fat foods, nutrients and eating habits. The expected benefit to society is the development of a drug-free and non-invasive treatment option to help manage pain and disability associated with osteoarthritis. This will give doctors and patients alternative ways to manage knee pain, which in turn may lead to improvements in the quality of life for patients.

## 7 What are the possible risks and disadvantages of taking part?

With any medical treatment there are: (i) risks we know about; (ii) risks we don't know about; and (iii) risks we don't expect. We have listed the risks we know about below. You may have none, some or all the effects listed below, and they may be mild, moderate or severe. If you have any of these side effects, or are worried about them, talk with the study coordinator.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

Possible Side Effect	How often is it likely to occur?	How severe might it be?	How long might it last?
Emotional distress due to involvement in research and completion of questionnaires	Rarely; although can occur when completing study questionnaires	Minimal	While completing the study questionnaires
Emotional distress due to diet assessment	Rarely; although can occur when assessing food intake prior to, or during, appointments	Minimal	While completing the food diary or assessment
Discomfort due to body measurements	Can occur while measurements are done by your dietitian or researcher	Minimal Mild	During appointment only
Discomfort due to blood test	Rarely; while blood is being collected	Mild	Bruising or swelling may last 1-3 days
Exposure to ionising radiation	1x 7-minute scan at initial, 12-week and 6-month appointment	Minimal	Effect too small to measure
Tiredness/change in bowel patterns with change in diet	Any change in diet can make you feel tired or have different bowel patterns	Minimal	1-2 weeks
Contraction of COVID-19	Can occur during the face-to-face assessments	Minimal Moderate	1-2 weeks

If you become upset or distressed because of your participation in the research, the study coordinator together with the qualified dietitian will assist you with appropriate support. We can also provide you information about services you can access to seek help for emotional distress.

**Risks associated with completing study questionnaires and diet assessment**

Completing questionnaires about your knee pain, function, quality of life and dietary intake may cause emotional distress. If you begin to feel upset or distressed when completing your questionnaires or dietary assessment, please let a member of the research team know. We will provide you with the appropriate support, including a document outlining services you can access to help with your emotional distress.

**Risks associated with blood test**

Having a blood sample taken may cause some discomfort or bruising. On very rare occasions, the blood vessel may swell, or blood may clot in the blood vessel, or the spot from which blood is taken could become inflamed. Some people may feel light-headed when having blood taken and may occasionally faint. Very rarely, there could be a minor infection or bleeding. A qualified person will take a very small amount of your blood (max 30mL each appointment (normal blood donation is 500mL)) using stringent infection control procedures. If you notice increased redness, swelling or other signs of infection in the days following your assessment, tell us immediately.

**Risks associated with eating low-inflammatory foods or low-fat foods**

As you adjust to the eating program you are assigned to, you may experience feelings of tiredness and/or changes in bowel habits and patterns. The researchers will assess your diet and ensure you are meeting your energy and nutrient needs throughout the study intervention. This eating program may be different than your normal diet and therefore influence your usual weekly shopping bill and expenses. As part of the consultations, you will be provided with some advice on how to follow the diet on a budget if required to ensure there is minimal financial burden.

**Exposure to ionising radiation**

If you choose to take part in this research, you will undergo three 7-minute DEXA scans (first, 12-week and 6-month assessments). DEXA scans are a non-invasive, fast and simple procedure. This research study involves exposure to a very small amount of radiation from a DEXA scan that you would not normally receive. As part of everyday living, everyone is exposed to naturally occurring background radiation and receives a dose of about 2 millisieverts (mSv) each year. The effective dose you will receive from all of these DEXA scans is approximately 0.03 mSv. At these

dose levels, no harmful effects of radiation have been demonstrated as any effect is too small to measure. The risk is believed to be minimal.

The scans we are taking are for research purposes and are not intended to be used like scans taken for a full clinical examination or to be used to help diagnose, treat or manage a particular condition. The whole-body DEXA scan may identify participants with a low bone mineral density. However, a whole body DEXA scan is not the established method for detecting low bone mineral density. Therefore, as a precaution if you are identified as having a low bone mineral density you will be encouraged to make an appointment with your General Practitioner to discuss the results.

Have you been involved in any other research studies that involve radiation? If so, please tell us. Please keep information contained within this Patient Information Sheet about your exposure to radiation in this study, including the radiation dose, for at least 5 years. You will be required to provide this dose to researchers of any future research projects involving exposure to radiation.

### **Contraction of COVID-19**

You may be at risk of contracting COVID-19 during one of the face-to-face appointments at La Trobe University. Prior to attending La Trobe University, you will be screened for signs and symptoms of COVID-19 by a member of the research team. You will also need to be fully vaccinated (or hold a valid medical exemption) to be able to attend La Trobe University for your assessments. The research team will put in place the appropriate control measures to reduce the risk of COVID 19 transmission. The risk is believed to be minimal.

## **8 What if I withdraw from this research project?**

You are under no obligation to continue with the research study. You may change your mind at any time about participating in the research. People withdraw from studies for various reasons, and you do not need to provide a reason.

You can withdraw from the study at any time by completing and signing the 'Participant Withdrawal of Consent Form'. This form is provided at the end of this document and is to be completed by you and supplied to the research team if you choose to withdraw at a later date.

If you withdraw from the study, you will be able to choose whether the study will destroy or retain the information it has collected about you. Information about you that has already been analysed (i.e., once you have been allocated to either program), may not be able to be destroyed to ensure accurate and unbiased study reporting. Personal details collected, such as your name and contact details, can be destroyed at any time upon study withdrawal.

## **9 What happens when the research project ends?**

At the completion of the research project, you may continue to use the resources provided and to follow the eating program principles if you choose to. If requested, we will provide you with your individual results including your body composition (DEXA) assessment and whole study results. We, or other researchers, may also use coded information (so that you cannot be identified) collected for this research study in future related studies. If you consent (tick the box on the consent form) to be contacted for future related research, we will store your contact details (name, address, phone number, email) on the secure La Trobe University research drive, only accessible to members of the research team, and may contact you about future related research projects.

## **Part 2 How is the research project being conducted?**

### **10 What will happen to information about me?**

By signing the consent form you agree to the relevant research staff collecting and using personal information about you for the research project. Any information obtained in connection with this research project that can identify you will remain confidential and securely stored. It will be disclosed only with your permission, or in compliance with the law.

**Storage, retention and destruction**

The anonymity of your participation is assured with our procedure, in which a code number (not your name) will identify you. Data will be kept securely at La Trobe University in a locked filing cabinet and password protected research computer. Identifiable data will be stored for 15 years, then destroyed (electronic records deleted, paper-files shredded). Data will be strictly handled confidentially under guidelines set out by the National Health and Medical Research Council. The principal investigator (Dr Adam Culvenor) is responsible for maintaining this confidentiality.

In accordance with relevant Australian and/or Victorian privacy and other relevant laws, you have the right to request access to your information collected and stored by the research team. You also have the right to request that any information with which you disagree be corrected.

The results of this project may be published and/or presented in a variety of forums and used by research students to obtain a research degree. In any publication, presentation or data files shared with other researchers, information will be provided in such a way that you cannot be identified, except with your permission.

**11 Who is organising and funding the research?**

This research project is being conducted by Dr Adam Culvenor and a team of researchers. It has been funded by the NHMRC (GNT2008523) and Dr Peter Brukner. Dr Peter Brukner is also an investigator on the project and has written a book and developed an app that will be used as part of the study. He will not be involved in data collection, analysis or the decision to publish results. No member of the research team will receive a personal financial benefit from your involvement in this research project (other than their ordinary wages).

**12 Who has reviewed the research project?**

All research in Australia involving humans is reviewed by an independent group of people called a Human Research Ethics Committee (HREC). The ethical aspects of this research project have been approved by the HREC of La Trobe University Human Ethics Committee.

This project will be carried out according to the *National Statement on Ethical Conduct in Human Research (2018)*. This statement has been developed to protect the interests of people who agree to participate in human research studies.

**13 Further information and who to contact**

For all enquiries, you can contact the Clinical Trial Manager, during business hours:  
Dr Adam Culvenor, Senior Research Fellow in Physiotherapy, La Trobe University  
Telephone: 03 9479 5116; E-mail: a.culvenor@latrobe.edu.au

If you have any complaints about any aspect of the project, the way it is being conducted or any questions about being a research participant in general, then you may contact:

Reviewing HREC: La Trobe University Human Research Ethics Committee  
Complaints Contact: Senior Human Ethics Officer, Ethics and Integrity, Research Office  
Telephone: 03 9479 1443 E-mail: humanethics@latrobe.edu.au  
\* Please quote the application reference number HEC22044

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool





## Consent Form - Adult providing own consent

**Title** Optimising outcomes for people with knee pain through food: FEAST randomised controlled trial

**Short Title** The FEAST trial

**Ethics Reference Number** HEC22044

**Project Sponsor** La Trobe University

**Coordinating Principal Investigator/  
Principal Investigator** Dr Adam Culvenor (La Trobe University)

**Associate Investigator(s)** Dr Brooke Devlin (University of Queensland)  
Prof. Peter Brukner (La Trobe University)  
Ass. Prof. Joanne Kemp (La Trobe University)  
Prof. Kay Crossley (La Trobe University)  
Dr Andrea Mosler (La Trobe University)  
Dr Josh Heerey (La Trobe University)  
Ms Lynette Law (PhD student, La Trobe University)  
Ms Amanda Attanayake (SAHHSS, La Trobe University)

**Location** La Trobe University

### Consent Agreement

I have read the Participant Information Sheet and I understand the purposes, procedures and risks of the research described in the project.

I understand that data files may be shared with other researchers, and that information will be provided in such a way that I cannot be identified, except with my permission.

I have had an opportunity to ask questions and I am satisfied with the answers I have received. I freely agree to participate in this research project as described and understand that I am free to withdraw at any time during the study without affecting my future health care.

I understand that, if I decide to discontinue the study treatment, I may be asked to attend follow-up visits to allow collection of information regarding my health status. I agree that data gathered for the study may be published provided my name or other identifying information is not used.

- ☐ I wish... / ☐ do not wish... to receive results of the study
- ☐ I consent... / ☐ do not consent... to be contacted for future related research
- ☐ I consent... / ☐ do not consent... to have my interview responses audio-recorded/transcribed.
- ☐ I consent... / ☐ do not consent... to have my samples/data used in future research

I understand that I will be given a signed copy of this document to keep.

Name of Participant (please print) \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

### Declaration by Researcher<sup>†</sup>

I have given a verbal explanation of the research project, its procedures and risks and I believe that the participant has understood that explanation.

Name of Researcher<sup>†</sup> (please print) \_\_\_\_\_

Signature \_\_\_\_\_ Date \_\_\_\_\_

<sup>†</sup> An appropriately qualified member of the research team must provide the explanation of, and information concerning, the research project.





STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	3
	2b	All items from the World Health Organization Trial Registration Data Set	ACTRN12622000440729
Protocol version	3	Date and version identifier	NA
Funding	4	Sources and types of financial, material, and other support	21
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	21
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	21
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	NA
<b>Introduction</b>			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4
	6b	Explanation for choice of comparators	4-5
Objectives	7	Specific objectives or hypotheses	5
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	5
<b>Methods: Participants, interventions, and outcomes</b>			

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6-7
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	8-13, Table 2, Supplementary File 1
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Table 2
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8-13, Table 2
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	13
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	13-18, Table 3
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	19
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7

### Methods: Assignment of interventions (for controlled trials)

#### Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7-8
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7-8
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7-8
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7-8

17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	NA
-----	--	----

#### Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	13
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	13
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	18
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	19
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	19
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	19

#### Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	18
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	19-20
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	NA

#### Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	20
--------------------------	----	---	----

Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	20
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	20
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	18
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Supplementary File 1
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	NA
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	20
	31b	Authorship eligibility guidelines and any intended use of professional writers	NA
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	NA
<b>Appendices</b>			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary File 1
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	Supplementary File 2

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-Non Commercial-No Derivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.